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Summary
Experimental mixed-mode solid-phase extraction columns of differing carbon
number and carbon loading were investigated for the efficient extraction of drugs of
abuse from biological matrices. Methadone and its two major metabolites (EDDP
and EMDP) were chosen due to the increase in methadone drug-related deaths in the
West of Scotland. Amphetamine and related compounds (methamphetamine, 3,4-
methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine
(MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA)) were chosen because
of the prevalence of use of "speed" and "ecstasy" throughout the United Kingdom
and the challenge these volatile drugs pose to the analyst.
Improved methods were developed for the efficient extraction of methadone, EDDP
and EMDP from whole blood and for amphetamine and related compounds from
whole blood and hair. These methods were successfully applied to the analysis of
postmortem samples.
The stability of methadone, EDDP and EMDP in whole blood was investigated using
the developed extraction method after storing at various temperatures for a period of
six months. Methadone remained stable in blood after six months. This was
confirmed by the analysis of postmortem cases samples which when re-analysed
within six months of the initial analysis, correlated well.
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Summary xvii
Postmortem hair samples proved useful for determining antecedent drug use history
whether extracted by solid-phase extraction or after screening with a Cozart enzyme
immunoassay kit, adapted for hair analysis.
Solid-phase extraction provides a clean and efficient means of extracting drugs of
abuse from whole blood and hair. Simple manipulation of the extraction system
(sample preteatment, pH, derivatisation) provides a versatile alternative to lengthy
liquid-liquid extraction techniques and has the added potential of automation.
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1. Introduction
1.1 Drug Use: An Overview
1.1.1 Introduction
The abuse of drugs both legal and illegal have a detrimental effect on society as a
whole. The risks from toxicity are compounded by the potential of long-term risks
effecting a greater number of the drug using population.
Tobacco smoking is thought to contribute to 100,000 premature deaths in the UK
every year and alcohol abuse is prevalent in a society where 90% of the adult
population drink.' 3,4-methylenedioxymethamphetamine (MDMA), a synthetic
stimulant used recreationally, has been associated with psychological and
behavioural complications 2. Drugs are used by many athletes as stimulants to reduce
tremor and heart rate, and to alter body composition 3.
The number of deaths caused directly from drug use, e.g. overdose 4 or indirectly,
e.g. road traffic accidents 5, have increased throughout the United Kingdom. In the
Strathclyde region alone, the number of deaths has increased from 9 in 1985 to 120
in 1998 6. Deaths occurring in the late 1980' s were attributed to heroin abuse, but at
the start of the 1990's the abuse ofbenzodiazepines featured much more 7.
The drug scene in the latter part of the 1990' s has seen a resurgence of heroin use 8.
Heroin is now being used by adolescents from more affluent backgrounds as a
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recreational drug and is commonly seen in small towns. This is in sharp contrast to
the typical heroin user of the past who almost exclusively lived and bought heroin in
the larger cities and was unemployed.
Methadone is often used in the treatment of opiate addiction and was introduced into
Scotland at the end of the 1980' s. This synthetic opioid analgesic has replaced heroin
as the most common cause of drug related death in South-East Scotland 9.
The number of drug related deaths in the Strathclyde Region resulting from
methadone alone or in combination with other drugs had increased from 1 in 1991 to
34 in 1996; highlighting the impact of this drug on drug users 10• Heroin deaths
however still contributed a larger proportion of the drug-related deaths in the region.
Drug use impairs psychomotor skills and causes hazardous driving 11-13. Individuals
who are in receipt of methadone are required to inform the authorities of their current
drug status. However, many do not and put themselves and other road users at risk 14.
Amphetamines are the most popular illicit stimulants, second only to cannabis IS. In
Particular, the ring-substituted amphetamines, e.g. 3,4-methylenedioxy-
methamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA) are
Widely used at organised dance events. "Herbal remedies" were recently introduced
into the dance scene and are thought by users to be "natural" and therefore safer.
Bateman et at 16 highlighted the dangers of these "herbal remedies" which are
extremely powerful and potentially lethal. At present there is a lack of regulations
governing products like "Khat" and "herbal ecstasy".
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1.1.2 Misuse of Drugs Act 1971
The aim of the Misuse of Drugs Act is to prevent the unauthorised use ('misuse') of
the drugs regulated under the Act. The Misuse of Drugs Act was introduced as law in
the United Kingdom to fulfill its obligation to control drugs in accordance with
international agreements.
Under the confines of the law it is illegal to be in possession of a drug with or
without the intent to supply to another person. To supply or offer to supply to another
person. To allow the use of premises which you occupy or manage to be used for
supplying. It is also illegal to produce or cultivate a drug or to import or export any
of the drugs regulated under the Act.
The exceptions to the general prohibitions are in the form of 'regulations' made
under the Act. The majority of controlled drugs have medical uses or may be of
scientific interest. The Act allows the government to authorise medical or scientific
organisations to possess, supply, produce and import or export the regulated drugs.
Controlled drugs are divided into five schedules. Schedule 1 includes drugs which
are most stringently controlled (e.g. cannabis, cannabis resin and raw opium).
Doctors cannot prescribe them or pharmacists dispense them. Schedules 2 through 4
involve the majority of controlled drugs. These drugs are available for medical use
and can be supplied or administered by doctors. Heroin is a schedule 2 drug and can
still be prescribed by a doctor. Schedule 5 lists preparations of drugs considered to
pose minimal risk of abuse. Many of these preparations are sold in pharmacies.
Application of Solid-Phase Extraction for the Analysis of Drugs in Biological Matrices
Chapter One: Introduction Page4
Within the Act controlled drugs are divided up in "classes" according to the
maximum penalties for these offences. Class A drugs incur the highest penalties as
they are thought to be the most harmful when misused, then class B and C. Class B
drugs in injectable form count as class A.
As new drugs are introduced onto the drug scene and require regulation, the Misuse
of Drugs Act is amended. A total of thirty-five phenethylamines will be added to Part
I of Schedule 2 of the Misuse of Drugs Act to become Class A controlled drugs.
They will be listed in Schedule I of the Misuse of Drugs Regulations. A thirty-sixth
phenethylamlne, cc-methylphenethylhydroxylamine will become a Class B controlled
drug 17.
1.2 Forensic Toxicology
1.2.1 Introduction
Toxicology is the study of poisons and the term 'poison' is used to describe any
substance which has a harmful effect on a living system. The toxicity of a drug does
not only depend on its toxic properties but also on the dose administered. However,
there is no direct relationship between the dose and the effects that it elicits.
'Forensic Toxicology' is defined as the study of the effects of drugs and poisons on
human beings and the investigation of fatal intoxication's for the purpose of a
medico-legal enquiry 18.
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Sample types analysed include urine, liver, vitreous humour and brain but more
commonly, blood. Alternative matrices, e.g. hair, saliva, sweat and nails 13 can also
be analysed for the presence of potential poisons. As a consequence of the increase in
demand for drug identification, it is the role of the forensic toxicologist to develop
methods, which are both rapid and reproducible for the analysis of a wide range of
analytes in biological matrices.
Systematic Toxicological Analysis (STA) is defined as the logical chemical -
analytical search for an unknown substance of toxicological relevance 11. The first
step is to establish whether the compound can be detected (screening) and secondly,
to identify the compound (identification and confirmation).
Biological samples have to undergo a series of sample pre-treatment steps, to remove
any endogenous materials and to increase the drug concentration, before being
introduced onto a chromatographic column.
Technological advances in chromatographic analytical equipment have afforded the
scientist with the means of separating a complex mixture of analytes and confirming
their presence. However, sample preparation techniques have not improved as
quickly and this remains the limiting factor for a totally automated analysis and is the
Source of greatest variability 19.
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1.2.2 Systematic Toxicological Analysis
The main purpose of 'Systematic Toxicological Analysis' (STA), is to detect and
identify unknown substances in a given matrix 20. Drug screening in systematic
toxicological analysis is an extremely important preliminary step in the analysis of
biological specimens and involves two main steps;
1. Sample Preparation (clean-up and extraction) and
2. Detection and Confirmation.
Sample pre-treatment produces a cleaner sample and leads to greater selectivity and
precision, by' eliminating any matrix effects, which may interfere with the analysis.
The extraction is optimised through adjustment of the pH, ionic strength and sample
concentration.
Traditionally, liquid-liquid extraction (LLE) techniques were used to separate
analytes from biological matrices. However, they were found to be tedious, time
consuming and were not always sufficiently reproducible.
Solid-phase extraction (SPE) emerged in the mid 1970's 21 as a simpler alternative to
liquid-liquid extraction and has since proved to be an extremely effective means of
extracting drugs from biological matrices with several distinct advantages over
liquid-liquid extraction 20. These include reduced solvent usage, cleaner extracts, no
emulsion formation and considerable reduction in analysis times.
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Several analytical techniques have been used for the screening of drugs, these
include, Thin Layer Chromatography (TLC), Immunoassay, High Performance
Liquid Chromatography (HPLC) and Gas Liquid Chromatography (GLC).
The ideal analytical method, should be specific, statistically defined (accuracy,
precision and sensitivity), and routinely reliable 22.
In forensic toxicology, capillary gas chromatography and capillary gas
chromatography - mass spectrometry are often the preferred methods for analyte
confirmation and quantification 23.
1.3 Solid-Phase Extraction
1.3.1 Introduction
Solid-phase extraction (SPE) was introduced as a simpler alternative to liquid-liquid
extraction (LLE) in the mid 1970's, to try and combat the problems encountered with
this method 20.
The first bonded phases used were of hydrophobic character, e.g. C18 and XAD
resins 24. These single - phase columns showed great promise for the analysis of
biological samples, however problems occurred with co-extraction of endogenous
materials.
Ion-exchange columns were introduced in the 1980's and successfully extracted a
wide range of compounds of differing chemistries, of both basic and acidic character.
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Improvements with sample clean up and recoveries were also reported, however
extraction of neutral compounds still remained a problem.
Mixed-mode bonded silicas, consisting of both hydrophobic and ion-exchange
properties in one single column e.g., Clean Screen®, first introduced in 1986 24,
enabled the extraction of a range of drugs, including neutral compounds 25.
Solid-phase extraction is a powerful pre-treatment technique for the clinical and
toxicological drug analysis of biological samples 26 and over the years has become
more and more acceptable in forensic laboratories 20,27, having very distinct
advantages over liquid-liquid extraction. These advantages include:
1. High selectivity
2. Cleaner extracts
3. No emulsion formation
4. Better reproducibility
5. Reduced solvent usage
6. Higher throughput due to automation 23,25,28
7. Less contamination of GC system.
1.3.2 Principles of Solid-Phase Extraction
1.3.2.1 Introduction
The extraction procedure in solid-phase extraction, involves the interaction between
a solid and a liquid phase, and is a physical extraction process, similar to liquid
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chromatography 29. However, the aims of solid-phase extraction are to isolate and
then concentrate the compounds of interest, while liquid chromatography aims to
separate the compounds, with good peak shape and height, and short retention times.
There are many different sorbent materials available, e.g. diatomaceous earth, silica
and bonded silica gels. Bonded silicas are the most frequently used sorbent as they
can be modified with different functional groups to produce highly stable non-
swelling stationary phases which allow for a wider range of extraction capabilities.
Secondary interactions also take place where the isolate molecules interact with the
silica substrate as opposed to the functional group 29.
The extractions can be separated into three types, depending on the functional groups
bonded to the silica; non-polar, polar and ion-exchange.
1.3.2.2 Non-Polar Interactions
Non-polar interactions result between the carbon-hydrogen bonds of the sorbent and
of the isolate and are caused by "Van der Waals" or "dispersion forces". The majority
of organic molecules have some non-polar character and so are retained on the
surface of sorbents containing non-polar functional groups.
Octadecyl silane (CI8) is the most frequently used non-polar sorbent and is non-
selective, resulting in the. retention of a variety of structurally unrelated isolates.
Retention of isolates onto non-polar sorbents is facilitated by the use of polar
solvents, while elution requires a solvent of sufficient non-polar character to disrupt
the non-polar interactions between the isolate and the sorbent.
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1.3.2.3 Polar Interactions
Groups with polar character include, hydroxy Is, amines, aromatic rings and hetero-
atoms, e.g. oxygen and nitrogen. These are retained on sorbents containing polar
functional groups due to hydrogen bonding, dipole/dipole, induced dipole/dipole, pi-
pi and other polar interactions resulting from the uneven distribution of electrons
between individual atoms in the functional group.
Secondary interactions due to the polar character of the silica substrate are present in
all bonded silicas. Retention of isolates onto polar sorbents is facilitated by the use
of non-polar solvents, while elution requires a polar solvent of sufficiently high ionic
strength to disrupt the polar interactions between the isolate and the sorbent.
1.3.2.4 Ionic Interactions
Ion-exchange occurs between groups present on the isolate and the sorbent with
opposite charges. There are two classes of these groups: cationic (positively
charged), e.g. primary, secondary, tertiary, and quarternary amines, and anionic
(negatively charged), e.g. carboxylic and sulphonic acids. Depending on the pH of
the solvent environment, these molecules can exhibit cationic or anionic character.
Two criteria have to be met before the retention of an isolate by an ion-exchange
mechanism can take place:
1. the pH of the system must be such that both isolate and sorbent are
charged, and
2. the system must not contain high concentrations of strongly competing
ionic species of the same charge as the isolate.
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The pKa is defined as the pH at which half of the molecules in solution are charged
and the other half are not. Increasing the pH to a value above the pKa of anionic
molecules, increases the number of charged anionic groups and decreasing the pH,
decreases the number of charged molecules. The opposite is found with cationic
groups.
In order to achieve retention of ionic groups, both the sorbent and the isolate have to
be charged, i.e. at a pH below the pKa of the cation and at a pH above the pKa of the
anion. A pH of at least two pH units below the pKa of the cation and two pH units
above the pKa of the anion is required for approximately 99% of the groups to be
charged.
Other factors, which are important in ion-exchange, are ionic strength and selectivity.
Ionic strength is a measure of the total ionic concentration of ionic species present
within the solvent/matrix environment. Ion-exchange is a competitive process and so
low ionic strength encourages retention of the isolates while high ionic strength
disrupts it. Selectivity describes the preference shown by ion-exchange sorbents for
certain types of ionic groups over others. Ionic secondary interactions also occur due
to unbonded silanols on the silica substrate.
Retention of an isolate onto a sorbent matrix occurs through the interaction of a
combination of the three extraction mechanisms, i.e. non-polar, polar and ion-
exchange, these interactions are dependent on the sample matrix and solvent
environments.
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1.3.3 Procedural Steps in Solid-Phase Extraction
In its simplest form, a solid phase extraction procedure consists of five steps: column
pre-conditioning, sample application, column wash, column drying and drug elution.
1.3.3.1 Column Preconditioning
Before applying a pre-treated sample to an extraction column, the active sites on the
column have to be activated with a suitable solvent. Bonded silica sorbents are dried
and packed and so are not available to interact with the analytes. Application of the
sample before solvation would result in low and irreproducible recoveries.
1.3.3.2 Sample Application
Once the column is solvated, the sample is applied onto the column under a light
vacuum. The flow rate of the sample through the column is very important, as a low
flow rate allows the necessary time for the maximum amount of drugs to interact
with the active sites on the column. Normally this would be 1.5 ml/min.
1.3.3.3 Column Wash
The wash step allows the removal of any endogenous components that were retained
by the active sites. Water or an appropriate solvent is used to selectively remove any
material that could interfere with the analysis. Selection of a solvent that will not
remove any of the relevant drugs can be difficult and so a compromise must be
reached between acceptable recoveries and removal of interfering compounds.
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1.3.3.4 Column Drying
This is an extremely important step, especially when gas chromatography is used for
the final analysis, as any residual water may cause damage to the GC column. The
water may be removed by applying a vacuum to the column or by the addition of a
solvent, e.g. methanol 27.
1.3.3.5 Elution of Relevant Drugs
In order to elute the drugs for analysis, a suitable solvent is chosen which will extract
only the drugs of interest and leave any remaining matrix interferents on the column.
The solvent should also be strong enough to displace all of the drugs into a small
eluent volume. Large eluent volumes have the disadvantage of diluting the extract,
extracting more impurities and increasing the extraction time. An evaporation step is
usually included at this stage to concentrate the drugs, however care must be taken
to prevent the loss of more volatile drugs, e.g. amphetamines.
1.3.4 Development of Solid-Phase Extraction
1.3.4.1 Introduction
The first materials to be used for the Solid-Phase extraction of urine samples were
first reported in 1970 with the introduction of Amberlite® XAD-2 resins (cross-
linked polystyrene - divinyl benzene by Rohm and Haas; Philadelphia, PA) 20. Use of
these resins included screening for drugs of abuse in urine 30 and more recently, the
extraction of cocaine and benzoylecgonine from postmortem blood 21.
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The need for large volumes of resin, multiple stepped analysis and the time required
to complete the extraction made these phases expensive and difficult to use. Sep-Pak
CI8 cartridges were introduced in 1978 by Waters Associates (Milford, MA) 20.
These smaller columns decreased the analysis time and costs associated with drug
analysis and proved useful for the extraction of tricyclic antidepressants from
vitreous humour 31 and benzodiazepines from urine 32. To obtain similar recoveries
from plasma, a deproteinization step was required.
New methods reported for solid-phase extraction, outnumber those reported for
liquid-liquid extraction, demonstrating the shift from liquid-liquid extraction to solid-
phase extraction in both clinical and forensic toxicological laboratories. One other
type of solid-phase used, is Extrelut (Merck, France) which has found applications in
the analysis of propoxyphene and related compounds 33 and benzodiazepines 34 in
blood. Extrelut is available as a prepacked column or in granular form.
Several single-mode columns have been introduced for the analysis of urine and
plasma samples including Bond Elut C235, Bond Elut CIS 36 and Detectabuse GCIMS
grade columns 37. These columns contain non-polar sorbent materials (C2, CIS) and
methods have been reported for analysis of individual drugs and groups of
structurally related drugs. Problems with low recoveries arose when screening
samples for a wide range of drugs using a single-mode column. Lillsunde and Korte
38 used a Chern Elut™ (Analytichem International) column to extract 300 drugs from
urine and reported recoveries ranging from 10 to 90%.
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Cosbey et aZ39, investigated the use of a two-stage process involving two cartridges
with different phases, 1. Supelclean-ENVlcarb (hydrophobic extraction using non-
porous carbon) and 2. Bondelut PRS cartridge (ionic extraction on a strong cation
exchanger), to extract basic drugs from whole blood. Recoveries for the drugs
studied were high, e.g. 89.9% for Quinine. However, the problems encountered with
single-mode columns remained with this two-stage method as the second extraction
can only separate the drugs extracted from the first column.
Logan et aZ40, reported the use of a Bond Elut strong cation exchange (SCX) column
(Analytichem), which contains silica particles with alkyl-bonded benzene-
sulphonylpropyl, which combined both cation exchange and non-polar properties.
This column was found to extract efficiently, over 100 basic drugs from urine, as
well as certain drugs which proved difficult with liquid-liquid extraction e.g.
morphine, benzoylecgonine, temazepam and oxazepam.
1.3.4.2 Mixed-Mode Columns
Improvements continued with the introduction of mixed-mode solid-phase extraction
columns: Clean Screen™ DAU (Worldwide Monitoring Corporation: Horsham, PA),
Bond Elut CertifyTM (Varian Sample Preparation Products: Harbor City, CA) and
narc2™spe (J.T. Baker: Phillipsburg, PA). These solid-phase extraction columns
have provided the analyst with the means of selectively extracting a broad range of
drugs from various biological matrices. The sorbent consists of both hydrophobic
and cation exchange groups. .
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Clean Screen™ DAU columns have been used for the extraction of cocaine and its
metabolites 41,42 from a variety of matrices and for screening plasma and urine for
drugs of different physicochemical properties 28. Bond Elut Certify'> has been used
for the analysis of single or groups of related drugs in plasma 43, whole blood 31,44
and urine 45-46 samples.
The advantages of using a mixed-mode column as opposed to a single-mode column
include, cleaner extracts and the ability to extract a wider range of drugs with
different physicochemical properties. As these mixed-mode sorbents are contained
in just one column, they have the added advantage of requiring less extraction steps
and so are easier to use, as well as being more cost effective than the dual column
procedure.
Chen et at 26, investigated the extraction of a broad range of acidic, neutral and basic
drugs from plasma and urine using Bond Elut Certify columns and from whole blood
using both Bond Elut Certify and Clean Screen DAU columns 27.
Sample pretreatment techniques are essential for the analysis of whole blood as the
presence of red blood cells causes problems with solid-phase extraction. Direct
application of whole blood onto an SPE column would result in the column
becoming blocked and producing low and irreproducible recoveries. The problem
associated with protein binding in plasma and serum, is of greater importance with
whole blood. Sonication of the blood was needed to break up the red blood cells, in
order to free the drugs which were bound to them, and the dilution step was utilised
to reduce the viscosity of the sample and prevent blockage of the column.
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1.3.4.3 Automation
Solid-phase extraction has a number of advantages over liquid-liquid extraction
outlined previously and one of these is the possibility of automation of the procedure.
Automation of present manual solid-phase extraction methods would ideally improve
reproducibility, give higher throughput, reduce labour costs, and extractions could be
carried out after working hours.
Automated solid-phase extraction systems available include, AASP® (Varian
Sample Preparation Products: Harbor City, CA), ASPEC (Gilson: Middleton, WI),
Millilab™ (Bedford: Milford, MA), Auto Speed™ (Applied Separations: Allentown,
PA) and Zymate™ (Zymark: Hopkinton, MA).
Krogh et al 23, described an alternative method for the analysis of opiates in plasma
and whole blood using the automated sequential trace enrichment of dialysate
(ASTED) system for automated sample preparation. On-line dialysis is used as a
purification step prior to chromatographic analysis, and with slight modifications can
be used for the analysis of other basic drugs. Approximately 100 plasma or whole
blood samples can be analysed in 24 hours.
Automated methods based on the extraction procedures used in manual SPE
methods, tend to concentrate on analysis of individual or groups of related drugs and
very few methods were reported for screening body fluids 25,28.
Chen et al 28, reported a semi-automated SPE procedure for screenmg usmg
CleanScreen DAU columns using the ASPEC system. The extraction method used
Was based on the method reported by Chen et al 26, and the procedure was semi-
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automated, as the collection tubes had to be changed manually to collect the two
fractions CAand B).
The recoveries ranged from 73% for methamphetamine to 96.3% for
methylphenobarbital, with relative standard deviations of less than 5%. The
recoveries were comparable to those achieved by manual SPE methods, and the
reproducibilities were better.
Chen et al 25, then reported an improved fully automated SPE procedure using the
ASPEC system with Bond Elut Certify with recoveries ranging from 80% to 103%,
with relative standard deviations less than 4.6%.
Hewlett Packard produce the HP7686 PrepStation allowing automated extraction of
biological samples to be linked directly to a gas chromatograph with mass selective
detection for analysis 47-48. Researchers have reported turn around times of between
2.5 and 3 hours from positioning the sample on the PrepStation to the print-out of the
search report 49-50.
The benefits of using a PrepStation are reported to include: reduced exposure to
hazardous sample and chemicals, better quality results, decrease in analysis costs and
unattended operation 51.
1.3.4.4 Solid-Phase Microextraction and Solid-Phase Extraction Discs
Solid-phase extraction discs are produced from the same sorbent phases as
conventional solid-phase extraction columns, however they are shaped like thin
discs. The larger cross-sectional area of the disc makes them ideal for the high
flowrates of larger sample volumes.
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Solid-phase micro extraction (SPME) involves a coated fused-silica fibre. The fibre is
introduced to the sample headspace and elution of the extracted analyte involves
either thermal desorption (gas chromatography) or liquid desorption (high
performance liquid chromatography).
Degel 52 conducted a comparison of various solid-phase extraction techniques by
comparing the recoveries of various drugs from urine. Mixed-mode solid-phase
extraction columns, liquid-liquid extraction and multi-modal discs gave the best
recoveries with respect to the broad spectrum screening. Both mixed-mode columns,
Bond Elut CertifyTMLRC and Isolute™ Confirm HCX, performed well, however the
HCX columns produced cleaner extracts.
SPME produced excellent recoveries for the more volatile substances, e.g.
amphetamines. The extraction of amphetamines from urine and blood using SPME
has been reported in various journals 53-55.
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1.4 Aims
This project was a continuation of work carried out and completed for a Masters
Degree in Forensic Toxicology 56. Experimental mixed-mode solid-phase extraction
columns with varying non-polar character were supplied by International Sorbent
Technology to investigate the effect this would have on drug recoveries. A variety of
drugs were extracted from whole blood under various conditions and the recoveries
noted.
The initial aims of this project involved the development of improved extraction
methods for the analysis of methadone and its metabolites from whole blood and for
the extraction of amphetamine and related compounds from hair.
Both projects were extended. The aims were to:
Methadone
• develop an optimised extraction method for the analysis of methadone and its
two major metabolites 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine
(EDDP) and 2-ethyl-5-methyl-3,3-diphenyl-l-pyrroline (EMDP) in whole blood,
• investigate the stability of methadone and its two major metabolites EDDP and
EMDP in whole blood under various conditions,
• and to investigate the applicability of the Cozart methadone microplate enzyme
immunoassay kit for the screening of methadone in hair.
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Amphetamines
• To develop an optimised extraction method for the analysis of amphetamine,
methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylene-
dioxymethamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine
(MDEA) in hair,
• adapt the developed method in hair to whole blood,
• and to investigate the effects on analyte recovery with the addition of tartaric acid
to the extraction solvent.
The final aim of the project was to apply the developed methods for the analysis of
forensic case samples.
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2. Methadone
2.1 Introduction
Methadone is an opioid analgesic and although structurally unrelated to morphine,
has similar pharmacological properties. Although methadone is often prescribed as a
substitute for other opioids, an alarming quantity of illicit methadone is available to
individuals not registered on a maintenance programme. Methadone is a class A,
schedule 2 drug in the Misuse of Drugs Act 1971 (UK). It is illegal to possess drugs
in schedule 2 without a prescription and class A drugs are thought to be the most
harmful when misused and as a result, the penalties are the highest.
The number of fatalities confirmed positive for methadone has risen sharply in the
West of Scotland since 1991, with the greatest increase coinciding with the
introduction of methadone maintenance programmes in 1994 10. Of the 173 deaths
identified in which methadone was detected, 51% (n = 89) were not enrolled on a
methadone programme at the time of their death.
The increase in casework requesting methadone confirmations requires development
of a robust routine method. In' addition, successful analysis of methadone and its
metabolites is important in order to fully understand the mechanisms involved in the
metabolism of methadone. This is of particular significance for the analysis of
biological samples in forensic and clinical applications.
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2.1.1 Chemistry of Methadone
Methadone hydrochloride (6-dimethylamino-4,4-diphenyl-3-heptanone
hydrochloride) was discovered by Max Bockmuhl and Gustav Ehrhart in Germany in
1937. A 2- dimensional structure (see figure 2.1), the molecule has two active sites,
at the nitrogen atom with hydrochloride bonded to one end, which is thought to act
on the peripheral nervous system. The two phenyl rings are thought to be necessary
for its opiate-like action on the central nervous system.
CH3
C2HsCOCCH2CHN(CH3)2
Figure 2.1
Table 2.1 summarises some important physicochemical properties of methadone (a
synthetic white or colourless crystalline powder).
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Table 2.1 Properties of Methadone Hydrochloride
Property Methadone
Molecular Weight (Free Base) 345.9 (309.5)
Melting Point eC) 233 ~ 236
Solubility:
in alcohol I in 7
in water 1 in 12
in chloroform 1 in 3
in ether practically insoluble
Dissociation Coefficient pKa 8.3
Distribution in Blood
Plasma: Whole blood 1.3
Protein Binding (Plasma) 90%
2.1.2 History of Use and Abuse of Methadone
In 1947, Isbell et al 57 carried out experimental work with humans, animals and
clinical work with medical patients and concluded that methadone had a high
addiction potential.
In 1977, Methadone was described by Thompson et al 58 as one of the most
Commonly used and abused drugs in the United States. The number of addicts
receiving methadone through maintenance treatment programmes had increased
along with the methadone positive drug screens in medical examiners autopsy cases.
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In the UK, the number of known methadone addicts increased from 21 in 1955 to
1687 in 1969, which was partly due to the setting up of clinics 59.
The first opiate addicts became addicted through treatment for pain relief. The early
1960's saw an increase in the number of opiate addicts, who were younger and taking
the drugs more for pleasure not as medication. Heroin first overtook morphine as the
most notified drug of addiction in 1962 and by 1966 there were 6 times as many
heroin addicts as morphine addicts 59, 1968 saw the introduction of new drug clinics
and the number of notified addicts rose to 2881 with 2240 addicted to heroin.
The 1970's saw the importation of illicit heroin for the first time. Drug clinics moved
from supplying injectable heroin to oral methadone, which was thought to be more
therapeutic, due to prescribing non-injectable drugs. The longer half-life of
methadone meant that it could be taken once daily, rather than every few hours.
Many of the new addicts at the clinics smoked heroin and therefore the clinics looked
on their role as promoting change and increasingly moved towards the use of oral
methadone.
The 1980's saw the second increase in heroin use, notified addicts increased slowly
through the 1970's from 509 (1973) to 607 (1979) to 1110 (1979), doubled from
1979 to 1982 and doubled again by 19846°.
Glasgow introduced methadone maintenance programmes in 1994, almost a decade
after Edinburgh 61. Prior to this, 1986, Scotland had been relatively methadone free
62
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2.1.3 Disposition in the Body
Methadone is soluble in body fats and following oral administration is rapidly
absorbed from the gastrointestinal tract into the blood stream. Distribution of
methadone occurs throughout various tissues, especially the lungs, kidneys, liver and
spleen. There is slow transfer of the drug between the organs and blood, and
methadone concentrations in these organs are higher than in blood.
Methadone is primarily broken down in the liver and the main metabolic reaction is
mono- and di-N-demethylation, followed by spontaneous cyclization to form two
major metabolites, 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and
2-ethyl-5-methyl-3,3-diphenyl-l-pyrroline (EMDP) 63. This metabolic pathway is
summarised in figure2.2.
There are at least eight known metabolites 6\ but with the exception of the small
amounts of methadol and normethadol produced, none of the metabolites are
pharmacologically active 65.
Methadone and its metabolites EDDP and EMDP are eliminated in urine and faeces
and are also excreted in saliva and sweat. High concentrations have been detected in
the gastric juices and during pregnancy, methadone concentrations in the placental
cord blood are approximately half the maternal level 59. Methadone levels in saliva
and gastric juice can be as high as 54 and 100 times those measured in blood 66-67,
respectively. Previously, the metabolites could not be detected in whole blood or
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plasma 68, however the primary metabolite, EDDP was detected in whole blood and
its structure confirmed by Ge/MS 66.
-
methadol normethadol
-
methadone EDDP EMDP
/
p-hydroxylation and glucuronide conjugation
Figure 2.2 Metabolism of Methadone
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In patients following a methadone maintenance programme, 20 to 60% of the dose is
excreted in urine over 24 hours. Up to 33% as unchanged methadone and up to 43%
as EDDP, with EMDP accounting for only 5 to 10% of the dose. When comparing
the drug levels of inpatients on a methadone maintenance programme to overdose
cases, the ratio of EDDP to unchanged methadone is lower in the simple overdose
cases 64. The concentration of unchanged drug in urine is pH-dependent, being
greater in acidic urine.
2.1.4 Toxicity
Methadone is one of the strongest opiates, and the combination of its delayed action
and a long half-life, can result in severe respiratory depression which is usually the
cause of death. In addition, muscle flaccidity, cold and clammy skin, pupillary
constriction, hypotension and coma, are all characteristic symptoms of overdosage
with methadone. 63
The minimum lethal dose in non-tolerant adults is estimated at 50mg, while addicts
on a methadone maintenance treatment programme may tolerate doses as high as
200mg or more 64. The lethal dose decreases in the presence of alcohol.
Nelson and Selkirk 69 gave details of 12 fatal methadone poisonings. Two of the
cases had no previous history of methadone abuse and was thought to be the result of
naivete with the injection of narcotic drugs and a lack of tolerance to methadone.
Methadone was found to be solely responsible for the deaths in four of the cases,
with the remainder being ~ttributed to multiple drug overdoses. Only one case
involved an amount of drug other than methadone, consistent with overdose levels.
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Tissue concentrations ranged in liver (0.05 - 2.8~g/g), stomach contents (0 - 7.0~g x
103), gall bladder (4.5-130 ug total), urine (0.2-25.4~g/ml), and blood (trace - 0.3~
g/ml). However, as blood methadone levels were not determined in all the cases, no
firm conclusions could be drawn.
A study carried out by Clark et at 70, of methadone deaths in Sheffield, in the UK,
included details of 18 fatalities between the years of 1991 and 1994. Ten of these
had been in receipt of regular methadone, with seven of the ten having only recently
started taking methadone. Post-mortem blood levels ranged from 200 - 1863ng/ml,
with a mean of 560ng/ml. 16 of the 18 deaths had other drugs present but the
concentrations were low, and methadone was more significant.
In Harris County, Texas, 91 deaths were recorded between January 1987 and
December 1992 with methadone positive post-mortem drug testing. Blood
methadone levels ranged from < 0.02 to ~ O.lmg/dl. However, the authors, Barrett et
at 71, pointed out that there was disagreement as to what constitutes a toxic or fatal
blood methadone level. Irey and Froede 72, gave toxic levels ranging from
0.02mg/dl to 0.45mg/dl. The Harris County Medical Examiner regards toxic levels
to range from 0.1 to 0.2mg/dl, whereas, McBay considers toxic levels to be 0.3mg/dl
or greater 73.
Interpretation of blood methadone levels is very difficult due to drug interaction.
Many methadone positive d~g screens include positives for other drugs, and a given
blood methadone level mayor may not be toxic, depending on the presence of these
drugs, which may augment or counteract the toxic effects of methadone 71.
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Hendra et al 74 reported the case of a 22-year-old man who overdosed on 420mg of
methadone, 3 hours before admittance to a hospital. Femoral methadone blood
concentration was 822ng/ml, stomach contents = 7ng/ml. The following
benzodiazepines were also detected at the respective concentrations, diazepam
(103ng/ml) and nordiazepam (165nglml).
A study of methadone positive fatalities in Strathclyde 10 reported 91% (n = 157) of
cases were positive for at least one other drug. Morphine was detected in almost one
third of decedents enrolled on a methadone maintenance programme. The most
frequently encountered drugs in combination with methadone were diazepam (47%),
temazepam (46%), alcohol (40%), morphine (30%) and cannabis (12%).
2.2 Analysis
Various techniques have been used to detect methadone in biological specimens,
including, immunoassay 75-78, thin-layer chromatography (TLC) 79, high
performance liquid chromatography (HPLC) 80-83, gas liquid chromatography (GLC)
69,84-86, and gas chromatography / mass spectrometry (GCIMS) 75,87-91.
Immunoassay techniques have been used for the determination of methadone in
haemolysed whole blood 76 and serum 77, and have proved useful in a clinical setting
for quantitative urine drug monitoring 78 and rapid measurement of plasma
methadone levels 75 in methadone maintenance programmes. These techniques are
very sensitive but are not specific and cannot distinguish between methadone and it's
two major metabolites.
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Metabolites of Verapamil were reported as causmg false-positive results in a
methadone enzyme immunoassay 92-93. Specific immunoassays for EDDP have been
developed by CEDIA® 94 and help identify methadone false negatives, i.e.
individuals who have a high metabolism (methadone negative, EDDP positive) and
cases where samples have been "spiked" with methadone (methadone highly
positive, EDDP negative).
Rio et at 95, reported a method using high performance liquid chromatography
(HPLC) to analyse methadone, propoxyphene and norpropoxyphene in post-mortem
blood and tissues, which was linear from 0.1 to 10mg/1. Logan et at 40 described a
method using the combination of solid-phase extraction (SPE) and a gradient elution
HPLC system using diode array detection (DAD). HPLC-DAD increased the range
and specificity of HPLC for the screening of 100 basic drugs and metabolites in
urine, which included methadone. However, gas chromatographic methods are by far
the method of choice.
Hartvig and Naslund 96 developed an improved method, usmg electron capture
detection to quantitate the benzophenone produced by the oxidation of methadone.
Several methods have been described for the analysis of urine 68,89,97-99, which did
not require an oxidation step. Schmidt et at 100 were able to analyse urine,
cerebrospinal fluid and plasma using one method, with a limit of quantitation for
methadone of O.Sng/ml.
Early analyses of blood samples involved liquid-liquid extraction (LLE) as sample
pre-treatment, prior to injection onto a gas chromatograph 58,66,101-102. All of these
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methods detected either methadone alone or in conjunction with its pnmary
metabolite, EDDP, but did not include EMDP (secondary metabolite). Thompson et
al 58 determined the recovery of EMDP to be in the range of 30-40%. An
explanation for this was, EMDP is a more active substrate for hydroxylation than
EDDP, and would therefore be conjugated and not detected by this procedure 103.
The analysis ofEMDP was not continued in the above study for the reason stated and
because the metabolite was not detected in the medical examiners cases studied.
Several authors have reported the analysis of EMDP in biological samples other than
blood 66,88,91,104.Quantifiable levels were detected in urine, and in one paper, trace
104
levels, below the limit of quantitation, were detected in rat hair . The recoveries of
104 58
EMDP from hair and whole blood were very low at 53% and 30-40%
respectively.
Detection of methadone and its metabolites in hair has great potential as a means of
monitoring patients compliance on maintenance programmes lOS. Several papers have
reported methods for determining methadone in hair using acidic 106-107or alkaline
digestion 104,108-109,p.glucuronidase110and methanol I11-112.The preferred method of
analysis involves gas chromatography/mass spectrometry with various detectors.
Radioimmunoassays have been used successfully to detect methadone in hair 109,113-
114however the problem of false positives was greater 108.No papers identified
during the literature search reported the use of enzyme immunoassay (EIA) as a
means of detecting methadone in hair, although most EIA kits available for
biological fluid analysis, claim to be able to screen for drugs of abuse in hair.
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Advances in solid-phase extraction have seen the advent of solid-phase extraction
discs. Rudaz et al lIS evaluated the efficiencies of discs and mixed-mode cartridges
with respect to retention, losses during sample loading, washing and elution using
radio labelled methadone. They concluded that the discs did not perform as well as
conventional cartridges caused, in part, by the limited capacity of the discs which
resulted in loss of radiolabelled methadone
Several internal standards (IS) have been used when analysing methadone including,
SKF-S2S-A 58,66,68,97,101, dextropropoxyphene 100 and Chirald 102. Lynn et al 66
synthesised SKF -S2S-A (2-dimethylamino-4,4-diphenyl-S-nonanone), which was
described as the ideal internal standard having several advantages over those
previously described. SKF-S2S-A is chemically similar to methadone, and because of
the basic centre, could be added at the beginning of the extraction procedure.
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2.3 Aims
A great deal of work has been published with respect to the analysis of methadone
and its primary metabolite, EDDP in various biological fluids. However, with the
increase in deaths involving methadone, the development of a robust routine method
for the analysis of methadone and both metabolites (EDDP and EMDP) from whole
blood would be advantageous to the forensic toxicologist. In addition, a method
optimised for both metabolites would aid in the understanding of the mechanisms
involved in the metabolism of methadone.
Following on from previous work 56, the solid-phase extraction method used by Chen
et al 27, was utilised as it was possible to screen for a variety of drugs with different
physicochemical properties. Previous work, using this method, produced methadone
recoveries from whole blood between 82.7 and 89.1% using mixed-mode solid-phase
extraction cartridges.
The mechanisms involved with the drug retention properties of mixed-mode
cartridges was investigated using methadone and its two metabolites extracted from
whole blood on cartridges of differing non-polar character.
Chirald was chosen as the internal standard (IS), as it was commercially available
and had been used successfully in the past for methadone analysis.
The majority of methods reported for the analysis of methadone in hair involved long
and time consuming extraction methods followed by GelMS confirmation. Initially
RIA was used however when compared with GeIMS, RIA identified false positives.
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Although enzyme-immunoassay (EIA) kits are available for detecting drugs of abuse
in hair, no literature was identified reporting relevant research. A methadone specific
EIA kit was obtained from Cozart Bioscience Limited (Oxfordshire, UK) and was
investigated as an alternative means of detecting methadone in hair samples. Of
particular interest was the detection of methadone in post-mortem hair obtained from
known drug users. Obtaining additional information from segmental hair analysis
could potentially provide a complimentary technique to post-mortem blood analysis
or as an alternative when blood is not available.
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2.4 Experimental
2.4.1 Chemicals
Methadone, EDDP and Chirald ((2S,3R)-(+)-4-Dimethylamino-I,2-Diphenyl-3-
Methyl-2-Butanol) were obtained from Sigma@ Chemical Co., (Dorset, UK). EMDP
was obtained from Alltech Associates (State College, PA) and deuterated, d3-
methadone, was obtained from High Standard Products Corporation (Inglewood,
CA). HPLC-grade methanol, acetone, chloroform and ethyl acetate were obtained
from Lab-Scan Analytical Sciences (Dublin, Ireland). Analytical-grade ammonium
hydroxide and glacial acetic acid and HiPerSolv grade potassium-dihydrogen
phosphate (KH2P04) were obtained from Merck (Poole, UK).
2.4.2 Stock Standards
Individual stock standard solutions (lmg/ml) of methadone, EDDP and EMDP were
prepared in methanol. Combined working solutions of all three drugs were prepared
in methanol at various concentrations (100, 10, 1ug/ml) by appropriate dilution of
the stock standard. Blood samples were spiked by evaporating 100)lL of the working
solution to dryness under a stream of nitrogen at room temperature and reconstituting
in lrnl of drug free whole blood or buffer before sonicating for 5 minutes. The
internal standards, Chirald and dj-methadone, were prepared in methanol to give
stock standard solutions of Img/ml, Working solutions of Chirald (Jug/ml) and d3-
methadone (Iug/ml) were prepared by dilution of stock standards with methanol.
All stock and working solutions were stored at -20°C.
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2.4.3 Instrumentation
2.4.3.1 Gas Chromatography
A Hewlett-Packard model 5890 Series II gas chromatograph equipped with a flame
ionisation detector (GC-FID) was used for recovery studies. A Hewlett-Packard, HP-
1, cross-linked methyl siloxane capillary cartridge,(30m, 0.25mm i.d., film thickness
0.25Ilm) was installed. The initial oven temperature of 80°C was held for 2 minutes.
The temperature was increased to 215°C at a rate of 20°C/min. and then to a final
temperature of 285°C at a rate of 5°C/min. and held for 2 min. at 285°C. The total
analysis time was 24.75 min. The injector and detector temperatures were 275°C and
310°C, respectively. Helium was used as the carrier gas. Injections of 21lL were
carried out in the splitless mode. Hewlett Packard ChemStation B.02.04 computer
software was used for data collection and processing.
2.4.3.2 Gas Chromatography - Mass Spectrometry
A Fisons model GC8000 series fitted with a HP-l capillary cartridge was used for
case sample analysis. The initial column temperature of 100°C was increased to 300°
C at a rate of 15°C/min. and held for 5 minutes. The injector temperature and
interface temperature were 280°C and 250°C, respectively. The carrier gas was
Helium. Injections were performed in the splitless mode.
The GC8000 was interfaced to a Fisons MD800 mass spectrometer and was operated
in the electron - ionisation mode at 70eV. The ion source temperature was 250°C
and the trap current was 70IlA. Selected ion monitoring data was collected using a
Lab Base 2, Release 2.11 data system. The ions monitored were mlz 72*, 165, 294
(methadone), mlz 178, 220, 277* (EDDP), mlz 178, 193, 208* (EMDP) and mlz
Application a/Solid-Phase Extraction/or the Analysis 0/Drugs in Biological Matrices
Chapter Two: Methadone Page 38
75(d3-methadone). The ions labelled n*n were used for quantitation. lul, injections
were carried out using a Fisons AS800 autosampler.
2.4.4 Chirald «2S,3R)-( +)-4-Dimethylamino-l ,2-Diphenyl-3- Methyl-2- Butanol)
(2S,3R)-( +)-4-Dimethylamino-l ,2-Diphenyl-3-Methyl-2-Butanol (Chirald) was
chosen as the internal standard due to its similar physical and chemical properties to
methadone, EDDP and EMDP. Chirald is commercially available and has been used
previously as an internal standard for the analysis of methadone in whole blood
samples 102. (see figure 2.3)
II
II
Figure 2.3 (2S,3R)-( +)-4-Dimethylamino-l ,2-Diphenyl-3-Methyl-2-Butanol
(Chirald)
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2.4.5 Optimisation of GLC Drug Separation
2.4.5.1 Experimental
An HP-l capillary cartridge (30m x 0.25mm i.d., 0.251lm film thickness) was used as
it had been shown previously to produce good retention and peak shape for
methadone 56.
Three different temperature programmes were investigated to determine the optimum
separation of methadone, EDDP, EMDP and Chirald (IS). These programmes are
summarised in Table 2.2.
Table 2.2 Temperature Programmes Used for Optimal Drug Separation
Programme Initial Temp. Rate Final Total Run
eC) Temp. eC) Time (mins.)
1 100 (2 mins.) 20°C/min. 290(2mins.) 13.5
2 100 (2 mins) 230°C (20°C/min.) ~ 290(2mins. ) 20
240°C (2°C/min.) ~
290°C (20°C/min.)
3 80 (2 mins.) 215°C (20°C/min.) ~ 285(2mins.) 24.75
285°C (5°C/min.)
2.4.5.2 Results and Discussion
The retention times of all four analytes at each of the temperature programmes are
summarised in Table 2.3.
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Table 2.3 Retention Times of Analytes at Temperature Programmes
Programme Retention Times (Rt - minutes)
EMDP EDDP Chi raid Methadone
1 8.946 9.428 9.547 9.993
2 8.978 9.596 9.767 10.521
3 9.049 9.760 9.951 10.745
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Figure 2.4
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Chromatogram showing baseline separation between EMDP, EDDP,
Chirald and methadone.
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As can be seen more clearly in Figure 2.4, the separation between Chirald (IS) and
EDDP (ED) is of greater importance as both EMDP (EM) and methadone (M) show
good baseline separation. Although temperature programme 3 has the longest run
time, the baseline separation between Chirald (IS) and EDDP (ED) with this
programme is better.
A combination of good analyte separation and short run time is ideal. The run time
could be shorter, however this programme was utilised in previous work 56 for the
screening of several basic drugs from whole blood. The possibility that this method
could be used in future work for screening a wide range of basic drugs was more
favourable to a shorter analysis time.
2.4.6 Retention Indices
2.4.6.1 Experimental
The retention indices were determined for each of the four analytes using a mixture
of seven alkanes (CI5, CIS, C20,C22,C24,C26)prepared in hexane. The retention index
(RI) is related to the retention time, but is more reliable and more useful for
comparability and reproducibility of retention data. 1J.lI was injected onto the GC
using the optimised temperature programme.
The retention index RI(A) of a compound A can be calculated using the following
equation:
10g[t(A) + t(X)]
RI(A) = [RI(Y) - RI(X)] + RI(X) .......... (1)
10g[t(Y) + t(X)]
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where,
teA) = net retention time of substance A
t(X) = net retention time of the n-alkane CxH2x+2 eluting immediately before A
t(Y) = net retention time of the n-alkane CyH2y+2 eluting immediately after A
RI(A), RI(X), etc. = retention index of substances A, X, etc ...
2.4.6.2 Results and Discussion
The calculated retention indices are summarised in Table 2.4 along with the average
retention times from multiple analyses (n = 6). Unfortunately no retention indices are
noted in the literature for EMDP, EDDP or Chirald for comparison.
Table 2.4 Retention Indices
Analytes Retention Index Calculated RI Average Rt
116 (Eqn.l) (mins.)
EMDP - 1944 9.051
EDDP - 2036 9.763
Chirald - 2059 9.952
Methadone 2145 2148 10.747
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2.4.7 Reproducibility of Retention Times
2.4.7.1 Experimental
An assessment of the reproducibility of retention times was carried out. 1ul of a
methanolic standard mixture of EMDP, EDDP, Chirald and methadone (2mg/l) was
injected six times.
2.4.7.2 Results and Discussion
The mean retention time, standard deviation (Std. Dev.) and coefficient of variation
(%C.V) were calculated for each analyte and are summarised in Table 2.5.
Table 2.5 Reproducibility of Retention Times
Run EMDP EDDP Chirald Methadone
1 9.049 9.760 9.951 10.745
2 9.050 9.762 9.951 10.746
3 9.051 9.762 9.952 10.747
4 9.050 9.762 9.951 10.746
5 9.052 9.764 9.953 10.747
6 9.053 9.765 9.955 10.750
Mean 9.051 9.763 9.952 10.747
Std Dev. 0.0015 0.0018 0.0016 0.0017
%C.V. 0.016 0.018 0.016 0.016
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The coefficients of variation are extremely low in each case indicating excellent
reproducibility.
2.4.8 Evaporation Study
2.4.8.1 Experimental
The absolute recoveries of methadone, EDDP and EMDP were determined after
evaporating the standard mixture to dryness at 40°C. lOOJ.llof the working solution
(1ug/ml) was evaporated to dryness and then reconstituted in lOOJ.lIof the internal
standard working solution (1ug/ml). The absolute recovery of Chirald (IS) was
determined by evaporating lOOJ.llof the working solution (lug/ml) to dryness and
then reconstituted in lOOJ.llof the standard mixture (lug/ml).
Peak area ratios (P.A.R.'s) were determined for EMDP, EDDP and methadone in
relation to the internal standard, Chirald. The P.A.R. 's for each sample were
compared to that of the standard to determine the analyte recoveries. The recoveries
of Chirald were determined in comparison to EDDP.
In addition, the relative recovenes were determined for each analyte after
evaporation of a standard containing methadone, EDDP, EMDP and Chirald at 40°C
and 50°C. The samples were reconstituted in 2ml, 2% ammoniated ethyl acetate and
were evaporated to dryness at each temperature to determine the extent of analyte
loss. The samples were finally reconstituted in IOOJ.llethyl acetate.
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2.4.8.2 Results and Discussion
The absolute recoveries determined at 40°C are summarised in Table 2.6.
Table 2.6 Absolute Recoveries of Methadone, EDDP, EMDP and Chirald (IS)
Sample EMDP EDDP Methadone Chirald (IS)
1 102 99.6 101 99.2
2 99.8 98.9 102 99.0
3 101 100 100 98.6
Mean 101 99.S 101 98.9
Std. Dev. 1.1 0.6 1.0 0.3
C.V. (%) 1.1 0.1 0.1 0.03
All analytes were stable after evaporation at 40°C.
The relative recoveries obtained at 40°C and SO°C are summarised in Tables 2.7 and
2.8 respectively.
The average recoveries at 40°C were greater than 94.1% with very low coefficients
of variation. However, at SO°C the recoveries ranged from 86.0 to 117% with higher
coefficients of variation (> 3.23%). At SO°C there was greater loss of both EMDP
and Chirald. As a consequence, evaporation of samples containing EMDP, EDDP,
Chirald and methadone was conducted at 40°C.
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Table 2.7 Analyte Recoveries at 40°C
Sample EMDP EDDP Methadone
1 98.5 93.6 103
2 98.3 94.2 103
3 98.6 93.6 103
4 95.9 94.0 103
5 101 95.0 105
Mean 98.5 94.1 103
Std. Dev. 1.81 0.58 0.89
C.V.(%) 1.83 0.61 0.87
Table 2.8 Analyte Recoveries at 50°C
Sample EMDP EDDP Methadone
1 85.8 115 107
2 85.6 113 109
3 75.7 116 109
4 104 123 130
5 79.0 117 109
Mean 86.0 117 113
Std. Dev. 10.95 3.77 9.65
C.V.(%) 12.7 3.23 8.56
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2.5 Whole Blood
2.5.1 Development of Extraction Procedure
The extraction method developed by Chen et al 27 was used successfully to extract
methadone from whole blood using the experimental mixed-mode solid-phase
extraction cartridges which are also investigated in this project 56. The extraction was
carried out using O.lM phosphate buffer at pH6 and pH7.4. The results are
summarised in Table 2.9.
Table 2.9 Percentage Methadone Recoveries from Whole Blood (n = 6) 56
Cartridge pH6.0 pH7.4
% Std. Dev. % Std. Dev.
HCX 89.1 2.1 98.4 1.2
HCX-2 84.8 3.3 102 1.0
HCX-3 88.3 3.5 84.7 2.4
HCX-4 86.9 1.6 60.4 3.6
These experiments were repeated using whole blood spiked with EMDP, EDDP and
methadone (1ug/ml), to determirte the optimum extraction conditions.
2.5.2 Solid-Phase Extraction of Whole Blood
2.5.2.1 Experimental
Analyte recoveries were determined for EMDP, EDDP and methadone using the
methods developed in previous work 56. This involved spiking whole blood and
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extracting the analytes of interest from the blood using the experimental mixed-mode
solid-phase extraction cartridges. O.IM phosphate buffer was used at pH6 and pH7.4.
Chirald was used as the internal standard and was added to the extraction solvent
prior to evaporation. The percentage recoveries were determined by comparing the
peak area ratios for the spiked samples to the unextracted standard.
2.5.2.2 Results and Discussion
The recoveries of EMDP, EDDP and methadone from whole blood were determined
at pH6 and pH7.4 and the results are summarised in Tables 2.10 and 2.11.
Table 2.10 Extraction Recoveries from Whole Blood (pH6)
Cartridge EMDP EDDP Methadone
HCX 38.4 83.1 94.0
HCX-2 36.2 84.5 93.4
HCX-3 40.1 88.5 99.3
HCX-4 39.2 76.9 87.5
Mean 38.5 83.3 93.6
Std. Dev. 1.67 4.81 4.83
C.V.(%) 4.3 5.8 5.2
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Table 2.11 Extraction Recoveries from Whole Blood (PH7.4)
Cartridge EMDP EDDP Methadone
HCX 72.7 98.9 107
HCX-2 69.0 86.3 105
HCX-3 68.0 90.0 108
HCX-4 69.5 95.4 105
Mean 69.8 92.7 106
Std. Dev. 2.03 5.60 1.50
C.V.(%) 2.9 6.0 1.4
The increase in average recoveries from using pH6 to pH7.4 phosphate buffer is
more pronounced than was evident in previous work (See Table 2.9). Possible
explanations for this include:
• Lot-to-lot improvement
• Improvement of extraction technique
• Freshness of buffer
The recommended shelf-life of phosphate buffer is one month. However, significant
loss in recoveries with buffers older than three to four weeks was observed. The
example summarised in Table 2.12 compares the average recoveries for EMDP,
EDDP and methadone for HeX-3 mixed-mode cartridges with fresh buffer and
buffer prepared four weeks earlier.
Application a/Solid-Phase Extraction/or the Analysis a/Drugs in Biological Matrices
Chapter Two: Methadone Page 50
Table 2.12 Comparison of extraction recoveries using fresh and four week old
phosphate buffer (pH7.4, O.IM)
Analyte Fresh Buffer 4 Week Old Buffer
EMDP 68.0 7.1
EDDP 90.0 73.8
Methadone 108 87.8
Subsequently phosphate buffer was discarded after two weeks and always stored in a
refrigerator until the expiry date.
In order to optimise the extraction conditions, the recoveries were noted for EMDP,
EDDP and methadone from whole blood using O.IM phosphate buffer over a range
of pH values.
2.5.3 Effect of pH
2.5.3.1 Experimental
Analyte recoveries were determined from spiked whole blood at six different pH
values (6, 7.4, 8, 9, 10 and 11). This was carried out using each of the experimental
mixed-mode SPE cartridges.
2.5.3.2 Results and Discussion
The average recoveries (n=3) for each analyte are summarised in Tables 2.10, 2.11
and 2.13 to 2.16.
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Table 2.13 Extraction Recoveries from Whole Blood (PH8)
Cartridge EMDP EDDP Methadone
HCX 88.2 89.6 100
HCX-2 93.3 93.9 98.0
HCX-3 89.0 82.1 85.4
HCX-4 98.4 91.1 99.8
Mean 92.2 89.2 95.8
Std. Dev. 4.69 5.04 6.99
C.V.(%) 5.1 5.7 7.3
Table 2.14 Extraction Recoveries from Whole Blood (PH9)
Cartridge EMDP EDDP Methadone
HCX 86.7 71.7 102
HCX-2 81.5 60.8 101
HCX-3 75.8 65.2 103
HCX-4 87.3 68.4 102
Mean 82.8 66.5 102
Std. Dev. 5.36 4.65 0.82
C.V.(%) 6,5 7.0 0.8
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Table 2.15 Extraction Recoveries from Whole Blood (PHI0)
Cartridge EMDP EDDP Methadone
HCX 89.7 55.9 107
HCX-2 77.8 49.3 99.6
HCX-3 72.5 57.9 103
HCX-4 84.2 59.6 99.5
Mean 81.1 55.7 102
Std. Dev. 7.49 4.51 3.55
C.V.(%) 9.2 8.1 3.5
Table 2.16 Extraction Recoveries from Whole Blood (PHil)
Cartridge EMDP EDDP Methadone
HCX 71.3 71.7 102
HCX-2 82.2 60.8 101
HCX-3 62.5 65.2 103
HCX-4 76.2 68.4 102
Mean 73.1 66.5 102
Std. Dev. 8.33 4.65 0.82
C.V.(%) 11.4 7.0 0.8
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There is little variation in recoveries between cartridges at each pH, represented by
the relatively low standard deviations and coefficients of variation for each analyte
summarised in Tables 2.10, 2.11, 2.13-2.16.
Table 2.17 Effect of pH on Mean Extraction Recoveries
pH EMDP EDDP Methadone
6 38.5 83.3 93.6
7.4 69.8 92.7 106
8 92.2 89.2 95.8
9 82.8 66.5 102
10 81.1 55.7 102
11 73.1 34.6 89.1
Mean 72.9 70.3 98.1
Std. Dev. 18.61 22.5 6.31
C.V.(%) 25.5 32.0 6.4
Each of the average recoveries was the result of triplicate analyses. Methadone was
least affected by the changes in pH compared with EDDP and EMDP. Table 2.17
summarises the mean recoveries obtained using all four mixed-mode cartridges at
each of the pH values.
In order to obtain the optimum recoveries for all three analytes, phosphate buffer at
pH8 was utilised in the extraction method. The effects of pH on the recoveries of
EMDP, EDDP and methadone from whole blood, is illustrated in Figure 2.5.
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Figure 2.5
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Optimisation of extraction pH for EMDP, EDDP and methadone.
2.5.4 Analysis of Fraction B Only
The total analyte recovery was determined by analysing Fractions A and B separately
and adding the recoveries. Although this resulted in a lengthy analysis time for each
extraction, combining Fractions A and B before evaporation resulted in significantly
lower recoveries of all three analytes. Chen et al 26 reported similar results when
combining the two fractions. When the two fractions were combined after
evaporation, that is, reconstituting Fraction Bin 50J.lLof ethyl acetate and then using
this volume to reconstitute Fraction A, the recoveries were still unacceptably low.
The total percentage recoveries of EMDP, EDDP and methadone were compared to
the % recoveries obtained in Fraction B alone. Table 2.18 summarises the recoveries
using HCX-2 cartridges and pH8 phosphate buffer.
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Table 2.18 Percentage Recoveries of Methadone, EDDP and EMDP using Isolute
Confirm HCX-2* at pH 8.
pH8 Total (A +B)t Fraction B Only
Methadone 98.4 ± 4.4 98.4 ± 4.4
EDDP 91.0 ± 5.1 82.0 ± 0.6
EMDP 93.1 ± 0.9 81.0 ± 1.4
* n=3
t Fraction A +Fraction B
The recoveries were greater than 80% for all three analytes in Fraction B alone.
Analysing only Fraction B, decreased analysis time by half without jeopardising
extraction reproducibility.
2.5.5 HCX-S and HCX-6 Mixed-Mode Cartridges
2.5.5.1 Experimental
Two additional experimental mixed-mode SPE cartridges were manufactured prior to
the completion of this project. The sorbent mixture in these two cartridges contains
different non-polar character to the other mixed-mode cartridges investigated in this
project. HCX-5 and HCX-6 contain C4 and C6 non-polar phases respectively.
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Analyte recoveries were determined for EMDP, EDDP and methadone as described
under section 2.5.2.1. The extraction was carried out using pH8 phosphate buffer
(O.lM) and only Fraction B was analysed.
2.5.5.2 Results and Discussion
The recoveries ofEMDP, EDDP and methadone from whole blood were determined
at pH8 and the results are summarised in Table 2.19.
The mean, standard deviation (Std. Dev.) and coefficient of variance (% C.V) are
also reported for each triplicate analyses.
Table 2.19 Extraction Recoveries from Whole Blood Using HCX-5 and HCX-6
HCX-5 HCX-6
Sample EMDP EDDP Methadone EMDP EDDP Methadone
1 81.3 79.1 97.2 65.5 82.4 101
2 89.3 83.8 101 77.8 80.4 101
3 81.7 88.4 105 66.9 80.0 96.0
Mean 84.1 83.8 101 70.1 80.9 99.3
Std. Dev. 4.51 4.65 3.90 6.73 1.29 2.89
C.V (%) 5.4 5.5 3.9 9.6 1.6 2.9
The recoveries obtained for HCX-5 were slightly better than with HCX-6 for each of
the analytes. In all cases the coefficients of variance are low (~ 9.6%) and are
acceptable for the present work.
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2.5.6 Effect of Carbon Loading on Analyte Recoveries
2.5.6.1 Introduction
Hartley et al 117 reported the recoveries of chlormethiazole from plasma using solid-
phase extraction. As part of their investigations they noted the different recoveries
obtained with Sep-Pak C18 and Bond Elut Cl, Cz, C4, C6, c, and CIS single-phase
cartridges. They concluded that the recoveries were not primarily affected by the
carbon number, which was secondary to the percentage carbon loading of the bonded
phase.
This was investigated using the results obtained during this project for mixed-mode
SPE cartridges in comparison to the single phases used by Hartley et all17 •
2.5.6.2 Results and Discussion
The recoveries of EMDP, EDDP and methadone using pH 8 phosphate buffer are
summarised in Table 2.20. The SPE cartridges have been listed in order of
decreasing carbon number in an attempt to assess the relationship between the
recoveries obtained for each analyte and the percentage carbon loading of the bonded
phase.
With the exception of HCX, as the carbon number decreases the percentage carbon
loading also decreases. There' does not appear from the data presented, to be any
obvious relationship between either factors and the recoveries obtained from whole
blood for EMDP, EDDP or methadone.
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Table 2.20 Carbon Loading and Analyte Recoveries
Cartridge Cn % Loading EMDP EDDP Methadone
HCX-3 18 13.5 87.9 82.1 85.4
HCX-2 12 12.1 81.0 82.0 98.4
HCX-4 8(Std)* 9.7 92.2 85.7 99.8
HCX-6 6 8.1 70.1 80.9 99.3
HCX 8(Non-Std) t 7.5 85.6 87.9 100
HCX-S 4 6.1 84.1 83.8 101
* Std - HCX-4 contains standard C8 non-end capped sorbent
t Non-Std - HCX contains non-standard low carbon loading C8 non-end capped
sorbent.
2.5.7. Establishment of Extraction Procedure
The optimised extraction method for the analysis ofEMDP, EDDP and methadone in
whole blood involves mixed-mode SPE cartridges and pH 8 phosphate buffer
(D.1M).
Not all case samples involve toxic to fatal levels therefore an alternative detector
with greater sensitivity is required. Gas chromatography - mass spectrometry was
employed and the extraction method validated.
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2.5.8 GCIMS Analysis
2.5.8.1 Experimental
Individual unextracted standards (Iug/ml) were analysed by GCIMS (Iul.) in the full
scan mode. Full mass fragment spectra for EMDP, EDDP, methadone and
methadone-d, was obtained. The object of obtaining the full spectra was to identify
the compounds of interest and to determine the optimum fragment ions for
monitoring purposes.
Once the correct ions for monitoring were identified, a selected ion monitoring
programme was created to increase the sensitivity of the method.
2.5.8.2 Results and Discussion
Figures 2.6 to 2.9 illustrate the full mass fragment spectra for EMDP, EDDP,
methadone, and methadone-de
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The ions monitored were m1z 178, 193, 208* for EMDP, m1z 178, 220, 277* for
EDDP, m1z 72*, 165, 294 for methadone and m/z 75 for methadone-dj. The ions
labelled with an asterix were used for quantitation.
2.5.9 Validation of Extraction Method
2.5.9.1 Experimental
Validation of the developed method involved carrying out linearity studies over a
concentration range of 0 to 0.6mg/1 and 0.5 to 5 mg/l. Aliquots of the stock standard
solutions were evaporated to dryness under a stream of nitrogen at 40°C and
reconstituted in 1ml of whole blood. The resultant samples were spiked at
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concentrations of 0, 5, 10, 50, 200, 400 and 600ng/ml and 0.5, 0.75, 1.25, 2.50 and
Smg/I for EMDP, EDDP and methadone in blood.
The internal standard (methadone-d.) was added to the samples at a concentration of
O.lmg/1 (0 to 0.6mg/l) and 0.5mg/1 (0.5 to Smg/l). Peak area ratios (mz 208/75 for
EMDP, mz 277/75 for EDDP and mz 72/75 for methadone), obtained at each
concentration were plotted as a calibration curve against their respective
concentration. Each data point was the mean of triplicate analyses.
2.5.9.2 Results and Discussion
Calibration curves for each of the three analytes were linear over the concentration
ranges, 0 to 0.6mg/1 and 0.5 to 5mg/1. The limit of detection was 5ng/ml at a signal-
to-noise ratio of 3: 1.
The results are summarised in Table 2.21. Figures 2.10 and 2.11 illustrate the linear
relationship between EMDP, EDDP and methadone over the concentration ranges, 0
to 0.6mg/1 and 0.5 to Smg/l respectively.
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Table 2.21 Linearity and Limits of Detection
Analyte Concentration r Limits of
Range (mgll) Detection (nglml)
EMDP 0~0.6 0.997 5
0.5 ~ 5.0
EDDP 0~0.6 0.999 5
0.5 ~ 5.0
Methadone 0~0.6 0.994 5
0.5 ~ 5.0
r - correlation coefficient
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Figure 2.10 Calibration Curves for EMDP, EDDP and methadone (0 to 0.6mg/l)
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2.6 Hair Analysis
2.6.1 Introduction
The ability to detect drugs in hair has enormous potential particularly with respect to
post-mortem hair samples, an area not commonly investigated.
In many cases the drug use history of the deceased is either not known or not
available for the investigation of the death. The drug levels detected in blood provide
valuable information regarding the short-term drug use of the decedent prior to death.
Segmental analysis of hair could be a possible source of additional information on
antecedent drug use history, which would aid in the interpretation of the analytical
findings and ultimately the cause of death.
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Amphetamine, methamphetamine 118 and codeine 119 were detected in root hairs 30
minutes after administration. Nakahara and Kikura 120 reported MDMA in the root
bulb of rat hair five minutes after administration. By collecting post-mortem hair
samples pulled from the scalp, it was possible to analyse the root bulb and investigate
the relationship between the drug levels detected in blood and those found in the root
bulb at the time of death.
Initially methanolic extraction's of hair spiked with methadone were screened using
enzyme immunoassay kits supplied by Cozart Bioscience Limited (Oxfordshire,
UK), then post-mortem hair samples were analysed by the described method.
2.6.2 Enzyme Immunoassay Screen
2.6.2.1 Introduction
The Cozart methadone microplate used for the EIA screening of hair samples spiked
with methadone was intended for use in the "qualitative and semi-quantitative
determination of methadone in serum or whole blood". The manufacturers
recommend adapting these kits for hair by substituting spiked hair samples at known
concentrations for the four protein matrix calibrators included in the kit. In addition
they recommend adding 50llL of hair extract to the sample wells as opposed to 251lL
added for serum or blood.
2.6.2.2 Immunoassay
The methadone microplate kits supplied by Cozart Bioscience Limited are
competitive immunoassays. Horseradish peroxidase labelled drug competes with
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unlabelled drug in the sample for antibody sites in wells on a polystyrene plate.
Excess enzyme is removed by washing after a 30 minute incubation period and then
substrate is added which produces a blue colour. The stop solution is added after a
further 30 minutes to produce a yellow colour and the absorbance is measured at
450nm. The absorbance is inversely proportional to the quantity of drug in the
sample.
2.6.2.3 Sample Preparation
Blank hair, washed and ground prior to use, was spiked with methadone at a
concentration of approximately lOOng/mg. This was achieved by adding lml of
methadone (IOug/ml in methanol) to 100mg of hair. A sample weight of 10 - 20mg
was required and to each hair sample was added O.Smlmethanol. Samples were
sonicated for one hour after containers were sealed with parafilm and incubated
overnight at 45°C.
The incubated samples were allowed to cool before decanting the methanol extract
into a clean vial and evaporating to dryness under a stream of nitrogen at 40°C. The
extract was reconstituted in 1ml of phosphate buffer saline (pH7.6).
Experiments were conducted. to determine whether or not hair spiked with
methadone could be detected by EIA, did not cause false positives and to assess the
use of reference hair standards for calibration controls.
2.6.2.4 Experiment A
Nine hair samples of varying concentration and one blank were prepared for EIA
screening as previously described. Table 2.22 summarises the hair weights,
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concentration of methadone present in the samples corrected for hair weight and the
EIA response.
Table 2.22 Experiment A - Summary of Hair Weights, Drug Concentrations and
EIA Response.
Sample Weight (mg) Concentration EIA Response
(ng)* (nglml)
1 10.04 1002 Too high+
2 10.43 100 66.43
3 10.24 10.0 Negative
4 10.24 1041 Too high
5 10.28 104 56.39
6 10.47 10.4 Negative
7 10.49 1022 Too high
8 10.78 102 77.70
9 10.17 10.2 Negative
Blank 10.37 0.0 Negative
* Concentrations (ng) corrected' for weight were done so by multiplying the sample
weight (mg) by the concentration of the hair spike (ng/mg).
t Too high - Indicated the sample was positive but at a level exceeding the highest
calibrator.
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The concentrations of methadone detected in hair were calculated with respect to the
serum calibrators supplied with the EIA kit (0, 5, 25 and 100ng/ml). The maximum
(Samples 1,4 and 7) and minimum (Samples 3, 6, 9) spiked hair concentrations were
above and below the highest and lowest serum calibrators. However, it was possible
to detect methadone in hair and the blank sample was negative, tentatively indicating
that no interferences were causing a false positive response.
The next step was to repeat experiment A with hair samples spiked over a greater
range of methadone concentrations.
2.6.2.5 Experiment B
Eight hair samples of varying concentration and one blank were prepared for EIA
screening as previously described. This experiment was conducted in triplicate and
the results are summarised in Table 2.23 for each sample.
Only nine samples of concentrations ranging from 5 to 26.3 ng were within the
highest and lowest serum calibrators and gave a positive response. All blank samples
gave a negative response. Three samples (50, 51.1 and 52.6ng) were positive for
methadone but the response was higher than the maximum calibrator.
The experiments thus far have involved hair spiked with methadone. To determine
whether or not methadone could be extracted and detected by EIA from drug users
hair, two post-mortem case samples were analysed where the deceased were known
to have used methadone prior to death.
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Table 2.23 Experiment B - Hair Concentrations and Corresponding EIA
Response Using Serum Calibrators
Batch A Batch B Batch C
Conen. Response Conen. Response Conen. Response
(ng) (ng/ml) (ng) (nglml) (ng) (nglml)
51.5 Too High 52.6 Too High 50.0 Too High
25.7 46.9 26.3 87.6 25.0 45.5
10.3 25.7 10.5 39.2 10.0 26.2
5.1 8.1 5.3 12.9 5.0 9.3
2.6 -ye 2.6 -ve 2.5 -ve
1.0 -ye 1.1 -ve 1.0 -ve
0.5 -ye 0.5 -ye 0.5 -ve
0.1 -ve 0.1 -ye 0.1 -ye
Blank A -ve BlankB -ve Blank C -ve
2.6.2.6 Experiment C
Two case samples (OC02 and OC03 - refer to Chapter 6 for case information) were
cut into segments prior to analysis. In both cases the hair samples were de-rooted.
OC02 was analysed in 3 segments: root (R), 1st 3cm (A) from root and in bulk (B).
(The bulk sample included the full hair sample with roots still attached). OC03 was
analysed in one segment only, the roots (R). Two spiked hair standards and one
blank were analysed in addition to the case samples.
Table 2.24 summarises the segments analysed and the results of the EIA screen
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Table 2.24 Experiment C - EIA Response Values Using Serum Calibrators
Sample Weight (mg) Response (nglml) Conen. (nglmg)
Standard 1 10.58 412.4 10.8
Standard 2 19.97 146.4 5.4
Blank (A) 16.16 -ve 0.0
GC02 (R) 17.75 Too high Too high
GC02 (A) 80.62 393.2 10.3
GC02 (B) 132.17 Too high Too high
GC03 (R) 53.19 48.3 1.3
Blank (B) 18.29 -ve 0.0
GC02 (R) * 17.75 312.7 40.9
GC02 (B) * 132.17 126.1 16.5
* The extracts of samples, GC02 (R) and GC02 (B) were diluted 1:5 with phosphate
buffer saline and re-analysed by EIA. The resultant EIA response was multiplied by
five prior to calculating the methadone concentration.
Using the supplied serum calibrators for quantitating methadone hair concentrations
was too restrictive. Hair spiked with methadone at four different concentrations was
investigated as alternative calibrators.
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2.6.2.7 Experiment D
Hair spiked calibrators were prepared at four concentrations: 0, 1, 10 and 100ng/mg
with equivalent nanogramme concentrations of 0, 24.5, 224 and 2576 nanogrammes.
In addition, 13 post-mortem cases were analysed. Table 2.25 summarises the data
and results from Experiment D.
The limit of detection for this assay was 24.5ng, based on a spiked hair calibrator
(24.03mg; 1.02ng/mg). A large proportion of the cases which were negative had
sample weights below 20mg, and may explain the number of false negative results.
All blank samples gave negative responses.
Table 2.25 Experiment D - Data and Results Summary
Sample Segment Weight(mg) Response (ng) Conen. (nglmg)
GCOI Root 20.75 -ve -ve
Bulk 35.16 -ve -ve
GC04 Bulk (W)* .. 50.04 113.5 2.3
Bulk (UW)t 38.55 963.4 25.0
GC05 1" 3cm 3.68 -ve -ve
Bulk 5.79 -ve -ve
GC07 Root 12.39 -ve -ve
Bulk 24.73 27.1 1.1
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Sample Segment Weight(mg) Response (ng) Conen. (nglmg)
GC08 Root 4.01 -ve -ye
Bulk 24.58 -ye -ye
GCll Root 4.90 -ye -ye
1"6cm 26.99 -ye -ve
2"U 6cm 11.78 -ve -ve
Bulk At 39.73 45.2 1.1
Bulk B§ 48.45 29.5 0.6
GC13 Root 4.80 -ye -ye
1S[ 3cm 45.35 46.7 1.0
Bulk 38.02 -ye -ye
GC16 1S[ 6cm 32.18 -ve -ye
2"06cm 23.93 30.5 1.3
Bulk 39.67 34.3 0.9
GC24 Bulk 46.80 418.7 8.9
GC27 Root 6.16 179.1 29.1
Bulk 27.25 479.8 17.6
GC30 Root 4.84 -ve -ye
Bulk 8.79 -ye -ye
GC35 Root 4.40 -ye -ye
Bulk 44.74 -ye -ve
GC36 Root 3.89 72.17 18.6
Bulk 43.60 139.5 3.0
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2.6.2.8 Discussion
It is difficult to interpret the results from Experiments A to D, as the EIA assay
functions primarily as a qualitative determination of methadone in serum or whole
blood. However, it can be concluded that the serum/whole blood EIA kit as adapted
could detect the presence of methadone in spiked hair and post-mortem case samples.
2.7 Conclusion
The ability to identify and confirm the presence of methadone and its two major
metabolites (EDDP and EMDP) in whole blood has been achieved using the
combination of solid-phase extraction and gas chromatography - mass spectrometry.
An optimal buffer pH of 8.0 was determined by comparing the percentage recoveries
obtained for each analyte following solid-phase extraction at six different pH values
(6.0, 7.4, 8.0, 9.0, 10.0, 11.0). Chirald was used as the internal standard. In addition,
the analysis time of the extraction was decreased significantly. The original method
27, involved collection of two eluates, however, optimising the pH enabled the
developed method to require only one eluate resulting in a faster and more
reproducible extraction method.
The resultant method was validated and was linear over a concentration range of 0 to
0.6mg/1 and 0.5 to 5 mg/l, The limit of detection for each analyte was 5ng/mi. The
concentration range and limit of detection were more than adequate for the routine
analysis of methadone, EDDP and EMDP in post-mortem blood samples and was
successfully applied to 46 forensic case samples. None of the 46 cases were positive
forEMDP.
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In general, as the carbon number of the mixed-mode solid-phase extraction cartridges
decreases so does the percentage carbon loading. Investigating the results obtained
for methadone, EDDP and EMDP, the percentage recoveries obtained do not appear
to be affected by either the carbon number or the percentage loading. This is in
contrast to the observation reported by Hartley et al 117 who concluded that the
recoveries of chlormethiazole from plasma using single-mode cartridges were not
primarily affected by the carbon number, which was secondary to the percentage
carbon loading of the bonded phase.
The importance of the percentage carbon loading and carbon number may depend on
the analytes in question and/or the sample matrix, however, in the case of
methadone, EDDP and EMDP in whole blood the pH of the extraction system is the
main factor determining high recoveries.
Adapting the Cozart methadone microplate for screening hair samples spiked with
methadone was achieved and the matrix did not appear to cause any interferences.
All blank samples gave a negative response. However, spiking hair results in hair
with surface bound drugs, which are easily removed and do not replicate the complex
binding involved with drug users hair.
In total, 15 post-mortem hair samples were segmented and screened for methadone
following methanolic extraction. Of these, ten samples gave a positive response for
methadone, and all blanks a negative response. The majority of the cases which were
negative had low sample weights below 20mg, and may have contributed to the
number of false negative results.
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3. Methadone Stability Study
3.1 Introduction
Drug stability in biological matrices depends on a variety of factors, including
physicochemical properties of the drug, the type of matrix and the storage
conditions employed. Delays of several days are common place between
sampling, blood alcohol analysis and the initial drug screens. Confirmation may
not take place for some time or may not be carried out until the case goes to court.
Drug stability is of particular concern in cases where analysis is carried out by
more than one institute. Most forensic laboratories are required by law to store
blood samples for a minimum of six months to years to enable reanalysis if
required.
3.2 Literature
There are a limited number of papers in the literature dealing with drug stability in
biological matrices. Forensic toxicologists deal primarily with post-mortem blood
and the majority of studies involve whole blood 121-124. Studies have also been
reported on other matrices including urine and plasma 10, and putrefying liver 125.
Al-Hadidi and Oliver investigated the stability of temazepam 122, morphine and
buprenorphine 123 in whole blood. They concluded that temazepam, morphine and
buprenorphine were reasonably stable after six months and one year respectively,
regardless of storage conditions. Skopp et at 124 reported a decrease in
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concentration of all 13 benzodiazepines studied in blood and plasma during a 240-
day interval when stored at 4°C.
Other studies investigating benzodiazepines in whole blood involved diazepam
126, midazolam 127 and bromazepam 128. Chlordiazepoxide is unstable in whole
blood and decomposes rapidly 129.
Giorgi and Meeker 121 conducted a five-year stability study of cocaine,
benzoylecgonine, morphine, codeine, methamphetamine, amphetamine and
phencyclidine in blood. Cocaine was not detectable after only three months, while
methamphetamine and phencyclidine were relatively stable up to five years.
Methadone positive drug related deaths have increased in the West of Scotland
from 1991 to 1996 10. Commonly used in the treatment of heroin addiction,
methadone has also been associated with illicit use. The increase in methadone
positive deaths has resulted in an increase in the number of requested methadone
confirmations.
No papers were identified in the literature which investigated the stability of
methadone in whole blood. Moody et aZ130 investigated the stability of methadone
and its two major metabolites in urine. Neither methadone or its metabolites
showed significant decreases indicative of instability when stored at -20°C.
Similar conclusions were reported by Alburges et al 91, who found methadone and
its metabolites to be stable in plasma and urine over a week long study involving
two cycles of freezing and thawing.
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The present study investigates the stability of methadone and its two metabolites
in spiked whole blood and deionised water. This allowed a comparison to be made
between the effects of chemical decomposition and putrefactive degradation for
each analyte. The spiked and blank samples were stored at -20°C, 5°C and 25°C
to reflect common laboratory storage temperatures.
3.3 Aims
The aims of the stability study were to:
• determine the stability of methadone, EDDP and EMDP in whole blood over a
period of six months,
• determine the stability of methadone, EDDP and EMDP in whole blood when
stored at three different temperatures (-20, 5 and 25°C) over the six month
period,
• investigate the effect of light on the stability of EDDP when stored in whole
blood under the above conditions,
• investigate the effect of silanising the vials on the recovery of methadone,
EDDP and EMDP in whole blood,
• investigate the contribution of chemical decomposition on the stability of
methadone, EDDP and EMDP.
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3.4 Experimental
3.4.1 Materials
HPLC-grade methanol, acetone, chloroform and ethyl acetate were obtained from
Lab-Scan Analytical Sciences (Dublin, Ireland). Analytical-grade ammonium
hydroxide and glacial acetic acid and HiPerSolv grade potassium-dihydrogen
phosphate (KH2P04) were obtained from Merck (Poole, U.K.). Methadone,
EDDP and Chirald «2S,3R)-( +)-4-Dimethylamino-1 ,2-Diphenyl-3-Methyl-2-
Butanol) were obtained from Sigma@ Chemical Co., (Dorset, U.K.). EMDP was
obtained from Alltech Associates (State College, PA).
3.4.2 Sample preparation and storage
Outdated blank whole blood and deionised water were spiked with methadone
(Iug/ml), EDDP (Iug/ml) and EMDP (Iug/ml), O.8mg of each analyte was
dissolved in IOml of methanol, transferred into conical flasks and evaporated to
dryness at 40°C under a stream of nitrogen. The analytes were then reconstituted
in blank whole blood and deionised water.
Aliquots (I5ml) of spiked sample were transferred into 30ml hypovials and were
sealed with butyl rubber septa. Standard solutions of methadone, EDDP, EMDP
and the internal standard, Chirald were prepared by adding lmg of each analyte to
IOOml of methanol (l Oug/ml), The EDDP standard was wrapped in aluminium
foil to prevent degradation of the light sensitive analyte.
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Three vials were stored for each measurement of whole blood and deionised water
spiked with methadone, EDDP and EMDP, and for blank blood and blank
deionised water. A further study was conducted for EDDP spiked samples. The
samples were prepared as described above but the vials were wrapped in
aluminium foil to investigate the effect of light degradation.
The sealed samples were stored at - 20°C, 4°C and 25°C. Three sealed vials were
removed from storage at regular time intervals over a six month period (two, four,
six and eight weeks and three and six months). In addition sets of hypovials were
silanised with dimethylchlorosilane and then washed with methanol and allowed
to dry before use. Three silanised vials were stored for six months for each sample
type under the three temperature conditions stated above.
3.4.3 Instrumentation
A Hewlett-Packard model 5890 Series II gas chromatograph equipped with a
flame ionisation detector (GC-FID) was used with an HP-I, cross-linked methyl
siloxane capillary column (30m, 0.25mm i.d, film thickness 0.25J.lm). The initial
oven temperature of IOO°Cwas increased to 300°C at a rate of 10°C/minute. The
total analysis time was 20 minutes. The injector and detector temperatures were
285°C and 300°C, respectively. Helium was used as the carrier gas. Injections of2
J.lLwere carried out in the splitless mode.
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3.4.4 Solid-phase extraction
The solid-phase extraction procedure used was developed specifically for the
optimised recovery of methadone, EDDP and EMDP 131 from whole blood as
detailed in Chapter Two. Spiked samples (Irnl) were prepared by sonicating for
15 minutes at room temperature before dilution with 6ml of O.1M phosphate
buffer (pH 8.0). The diluted blood was then vortexed for 30 seconds before
centrifuging at 2000 rpm for 15 minutes. The supernatant was collected for
analysis and the residual pellet was discarded.
Isolute™ Confirm HCX (130mg) solid-phase extraction columns (International
Sorbent Technology LTD (Hengoed, U.K.» were conditioned with methanol and
phosphate buffer (pH 8.0). The diluted samples were applied to the column and
then washed with deionised water. The pH was adjusted with O.OIMacetic acid
(pH3.3). The columns were air dried under a full vacuum (15in. Hg) for 4
minutes, solvated with methanol and then dried under full vacuum for a further
minute.
Acidic, weak basic and neutral drugs were eluted with acetone-chloroform (1:1)
and discarded. Methadone, EDDP, EMDP and Chirald were eluted with 2%-
ammoniated ethyl acetate, evaporated to dryness at room temperature under a
nitrogen stream and reconstituted in 50J..lLethyl acetate.
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3.5 Results and Discussion
3.5.1 Introduction
Analyte recoveries were determined by comparing the peak area ratios obtained
from the extracted stored samples with freshly prepared spiked samples. The
recoveries were calculated relative to the initial recovery of 100% obtained on day
zero. The mean recovery (n = 3) was determined for each sample type. Standard
deviations were low with coefficients of variance ranging from 0 to 11.6% (mean
= S.S%).
3.5.2 Methadone
Figure 3.1 shows the relative recovery of methadone after six months of storage in
spiked blood and deionised water. Methadone is stable in blood when stored at -
20°C for up to six months with recovery of89.8% of the original concentration.
The recoveries decreased to 88.1% at SOCand 83.S% at 2S0C. The decrease in
recoveries of methadone from deionised water was less pronounced with
recoveries of 101% and 91.3% at -20°C and 2SoC respectively. The exception to
this being the recovery of methadone from deionised water stored at SOCwith a
recovery of 87.8%, similar to that obtained from blood.
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Figure 3.1 Changes in methadone recoveries from (A) deionised water and
(B) blood with time.
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3.5.3 EDDP
Slightly lower recoveries were obtained for EDDP in comparison to those for
methadone. However, in contrast the recoveries of EDDP from deionised water
were lower than the recoveries from whole blood (See figure 3.2).
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Figure 3.2 Changes in EDDP recoveries from (A) deionised water and (B)
blood with time.
3.5.4 EDDP (Foil wrapped)
Foil wrapped hypovials reduced the loss of EDDP from both blood and deionised
water samples. The recoveries ofEDDP (foil wrapped), see figure 3.3, are greater
than 80.1% in deionised water compared with 74.8% in unwrapped vials. Greater
than 94.9% of the original EDDP concentration was recovered in whole blood
(foil wrapped) compared with 85.4% in unwrapped vials. The difference in
recoveries is not significant enough to warrant the expense incurred by using light
sensitive containers for all samples taken for toxicological analysis.
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Figure 3.3 Changes in EDDP (foil wrapped) recoveries from (A) deionised
water and (B) blood with time.
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3.5.5 EMDP
Figure 3.4 shows the rapid decline in EMDP concentration in deionised water and
in particular in whole blood, over the six month study period. The storage
conditions playa significant role in EMDP stability. In both cases, samples stored
at -20°C resulted in the greatest recoveries (72.1% from deionised water and
57.6% from whole blood) after six months of storage. At temperatures of 5 and
25°C, EMDP recoveries of only 5.3 and 2.1% respectively were noted.
Corresponding recoveries from deionised water were 41.3 and 25.3% at 5 and
25°C respectively.
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Figure 3.4 Changes in EMDP recoveries from (A) deionised water and (B)
blood with time.
EMDP had not been detected in postmortem cases 58,131 during the period of this
research. The instability of this analyte in whole blood demonstrated above could
explain the lack of EMDP positive cases. In addition, the results presented may
confirm the observation by Sullivan and Due 103, that EMDP is a more active
substrate for hydroxylation than EDDP.
3.5.6 Silanised Hypovials
Table 3.1 summarises the recoveries of each analyte from whole blood after six
months of storage in silanised and non-silanised hypovials. Under each
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temperature condition, there was no significant change in analyte recovery
between vials, which were silanised, and those, which were not silanised.
Table 3.1 Average Recoveries of Analytes from Whole Blood after Six
months Storage in Silanised (S) and Non-Silanised (NS)
Hypovials.
-20°C SoC 2SOC
Analyte S(%) NS(%) S(%) NS(%) S(%) NS(%)
Methadone 81.6 89.8 93.3 88.1 80.1 83.5
EDDP 88.8 95.5 89.1 87.2 86.0 85.4
EDDP(F) 100 99.5 99.8 97.0 92.2 98.8
EMDP 52.4 57.6 5.8 5.3 2.2 2.1
3.6 Conclusion
Methadone and its primary metabolite, EDDP remain stable in whole blood for up
to six months when stored at -20°C. When stored at 25°C, the recoveries were still
greater than 83.5 and 85.4% for methadone and EDDP respectively. Foil wrapped
vials did not improve recoveries significantly to warrant the use of light sensitive
sample containers.
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EMDP is extremely unstable in whole blood at storage temperatures of 5 and
25°C. Storage of samples at -20°C only resulted in recovery of 57.6% of the
original concentration of EMDP after six months storage.
Silanising the hypovials prior to storage did not result in greater recoveries of
methadone, EDDP or EMDP from whole blood.
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4. Amphetamines
4.1 Introduction
Amphetamine is a synthetic stimulant, used primarily to treat a number of disorders
including catalepsy and obesity. Methamphetamine the N-methyl derivative of
amphetamine, has also been used in the treatment of obesity. Both drugs are abused
for their stimulant effects, especially in the United States, Sweden and Japan 132.
Amphetamine and methamphetamine are Class B, Schedule 2 drugs in the Misuse of
Drugs Act 1971(UK).
The ring-substituted amphetamines, in particular 3,4-methylenedioxyamphetamine
(MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxy-
ethylamphetamine (MDEA) are abused for their hallucinogenic properties. MDMA
along with MDA and MDEA are Class A, Schedule 1 drugs in the Misuse of Drugs
Act 1971 (UK) and are most stringently controlled.
"Ecstasy" is widely used in the United Kingdom and has caused considerable
concern following a number of cases of serious toxicity and death, thought to have
resulted from use of "ecstasy". '
Current information concerning the toxicity of "ecstasy" or the role of adulterants in
tablets sold as "ecstasy" is insufficient. "Ecstasy" tablets have reportedly contained
amphetamine 133, MDA 134-136, MDEA 135-138 and paramethoxyamphetamine (PMA)
139 in addition to or in place ofMDMA.
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To fully understand the toxic effects of the phenylethylamines and their metabolism,
toxicologists require a method, which will successfully extract and confirm the
presence of amphetamine and its related compounds in biological matrices.
4.1.1 Chemistry of Amphetamine and Its Related Compounds
Amphetamine is commonly available as the sulphate salt, a white crystalline salt,
first synthesized in 1887. The d-isomer of amphetamine has 3-4 times the central
activity of the l-form, Methamphetamine hydrochloride was first prepared in 1919
and forms white crystals or crystalline powder. (See Figure 4.1)
Amphetamine Methamphetamine
Figure 4.1 Amphetamine (C9H13N) and Methamphetamine (CIOHJsN)
3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxymethamphetamine
(MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA) are ring-substituted
amphetamines that have stimulant and hallucinogenic qualities in addition to unique
pharmacological and psychological properties. (See figure 4.2)
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MDMA was first synthesized in the early part of the zo" century. Similar to
amphetamine, the d-isomer ofMDMA has higher central activity than the l-isomer.
Table 4.1 summanses some important physicochemical properties of the
amphetamines.
MDA
MDMA MDEA
Figure 4.2
Application a/Solid-Phase Extraction/or the Analysis a/Drugs in Biological Matrices
Chapter Four: Amphetamines Page 93
Table 4.1 Properties of Amphetamine, Methamphetamine, MDA, MDMA and
MDEA 64
Drug Molecular Weight M.P. eC) pKa
AP 135 300 9.9
MA 149 172 -174 10.1
MDA 179 187 - 188 l'IV -
MDMA 193 148 - 153 ,<tv -
MDEA 204 201 - 202 ,<tv -
4.1.2 History of Use and Abuse of Amphetamine and Its Related Compounds
Amphetamines are the most popular illicit stimulant in the United Kingdom, second
only to cannabis IS. During the Second World War, amphetamine tablets were given
to soldiers to combat the effects of battle-fatigue 141. In the 1960's amphetamine
abuse was widespread especially in London's West End clubs. Young people
consumed large quantities of Drinamyl (known as 'purple hearts'). These tablets
were withdrawn but amphetamine abuse continued.
Methamphetamine gained popularity during the 1970's, when it was claimed that it
gave a better 'high' than amphetamine. Interest in the drug dwindled after it was
associated with strange and violent behaviour 141.
Application of Solid-Phase Extraction for the Analysis of Drugs in Biological Matrices
Chapter Four: Amphetamines Page 94
A drug misuse survey conducted in 1996 142, reported that the most significant rise in
drug use over the last decade is the 'dance drugs' in particular, amphetamine, LSD
and "ecstasy".
"Ecstasy" was patented as an appetite suppressant for soldiers in the First World War
143. In the United States the drug was used as an adjunct to psychotherapy 144, and in
the 1980's became popular among drug users. The late 1980's saw the introduction
of "ecstasy" in the United Kingdom where it became popular at dance events or
"raves" 145. In Britain alone, an estimated 500,000 people use "ecstasy" each
weekend 146.
Forsyth 147 interviewed 135 participants in the Glasgow rave scene, and concluded
that although "ecstasy" was by far the most commonly used drug at raves, poly-drug
use was most prevalent. This was further supported by Hammersley et al 148 who
interviewed 209 individuals who had used "ecstasy" at least once, but found no
individuals who used "ecstasy" without using at least one other controlled drugs.
This is not a feature of the rave scene in Glasgow alone, Handy et al 149 conducted a
study of "ecstasy" use in the Cardiff area of South Wales (n = 389) where poly-drug
use and experimentation was prevalent. They concluded from their study that the
pattern of drug use had changed from the early 1990's and "ecstasy" was no longer a
central feature of the dance.
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4.1.3 Disposition in the Body
4.1.3.1 Amphetamine
Amphetamine is readily absorbed after oral administration, followed by deamination
to phenylacetone which is oxidised to benzoic acid and excreted as conjugates. A
small amount of amphetamine is converted to norephedrine by oxidation. (See figure
4.3)
Approximately 30% of the dose is excreted unchanged in urine in 24 hours, however
this is greatly dependent on urinary pH. Acidic urine may increase the amount of
unchanged dose to 74% or decrease to 1% in alkaline urine. Amphetamine is also a
metabolite of methamphetamine, benzphetamine 150 and selegiline 64.
norephedrine amphetamine phenylacetone
.:
glycine conjugation
p-hydroxylation
and conjugation
glucuronide and
benzoic acid
Figure 4.3 The metabolic pathways of amphetamine in the human body
ApplicationofSolid-PhaseExtraction/or theAnalysisofDrugs inBiologicalMatrices
Chapter Four: Amphetamines Page 96
4.1.3.2 Methamphetamine
Similar to amphetamine, methamphetamine is readily absorbed after oral
administration and the amount of unchanged drug excreted in urine in 24 hours is pH
dependent. Up to 43% of a dose is excreted unchanged as the parent drug, under
normal conditions. This can vary from as low as 2% in alkaline conditions to 76% in
acidic conditions.
Methamphetamine undergoes N-demethylation to amphetamine. Approximately 4-
7% of the dose is excreted as amphetamine (See figure 4.4). Methamphetamine is a
metabolite ofbenzphetamine 150 and selegiline.
methamphetamine amphetamine norephedrine
/
deamination, p-hydroxylation and conjugation
Figure 4.4 The metabolic pathways of methamphetamine in the human body
4.1.3.3 Ring-substituted Amphetamines
Metabolism studies of the ring-substituted amphetamines are few and only limited
data can be found in Clarke 64 or Baselt and Cravey 63
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Methylenedioxymethamphetamine (MDMA) is metabolised by N-demethylation to
methylenedioxyamphetamine (MDA). 65% of the dose is excreted as the parent drug
and 7% as MDA within three days 151.
Y CH, y- CH, P CH,l CH,CHNHR' - R CH2CHNHR' --- R CHlHNHR'
H3
MDMA ! R' = CH3 ! jMDEA R' = CH2CH3Y CH, y- CH, P CH,I. CH,tHNH, --- R CH2CHNH2 --- R CH2CHNH2
H3
MDA
1 1 1
--- R ---
CH3 CH3 CH3
(phase I: R =H, phase II: R = sulphate or glucuronic acid)
Figure 4.5 The metabolic pathways of MDA, MDMA and MDEA in the human
body 152.
Applicationof Solid-PhaseExtraction/or theAnalysisofDrugs in BiologicalMatrices
Chapter Four: Amphetamines Page 98
Maurer 152 investigated the metabolism of MDA, MDMA, MDEA and their
metabolites in urine by GC/MS. The ring-substituted amphetamines undergo two
overlapping metabolic pathways, O-dealkylation of the methylene dioxy group to
form dihydroxy derivatives which is then followed by methylation of a hydroxy
group and degradation of the side chain to N-dealkyl and deaminooxo metabolites
152. MDA, MDMA and MDEA are further metabolised to glycine conjugates of the
corresponding 3,4-disubstituted benzoic acids (hippuric acids) 152 (See figure 4.5).
4.1.4 Toxicity
4.1.4.1 Amphetamine
Amphetamine plasma concentrations are usually below O.lmg/L after normal
therapeutic doses. Chronic usage of amphetamine is characterised by weight loss,
hallucinations and paranoid psychosis 153. In addition, increased heart rate and blood
pressure are also symptomatic of amphetamine use.
Deaths resulting from amphetamine overdosage are rare. The minimum lethal dose in
non-tolerant adults is estimated at 200mg 64.
Toxic effects may be produced with blood concentrations of 0.2 to 3mg/L, with
levels greater than 0.5mg/L resulting from fatalities 64. Amphetamine tolerant adults
who orally consumed 100mg of amphetamine daily 154, maintained a steady-state
blood concentration of 2.0 - 3.0 mg/L. Table 4.2 summarises the fatal levels of
amphetamine (mg/L or mg/kg) reported in the literature.
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Table 4.2 Fatal amphetamine levels (mg/L or mg/kg) detected III vanous
biological matrices.
Reference Blood Brain Liver Kidney Urine
63 0.5 - 41 2.8 - 3.0 4.3 -7 3.2 - 52 25 -700
(n = 11) (n= 2) (n = 11) (n= 6) (n= 8)
138 1.54 nla* nla nla nla
155 2.44 5.50 11.7 3.85 33.4
156 0.25 - 2.6 nla nla nla nla
(n =3)
157 0.45 - 2.18 nla nla nla nla
(n= 6)
158 nla nla nla nla < 0.5 - 320
(n = 11)
* n/a - matrix not analysed
4.1.4.2 Methamphetamine
Therapeutic doses of methamphetamine result in plasma concentrations in the range
0.01 to 0.05 mg/L. Chronic users may develop paranoid psychosis, while overdosage
causes anxiety, hallucinations, cardiac arrhythmias, convulsions and coma.
Similar to amphetamine, deaths resulting from methamphetamine overdosage are
rare. The minimum lethal dose in non-tolerant adults is estimated at 1g 64.
Methamphetamine blood concentrations of 0.15 - 0.56 mg/L were reported in seven
methamphetamine abusers who exhibited violent and irrational behaviour 159
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Methamphetamine levels of 1.7 and 2.1mglL were detected in two women found
asleep in their car. Table 4.3 summarises the fatal levels of methamphetamine (mg/L
or mg/kg) reported in the literature.
Table 4.3 Fatal methamphetamine levels (mg/L or mg/kg) detected in various
biological matrices.
Reference Blood Brain Liver Kidney Gastric Urine
63 5.6 n/a n/a n/a n/a 320
63 2.0 n/a 4.8 n/a 1.5 28
0.3 AP 0.7 AP 0.1 AP 2.7 AP
160 1.33 n/a* n/a n/a n/a n/a
161 43 102 174 75 1557 277
0.35 AP 0.86 AP 1.3 AP 0.7 AP 2.0AP 10AP
162 40 n/a 206 n/a n/a n/a
163 0-0.6 0.2 - 0.8 0.4 - 0.7 0.4 - 0.6 n/a 1.0
(n = 3) (n = 3) (n = 3) (n = 3) 4.0AP
0-0.5 0-0.8 0-0.3 0-0.3
AP AP AP AP
(n= 3) (n=3) (n = 3) (n = 3)
* n/a - matrix not analysed
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4.1.4.3 Ring-substituted amphetamines
A literature search revealed very little data on toxicity with respect to 3,4
methylenedioxyamphetamine (MDA), 3, 4 methylenedioxymethamphetamine
(MDMA) and 3, 4 methylenedioxyethylamphetamine (MDEA).
The estimated lethal dose of MDA for non-tolerant adults is 0.5g. Symptoms from
MDA overdosage include, tachycardia, hyperthermia, muscular rigidity, convulsions
and coma.
A non-fatal overdose of MDA resulted in an admission urine concentration of
131mg/L ofMDA 63. The victim, a one year old child presented with muscle rigidity,
seizures and was unconscious. Table 4.4 summarises the reported toxic levels of
MDA (mg/L or mg/kg) reported in the literature.
Table 4.4 Fatal MDA levels (mg/L or mg/kg) detected in various biological
matrices.
References Blood Liver Bile Urine
164 6-26 8 -17 5-9 46 -160
(n = 5) (n= 3) (n = 3) (n =3)
165 2.3 11 7 175
As "ecstasy" use increases, so the numbers of reports of adverse medical reactions
and fatalities increase. Acute clinical toxicity following MDMA ingestion results in
hyperthermia and the 'serotonin syndrome' 166-167. Sudden cardiac death 168, cerebral
oedema 169, hyperthermia 170, disseminated intravascular coagulation (DIe) 134
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severe acute hepatitis 171-172 and rhabdomyolysis 173-174 are commonly cited in cases
of fatal and non-fatal toxicity following MDMA use.
Unusual cases have also been reported. A 17 year old female collapsed after taking
two tablets of 'speckled dove', a combination ofMDMA, heroin and cocaine 175. She
was unconscious, unresponsive, and hypothermic with a core temperature of 32.4 QC.
No postmortem toxicological results were reported in this case.
Jorens et al176 reported a case of suicidal ingestion of MDEA and heroin. The 25
year old male involved had a history of previous suicide attempts and was thought to
have consumed a total of 40 tablets (approximately 4g) of MDEA and 12g of heroin,
two hours prior to admission.
High serum levels of both drugs were detected, however he did not present with
classical signs and symptoms associated with intoxication from these drugs. Full
recovery followed symptomatic treatment. The authors concluded that the opposite
pharmacological properties of the two drugs prevented the patients death.
Survival following a massive overdose of MDMA was reported by Ramacharan et al
177. A 30 year old male was admitted to hospital after consuming 50 tablets of
"ecstasy", ten tablets of oxazepam and five units of alcohol over a period of four to
five hours.
The unpredictable nature of "ecstasy" is reflected in the fact that thousands of people
have consumed "ecstasy" yet very few deaths have been reported. Fatalities
following the ingestion of just one "ecstasy" tablet, yet survival after consuming 50
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"ecstasy" tablets questions the toxicity of the ring-substituted amphetamines. Two
possible explanations for the unpredictable responses are contamination of "ecstasy"
or genetic predisposition.
In addition to the short-term risks from the toxic effects of MDMA, further research
is needed on the long-term effects on the brain, liver and heart 137. Semple and
Johnstone 178 are currently studying the long-term effects of "ecstasy" use on damage
to the nerve cells.
MDMA has been implicated with the onset of both psychological and behavioural
complications. Researchers have reported an apparent association between MDMA
use and serotonergic alterations 179-180. Other studies have found a correlation
between suicide and low levels of cerebrospinal fluid 5 - hydroxyindoleacetic acid,
he nri b 1· f . 181-182t e pnmary meta 0 ite 0 serotomn .
Its is believed that the long-term consequences of neurodegeneration associated with
MDMA use is greater then the risk of death from acute toxicity 183. Evidence of
suppressed immune function of rats after a single dose of MDMA has been reported
184
Amphetamine and related compounds are responsible for a number of deaths,
directly (adverse drug reactions, overdoses) or indirectly (traffic accidents, suicides)
156. Although there is a relatively low number of reported cases of adverse reactions
and fatalities in comparison to the vast numbers using "ecstasy", a great deal of cases
will go unreported 185.
The use of amphetamines impairs mental function and has resulted in a number of
c. 1·· fr d ffi id 186-188lata ities om roa tra IC acci ents .
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A total of 48 patients were admitted to an Accident and Emergency department over
a 15 month period after consuming MDMA at a night club 189. The mean number of
"ecstasy" tablets consumed was two. Polydrug use was common with around 40%
having consumed "ecstasy" prior to this occasion. A wide range of adverse effects
were described from feeling dizzy or weak (n = 15; 31.3%) to feeling excessively
hot, cold, feverish, shivering (n = 7, 15%). There were six episodes, which were
classified as severe adverse effects. These included delirium in two cases, seizures in
three cases, and unconsciousness (coma) in one case.
No toxicology data was available in this study and the authors, Williams et al 189
conceded that this was a major limitation in that confirmation of amphetamine or its
related compounds had not been carried out.
The exact number of patients admitted to Accident and Emergency Departments
within the United Kingdom with "ecstasy"-related symptoms is not known at this
time. Monitoring these cases would present a clearer picture of the toxic effects of
"ecstasy". Full toxicological screening of admission urine and blood samples would
help rectify the lack of available toxicity data for the ring-substituted amphetamines
and would be of great benefit to the toxicologist.
Table 4.5 summarises the reported toxic levels of MDMA and MDEA (mg/L or
mg/kg) reported in the literature.
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Table 4.5 Fatal MDMA and MDEA levels (mg/L or mg/kg) detected in whole
blood.
Reference MDA MDMA MDEA
134 nld 0.19 1.6
138 0.25 0.43 0.30
156 0.49 4.1 nld
157 0.04 -2.4 2.1-5.4 nld*
(n = 3) (n= 4)
157 0.18 - 2.0 0.04 -1.2 9.0 - 33.0
(n = 3) (n= 2) (n = 3)
190 0.02 - 0.06 0.06 - 0.53 =0.09
(n=4) (n= 7) (n = 1)
191 nld 1.0 nld
* n/d - not detected
4.2 Analysis
The analysis of amphetamines 'in biological matrices reported in the literature deal
predominantly with urine 46,152,192-196. Liquid-liquid extraction (LLE) has long been
the preferred method however over the past five years solid-phase extraction (SPE),
with its inherent advantages, has become more common place 197-201.
Alternative matrices e.g. serum 190,202-203, plasma 190,204, hair 205-209 and brain 210-211
have also been investigated.
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The analysis of amphetamines in biological fluids still presents a challenge to the
toxicologist due to their volatility. However, a routine method for the analysis of
amphetamines in whole blood is an essential confirmation technique in the forensic
toxicology laboratory.
Very few papers published in the literature deal with the analysis of amphetamine,
methamphetamine, MDA, MDMA and MDEA in whole blood. Published research
involve liquid-liquid extraction (LLE) 212, solid-phase extraction 199,213 and solid-
phase microextraction 54. Gas chromatography - mass spectrometry is the method of
choice for confirming the presence of amphetamines in biological matrices.
Hara et al 199 reported a method combining solid-phase extraction with Extrelut
columns and heptafluoro-n-butyryl derivatisation for the analysis of amphetamine,
methamphetamine and their metabolites, 4-hydroxymethamphetamine (HMAMP)
and 4-hydroxyamphetamine (HAMP). Recoveries of 79 and 84% were obtained for
amphetamine and methamphetamine from whole blood, respectively.
Peschier et al 213 developed a solid-phase extraction method for the analysis of
amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyethyl-
amphetamine (MDEA) in whole blood. The multi-step method involved evaporating
the eluate to 200f..l1in a vacuum centrifuge prior to derivatisation with HFBA.
Recoveries of 60% were' reported for amphetamine and MDA, 79% for
methamphetamine, 84% for MDMA and 98% for MDEA.
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The analysis of amphetamines in hair has been studied extensively, predominately
using liquid-liquid extraction (LLE) 214-217. In general, the majority of methods use
either acidic 218-219 or alkaline 220-221 digestion of the hair, but some use enzymatic
digestion 222-223 and j3-glucuronidase/arylsulphatase 224-225 in order to free the drugs
from the tightly bound matrix.
Sachs and Raff 226 compared different extraction methods for the analysis of opiates,
cocaine and benzoyl ecgonine in hair samples. They found that extraction after
enzymatic digestion led to higher results, than after treatment with NaOH. In
addition, the authors found that although j3-glucuronidase/arylsulphatase and
methanol did not fully digest the hair, this was not necessary, as the drugs appeared
to be extracted sufficiently, with the added advantage that screening for common
basic drugs was possible.
Gas chromatography - mass spectrometry is the preferred method for hair analysis,
but methods have been published using other techniques. Takahashi 227 described a
gas chromatographic method for the detection of methamphetamine and
amphetamine in the hairs of monkeys. Nagai et al 228, reported a method for the
detection of methamphetamine and amphetamine in the hair of addicts, as well as in
hair, bones and teeth after animal experiments.
Kintz et al 216, developed a method for the simultaneous determination of
amphetamine, methamphetamine, MDMA and its primary metabolite MDA. This
involved liquid-liquid extraction (LLE) of the drugs, after incubating the hair with
1M NaOH to destroy the matrix whilst in the presence of deuterated internal
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standards(IS). Recoveries of greater than 75% were reported for all four drugs.
Previously, only one other paper reported the analysis ofMDMA in hair 229, but this
did not include the analysis ofMDA.
Nakahara et aZ230, developed a solid-phase extraction (SPE) method for the analysis
ofMDMA and MDA in hair. This method involved the extraction of the hair sample
in 2ml of methanol-5N HCl containing the deuterated internal standards for one hour
under ultrasonication, followed by storage at room temperature overnight. After
filtration of the hair, the filtrate was subjected to solid-phase extraction using Bond
Elut Certify mixed-mode columns. Levels were reported in the range of 0.3-
l.4ng/mg for MDMA and MDA in human hair samples. Both methods involved the
derivatisation of the samples to prevent loss of the volatile drugs during evaporation
steps.
Solid-phase extraction (SPE) followed by gas chromatography - mass spectrometry
combines improved separation of analytes from biological fluids with greater
sensitivity.
Increased analyte stability has been reported with varying degrees of success with
derivatisation 216,221,231-235, including on-disc 236 and on-line 197 derivatisation and
acidification 216,232,237. Central to the majority of these techniques, involves
derivatising at temperatures greater than 40°C for extended periods of time (> 20
minutes). These conditions can result in significant loss of the analytes, which leads
to lower recoveries and poorer reproducibility.
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4.3 Aims
The work completed in this chapter involved two separate projects. The first project
involved collaboration with The Scottish Centre for Criminology who investigated
the use of "ecstasy" in Glasgow 148. This study was funded by the Chief Scientist at
the Scottish Office (Grant Ref.: KlOPRl2/2/D125). Subjects were questioned on their
drug use histories over the previous year and were asked to donate a hair sample.
A method was required which could identify the presence of amphetamine and
methamphetamine to confirm "speed" use and 3,4-methylenedioxyamphetamine
(MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxy-
ethylamphetamine (MDEA) to confirm "ecstasy" use in hair. The developed method
was required to analyse 100 hair samples by segmental analysis.
The second project involved a collaboration with the University of Arizona. They
had completed an investigation into the addition of tartaric acid as an aid in
preventing losses of the small amines, namely, amphetamine and methamphetamine
during evaporation and derivatisation. This work was reproduced and then the
incorporation of this step into the routine analysis of amphetamines in whole blood
and hair was investigated.
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4.4 Experimental
4.4.1 Chemicals
Amphetamine (AP), methamphetamine (MA), 3,4-methylenedioxyamphetamine
(MDA), 3,4-methylenedioxymethamphetamine (MDMA), dj-arnphetamine (d3-AP),
lauryl sulfate (sodium dodecyl sulphate (SDS)) and p-glucuronidase (activity =
300,000 - 400,000 units/g solid, sulphatase activity = 15,000 - 40,000 units/g solid)
were obtained from Sigma@ Chemical Co., (Dorset, U.K.). 3,4-methylenedioxy-
ethyl amphetamine (MDEA) was manufactured by Radian International and supplied
by Promochem, (Herts., U.K.). Pentafluoropropionic anhydride (PFPA) was
supplied by Fluka Chemicals (Dorset, U.K.). HPLC-grade methanol, acetone,
chloroform, deionised water and ethyl acetate chromatographic (HPLC) grade were
obtained from Lab-Scan Analytical Sciences (Dublin, Ireland). Analytical-grade
ammonium hydroxide and glacial acetic acid and HiPerSolv grade potassium-
dihydrogen phosphate (KH2P04) were obtained from Merck (Poole, UK).
4.4.2 Stock Standards
A combined stock standard solution (O.lmg/ml) of AP, MA, MDA, MDMA and
MDEA was prepared in methanol. Working solutions were also prepared in methanol
(10, l ug/ml) by appropriate dilution of the stock standard. The internal standard
(I.S.), amphetamine - dj, was prepared in methanol to give a stock standard solution
of O.lmg/ml. Working solutions of AP- dj (10, lug/ml) were prepared by dilution
of the stock standard with methanol. All stock and working solutions were stored in
a freezer at -20°C.
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4.4.3 Instrumentation (GCIMS)
A Fisons model GC8000 series was used, fitted with a HP-l capillary column. The
initial column temperature of 55°C was held for 2 minutes and then increased to
280°C at a rate of 20°C/min. and held for a further 5 minutes. The carrier gas used
was Helium. Injections were made in the splitless mode.
The GC8000 was interfaced to a Fisons MD800 mass spectrometer operated in the
electron - ionisation mode at 70eV. The ions monitored were mlz 118, 190* (AP),
mlz 118, 160,204* (MA), mlz 135, 162, 190,325* (MDA), mlz 135, 162,204,339*
(MDMA), mlz 135, 162, 190,218,353* (MDEA) and mlz 193* (AP- dj), The ions
labelled "*" were used for quantitation.
4.4.4 Derivatisation and GCIMS Analysis
Standard solution or extract was evaporated to dryness under a stream of nitrogen at
room temperature. The drugs were then reconstituted using 50f.!1of PFPA:Ethyl
acetate (1: 1) sealed and allowed to derivatise at 50°C for 15 minutes. After
derivatisation was complete, the samples were evaporated to dryness as before and
reconstituted in 50f.!1of ethyl acetate. 1f.!lwas injected for analysis by GCIMS.
4.4.5 Mass Spectra
4.4.5.1 Experimental
Aliquots of individual stock standards (l00f.!1, O.lmg/l) were evaporated to dryness
and derivatised as described above. lul was injected onto the GCIMS. The full mass
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fragment spectra were obtained for amphetamine, amphetamine-dj
methamphetamine, MDA, MDMA and MDEA using the full scan mode.
Once the optimum ions for monitoring the amphetamines were identified, a selected
ion monitoring programme was created to increase the sensitivity of the method.
4.4.5.2 Results and Discussion
Figures 4.6 to 4.11 illustrate the full mass fragment spectra for amphetamine,
amphetamine-dj methamphetamine, MDA, MDMA and MDEA
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The ions monitored were rnJz 118, 190* (AP), rnJz 118, 160, 204* (MA), rnJz 135,
162, 190,325* (MDA), rnJz 135, 162,204,339* (MDMA), rnJz 135, 162, 190,218,
353* (MDEA) and rnJz 193* (d3-AP). The ions labelled "*" were used for
quantitation.
4.4.6 Optimisation of Derivatisation Step
4.4.6.1 Experimental
Pentafluoropropionic anhydride (PFPA) is commonly cited in the literature 193,238-239
as a derivatising agent for amphetamines prior to analysis by GC/MS. The
temperature and length of derivatisation used, differs widely from 40 to 70 QCfor a
total time of between 15 to 45 minutes. In order to assess the effect of different
temperatures and derivatisation times, AP, MA, MDA, MDMA and MDEA in the
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presence of the internal standard (AP-dJ) were derivatised with PFPA for 15, 30 and
45 minutes at four different temperatures (40, 50, 60 and 70 QC).
4.4.6.2 Results and Discussion
Table 4.6 summarises the results for the optimised derivatisation conditions for
amphetamine, amphetamine - d), methamphetamine, MDA, MDMA and MDEA.
The detector response was noted for the following ions; m1z 190 (AP), m1z 193 (AP-
dJ), m1z 325 MDA, m1z 339 (MDMA) and m1z 353 (MDEA).
The difference in detector response was more pronounced with the more volatile
amphetamines (amphetamine, amphetamine-d, and methamphetamine). In all cases,
derivatisation for longer than 15 minutes resulted in lower response values. The
optimum temperature to carry out the derivatisation step was at 50 QC.Figures 4.12
to 4.17 illustrate the effects of temperature and derivatisation time on the detector
response for amphetamine, amphetamine - d), methamphetamine, MDA, MDMA
and MDEA respectively.
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Table 4.6 Optimisation of the Derivatisation Temperature and Duration for
Amphetamines using PFPA.
Analyte T·eC) Peak Area (Detector Response)
15 minutes 30 minutes 45 minutes
AP 40 31543942 22737862 12109251
50 69531288 24425318 16470126
60 51540912 18037396 11986538
70 42117208 22828872 12091415
AP-d3 40 32270562 28011310 14571298
50 65439980 24834690 16725190
60 49514524 26144044 15678454
70 44196360 25963622 12736432
MA 40 48017672 29281044 14978060
50 78205000 29778634 16746971
60 55423488 21968266 13434037
70 55299776 26678398 14502206
MDA 40 1290022 1278518 1095517
50 1629581 1199926 1077586
60 1390941 1062945 1087454
70 1205106 933119 914120
MDMA 40 1135886 1182279 860629
50 1519512 1106719 931391
60 1267306 891722 864978
70 1122389 765132 799930
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MDEA 40 311420 322098 229643
50 384998 284700 236805
60 362644 261200 234105
70 308229 216297 204556
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Figure 4.12 Effect of temperature and derivatisation time on the detector response
for amphetamine
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Figure 4.14 Effect of temperature and derivatisation time on the detector response
for methamphetamine
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Figure 4.15 Effect of temperature and derivatisation time on the detector response
forMDA
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Figure 4.16 Effect of temperature and derivatisation time on the detector response
forMDMA
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Figure 4.17 Effect of temperature and derivatisation time on the detector response
forMDEA
The optimum conditions for derivatisation of the six amphetamines was at 50°C for
15 minutes.
4.4.7 Solid-Phase Extraction of Hair
4.4.7.1 Introduction
Nakahara et al 230 developed a solid-phase extraction method to identify MDA and
MDMA in hair, along with other hallucinogens (LSD and PCP). This method
involved treating the hair with 2ml of methanol - 5N HCI (20: 1) in the presence of
deuterated internal standards, followed by a standard solid-phase extraction
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procedure. p-glucuronidase has been used successfully m the past to extract
amphetamines and various other drugs from hair 224-225.
A method combining p-glucuronidase sample pretreatment and a solid-phase
extraction procedure, optimised for the analysis of amphetamines in whole blood 56,
was investigated as a means of extracting amphetamine, methamphetamine, MDA,
MDMA and MDEA from hair.
4.4.7.2 Sample Pre-treatment
Hair samples were washed once with 0.1% SDS in deionised water and then in
triplicate with deionised water. Each wash step was carried out by sonicating for 15
minutes. The hair was then rinsed with methanol and allowed to dry overnight in a
dessicator.
The dried hair was measured and cut to the appropriate lengths, before being ground
to a fine powder under liquid nitrogen using a mortar and pestle. The powdered hair
was placed in a clean vial and weighed accurately.
Each hair sample was treated with 50 !J.Iof p-glucuronidase [O.Img/ml in phosphate
buffer (pH7.4, O.1M)] and 2 ml of phosphate buffer (pH7.4, O.1M). 100 !J.Iof the
internal standard, AP- dj (IOng/mg based on a lOmg hair sample) was added and the
samples were incubated at 40°C for two hours. The samples were allowed to cool to
room temperature, and then the supernatant was removed following centrifugation
(2000 rpm, 5 min.). A further 2 ml of phosphate buffer was then added, centrifuged
as before and the two supernatants combined for further analysis.
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4.4.7.3 Solid-Phase Extraction
To separate the drugs from the hair matrix, solid-phase extraction was carried out on
Isolute" Confirm HCX-3 (130 mg) SPE columns [manufactured by International
Sorbent Technology LTD (Hengoed, U.K.) and supplied by Crawford Scientific
(Strathaven, U.K.)]'
The method used was previously reported for the analysis of methamphetamine and a
mixture of different analytes 56. The SPE columns were conditioned with methanol
and phosphate buffer (pH7.4, O.lM). The supernatant was applied onto the column,
which was 'then washed with deionised water. The pH was adjusted with O.OIM
acetic acid pH 3.3 and the column subjected to two drying steps before elution of the
drugs. The first fraction (A) was eluted with acetone:chloroform (1: 1v/v) and was
discarded as no quantifiable levels of the drugs were detected. The analytes of
interest were eluted into the second fraction (B) using 2 ml of 2 % ammoniated ethyl
acetate.
The extracts were derivatised as described in section 4.4.4.
4.4.8 Validation of the Extraction Procedure
4.4.8.1 Experimental
The developed method. was validated using blank hair spiked with the five
amphetamines over a concentration range of 0 to 1000ng. In addition, recoveries of
each of the five amphetamines from hair were determined by extracting blank hair
spiked with three different concentrations (50, 100 and 200 ng), using approximately
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10 mg of hair. The internal standard (amphetamine-d) was added to the extract
following solid-phase extraction. The peak area ratios (P.A.R.'s) of the extracted
samples were compared to the peak area ratios of the unextracted standards.
Hair samples were spiked by adding a set volume of the working solution to 100mg
of ground blank hair (washed prior to milling). The methanol was allowed to
evaporate to dryness overnight at room temperature. The hair was then mixed
thoroughly to ensure homogeneity of the sample.
4.4.8.2 Results and Discussion
The average recoveries from the spiked hair were greater than 70 % for all five
amphetamines with coefficients of variance ranging from 2.0 to 10.6. The extraction
method was linear in the concentration range 0 to 1000 ng with limits of detection
(L.O.D.) of Sng for AP and MA and 1ng for MDA, MDMA and MDEA (signal-to-
noise ratio of3:1). The results are summarised in Table 4.7.
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Table 4.7 Recovery and linearity results for the extraction of amphetamines
from hair
Analyte* Concn. Standard Sample Recovery/ Linearity L.O.D.
(ng) t P.A.R* P.A.R. (n=3) C.V.§ (r)** (ng)
AP 50 1.446 1.021 70.6/8.7
100 3.139 2.342 74.6/8.5 0.990 5
200 5.824 4.281 73.5/2.5
MA 50 3.705 2.942 79.4 / 6.6
100 5.194 4.721 90.9/10.6 0.993 5
200 8.750 7.219 82.5/2.7
MDA 50 0.249 0.205 82.2 / 7.6
100 0.434 0.313 72.2 /2.8 0.993 1
200 0.826 0.594 71.9/2.0
MDMA 50 0.170 0.148 87.1/6.6
100 0.320 0.264 82.5/10.2 0.995 1
200 0.660 0.549 83.2/5.1
MDEA 50 0.132 0.113 85.4 / 4.1
100 0.191 0.182 95.4 5.9 0.996 1
200 0.383 0.355 92.7/4.0
* AP: amphetamine, MA: methamphetamine, MDA: 3,4-
methylenedioxyamphetamine, MDMA: 3,4-methylenedioxymethamphetamine,
MDEA: 3,4-methylenedioxyethyl-amphetamine
t Concentration (nanogrammes)
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~ Peak Area Ratio
§ Coefficient of variance
* * Correlation Coefficient
Figure 4.18 illustrates the linear relationship between amphetamine,
methamphetamine, MDA, MDMA and MDEA and the peak area ratios over the
concentration range 0 to 1000ng, spiked in hair.
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Figure 4.18 Calibration Curves for amphetamine, methamphetamine, MDA,
MDMA and MDEA (0 to 1000ng)
This extraction method was used successfully for the analysis of amphetamine,
methamphetamine, MDA, MDMA and MDEA in 139 hair segments as part ofajoint
project with The Scottish Centre for Criminolgy (See section 5.8.1).
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4.4.9 Deuterated Internal Standards
4.4.9.1 Experimental
Amphetamine-d, (100f.Lg/ml),methamphetamine-d, (lOOf.Lg/ml),MDA-ds (lmg/ml),
MDMA-ds (lmg/ml) and MDEA-d6 (lmg/ml) standards manufactured by Radian
International and supplied by Promochem, (Herts., U.K.), already prepared in 1ml of
methanol, were investigated as alternative internal standards.
A working mixture (l Oug/ml) of all five deuterated amphetamines was prepared in
methanol. lOOf.LIof the working solution was evaporated to dryness (N2 stream, room
temperature) and derivatised with PFPA as described previously. 1f.LIwas injected
onto the GC/MS and analysed using the full scan mode.
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4.4.9.2 Results and Discussion
Figures 4.19 to 4.23 illustrate the full mass fragment spectra of amphetamine-de,
methamphetamine-de, MDA-ds, MDMA-ds and MDEA-d6
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Figure 4.22 Full Mass Fragment SpectrumofMDMA-ds
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Figure 4.23 Full Mass Fragment Spectrum ofMDEA-d6
Ideally the non-deuterated ion (Do) used for quantitation would be absent or in
negligible quantities in the deuterated standard. This would ensure no false positive
results when using deuterated standards as internal standards.
Table 4.8 summarises the ratios (non-deuterated.deuterated; DolDn) of the
quantitation ions obtained for each of the analytes. A comparison was made between
the ratios obtained in this study and those supplied by the manufacturers.
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Table 4.8 Non-deuterated:deuterated (DolDn) ratios of the quantitation Ions
obtained for each of the deuterated standards.
Analyte Ratio Results Manufacturer
(DoIDn) (DolDn)% (DolDn)%
Amphetamine 190/194 0.10 0.13
Methamphetamine 204/208 7.4 0.11
MDA 325/330 3.0 0.12
MDMA 339/344 49.7 ----
MDEA 353/359 153.8 0.03
The amount of non-deuterated quantitation ion present in methamphetamine, MDA,
MDMA and MDEA was unacceptably high. Only the ratio obtained with
amphetamine - ds agreed with the manufacturers stated value. Amphetamine - ds
could be used as an internal standard without causing a false positive response, and
was used as a replacement for amphetamine - d3. The main reason for changing the
internal standard being the ease of preparing stock standards from a methanolic
solution of known concentration.
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4.4.10 Addition of Tartaric Acid Step
4.4.1 0.1 Introduction
The University of Arizona, Tucson investigated tartaric acid as an aid in preventing
losses of the small amines, namely, amphetamine and methamphetamine during
evaporation and derivatisation.
OH
HO
o
OH
HO
Figure 4.24 Structure of Tartaric Acid (CHOH.COOH)2
The developed method was then reproduced in the laboratories of the Department of
Forensic Medicine and Science, University of Glasgow. However, biological fluids
are routinely screened for AP, MA, MDA, MDMA and MDEA when determining
"speed" and/or "ecstasy" use, so all five amphetamines were included during method
development. This also ensured that the addition of tartaric acid did not have a
detrimental effect on the methylenedioxyamphetamine derivatives or indeed improve
their recoveries. Tartaric acid (dextro-rotatory), [(CHOH.COOH)2, M.W. = 150.09)],
see figure 4.24, was obtained from Merck (Poole, U.K.)
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4.4.10.2 Experimental
To investigate the usefulness of tartaric acid, derivatisation was carried out at room
temperature (Method A) and 70°C (Method B) for 2, 5, 10, 15 and 20 minutes.
Derivatisation at 70°C for 20 minutes was used as the standard reaction conditions to
represent those commonly cited in the literature for producing PFP-amphetamine
derivatives.
Methods A and B, were then compared to the derivatisation conditions used previous
to this investigation. Derivatisation was carried out at 50°C (Method C) and did not
involve the addition of tartaric acid. To enable a direct comparison, Method C was
conducted at each time interval.
The comparison of these three methods involved the preparation of a methanolic
standard solution of AP, MA, MDA, MDMA and MDEA (Sug/ml). A three-point
calibration curve was obtained using solvent volumes of 20, 50 and lOOll1 of the
standard solution.
To each standard was added IOOIlI of tartaric acid (Irng/ml) in ethyl acetate, and
50111of 2% ammoniated methanol (to replicate the basic elution solvent). The
samples were then evaporated to dryness (room T, stream N2). They were derivatised
with PFPA:Ethyl acetate (1: 1), after which they were evaporated to dryness as before
and then reconstituted in 50111of a lug/ml solution of butylated hydroxy toluene
(BHT) in ethyl acetate.
Application of Solid-Phase Extraction for the Analysis of Drugs in Biological Matrices
Chapter Four: Amphetamines Page 134
Analysis was conducted by Ge/MS and quantitation was carried out using the ion
ratios of the analytes to BHT (205*, 220). The ion indicated with an * was used for
quantitation. These ions were chosen after obtaining the full mass fragment spectrum
ofBHT (see figure 4.25).
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Figure 4.25 Full Mass Fragment Spectrum of BHT
4.4.10.3 Results and Discussion
Figure 4.26 shows the retention time of BHT in relation to the PFP-amphetamine
derivatives studied. The. chromatogram shows good peak separation with no
interfering peaks.
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Figure 4.26 Chromatogram showing the retention time of BHT in relation to AP,
MA, MDA, MDMA and MDEA.
Derivatisation was conducted at room temperature (Method A) and 70°C (Method B)
for 2 to 20 minutes. Methods A and B, were compared to Method C which did not
involve the addition of tartaric acid and involved derivatisation at 50°C.
The results of these experiments are summarised in figures 4.27 and 4.28 for the
amphetamine derivative (AP-PFP) and methamphetamine derivative (MA-PFP),
respectively.
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Figure4.27 Recoveries obtained with Methods A and B compared to Method C
which did not involve the addition of tartaric acid for amphetamine
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Figure4.28 Recoveries 'obtained with Methods A and B compared to Method C
which did not involve the addition of tartaric acid for
methamphetamine
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No appreciable difference in recoveries was seen for MDA, MDMA and MDEA and
so the results are not included. With the exception of the reaction time of 20 minutes,
derivatisation conducted at room temperature gave consistently better recoveries than
at 70°C.
The recoveries resulting from these reaction conditions compared well with those
conducted at room temperature. However, when carried out at each of the times
shown, the two methods involving tartaric acid gave much better recoveries after
only 2 minutes.
From these 'results it would appear that with the addition of tartaric acid the kinetics
of the acetylation reaction are such that the samples do not require elevated
temperatures to complete the derivatisation procedure. The developed method is
simple and produces no interferences and the analysis time was reduced
significantly, with a derivatisation time of just 2 minutes.
4.4.11 Re-validation of Extraction Procedure for Hair and Whole Blood
4.4.11.1 Experimental
The next step was to determine whether or not the addition of tartaric acid would
improve the already existing extraction method for blood and hair. Recoveries from
blood and hair were, determined using spiked samples at three different
concentrations. (Blood: 0.1-,0.5 and 1mg/l; hair: 50, 100 and 200ng). Peak area ratios
of each analyte to the internal standard (amphetamine - ds) were determined for each
extracted spiked sample and compared to that of the unextracted standards.
Application of Solid-Phase Extraction/or the Analysis 0/Drugs in Biological Matrices
Chapter Four: Amphetamines Page 138
Calibration curves were obtained by spiking blank blood and hair over concentration
ranges ofO to 500ng/ml and 0.5 to 5mg/l, and 0 to 1000ng respectively.
4.4.11.2 Results and Discussion
The results of the validation experiments are summarised in Table 4.9.
Table 4.9 Recovery and Linearity Results for the Extraction of Amphetamines
from Blood and Hair with the Tartaric Acid Step.
Blood Hair
Analyte Recovery Linearity (r) Recovery Linearity (r)
(%)* o ~ 500nglml (%)t o ~ 1000ng
/ 0.5 ~ 5 mgll
AP 87.2 0.995 /0.997 91.3 0.993
MA 90.2 0.999/0.995 94.9 0.996
MDA 93.4 1.000/0.996 92.0 0.996
MDMA 95.6 0.998/0.997 97.6 0.997
MDEA 97.3 0.996/0.998 98.0 0.998
A recovery of greater than 87% was obtained in blood and greater than 91% in hair.
In both cases amphetamine (AP) had the lowest recovery. The recoveries of
amphetamine from hair increased substantially over the previous method (91%
compared to 72.9%), which did not involve the addition of tartaric acid and from
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84.3% to 94.9% for methamphetamine. Improvements in recovery was also noted for
all three methylenedioxyamphetamine derivatives from hair.
The range of concentrations studied were 0 to 500ng/ml and 0.5 to 5llg/ml in blood
and from 0 to lOOng/mg in hair. The methods were linear with r squared values of
greater than 0.993 for blood and 0.995 for hair, see figures 4.29 to 4.31.
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Figure 4.29 Calibration Curves for amphetamine, methamphetamine, MDA,
MDMA and MDEA (0 to lOOOng) for hair after addition of tartaric
acid
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Figure 4.30 Calibration Curves for amphetamine, methamphetamine, MDA,
MDMA and MDEA (0 to SOOng/ml)for blood after addition of
tartaric acid
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Figure 4.31 Calibration Curves for amphetamine, methamphetamine, MDA,
MDMA and MDEA (0.5 to Smg/l) for blood after addition of tartaric
acid
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4.5 Conclusion
The initial method combining enzymatic treatment, solid-phase extraction,
derivatisation and GC/MS, successfully detected all five amphetamines (AP, MA,
MDA, MDMA and MDEA) in hair and was successfully applied to the analysis of
over 100 hair segments (see Chapter Five). The method was adapted for the analysis
of whole blood, which involved separate sample pretreatment steps but the same
solid-phase extraction and derivatisation steps.
This method was further developed with the addition of tartaric acid pnor to
evaporating an extracted sample or analytical standard to dryness. By the simple
addition of tartaric acid prior to evaporation, recovery of the small amines was
greatly improved and derivatisation complete in only two minutes at room
temperature. The method is simple and produces no interferences.
In addition to the significant reduction in the total time of analysis, the recoveries
from blood and hair improved and were greater than 87% for all five amphetamines.
The method was successfully applied to the analysis of postmortem samples (see
Chapter Six).
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5. Hair Analysis
5.1 Introduction
Over the past decade hair testing for drugs of abuse has developed into an important
tool with both forensic and clinical applications. In the United States, Japan and
several European countries, hair testing is routinely used as an alternative or
complementary technique to urinalysis and as evidence in court cases. This is not the
case in the United Kingdom. Only two private companies offer hair testing for drugs
of abuse and to date the detection of these drugs in hair has not been accepted as
evidence in British courts.
Hair analysis offers several advantages over urinalysis:
• collection of a hair sample is less intrusive and causes less embarrassment,
• hair is a strong, stable tissue which results in a test unaffected by adulterants or
short-term abstinence
• hair does not require refrigeration and can be stored indefinitely.
• hair grows at approximately 1cm per month and it is proposed that utilising
segmental analysis can provide an individuals drug use history,
• if required a second representative hair sample can be analysed
The importance of hair analysis is in its ability to confirm long-term drug use, while
biological fluids yield short-term information. The two techniques compliment each
other, aiding the toxicologist to interpret the role if any, of drugs in each case.
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5.2 Hair Anatomy and Physiology
5.2.1 Introduction
Although hair testing has great potential as a technique for determining drug use,
there is still little understood as to how drugs are incorporated into hair, including the
influence of individual variations and the role of contamination.
In order to fully understand and interpret the results of hair tests, its is important to
have some basic understanding of the biology of hair.
5.2.2 Hair Structure
Hair is a complex tissue of cylindrical shafts of tightly packed cells (Figure 5.1). The
cuticle is the outermost layer, which serves to protect the interior of the hair shaft.
The cuticle consists of a single layer of flat, overlapping cells, which can be damaged
or destroyed by heat, light and chemical treatments.
The cortex constitutes the bulk of the hair and contains long keratinised cells that
form long fibres. The cortical cells contain a variety of chemicals including melanin,
the principal pigment of hair. The colour of human hair varies with the quantity,
distribution and type of pigments present.
The medulla is the innermost region of hair and is made up of a framework of
spongy keratin and air spaces. In human hair the medulla may be discontinuous or
absent.
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Figure 5.1 Cross-section of a Hair Shaft (Copyright © Elsevier Scientific
Publishers, 1993)
Hair contains sulphur rich proteins called keratin, which accounts for approximately
65 to 95% of hair content. Lipids, trace elements, heavy metals and water are also
present.
5.2.3 The Hair Follicle
Hair follicles are extremely complex structures embedded in the epidermal
epithelium of the skin. There are estimated to be between 80,000 and 100,000 in the
human head alone 240. A simplified structure of the hair follicle is shown in Figure
5.2.
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Figure 5.2 The Hair Follicle and Surrounding Structures (Copyright © Elsevier
Scientific Publishers, 1993)
The sebaceous and apocrine glands secrete directly into the hair follicle, while the
eccrine sweat glands secrete near the exit of the hair follicle 241. Both the sebaceous
and eccrine glands are located over nearly the entire surface of the body. The
apocrine glands are localised in the eyelids, axilla, the external auditory meatus and
the perineal region.
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In addition to the secretory glands, a dense capillary network at the base of the bulb
and the cutaneous plexus may nourish the hair follicle. It is possible that secretory
glands and capillaries are sources of drugs present in hair 242.
Biological synthesis of hair cells is located within the hair bulb. The keratogenous
zone is located above the hair bulb and is the site of keratinization, where hair cells
differentiate, lose water and harden to form the hair shaft.
5.2.4 The Hair Growth Cycle
There are three recognised stages in hair growth, the anagen, catagen and telogen
phases. During the anagen phase, there is an increase in metabolic activity, cell
division and growth. It is at this time that drugs and trace elements are thought to be
incorporated into hair 243.
Following this period of active growth, cell division stops, the hair shaft becomes
fully keratinised and the bulb begins to degenerate. This is termed the catagen phase,
which is a short transitional stage, the length of which varies with the hair type.
The telogen phase is a period when there is no hair growth, the follicle is short and
can be easily removed by pulling. The length of time that hair is in this phase is
dependent on the hair type and increases with age.
Other factors affecting hair growth include pregnancy, metabolic and genetic
disorders, nutrition, endocrine dysfunction and seasonal changes 244. Routinely, an
average growth rate of 1cm/month is assumed, however this is an oversimplification
with reported growth rates ranging from 0.75 - 1.35cmlmonth 245 and 0.6 -
3.36cmlmonth 242.
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This wide window of variation makes interpretation of hair analysis very difficult. It
has been suggested that individual hair growth rates should be calculated by
bleaching or colouring a hair strand directly above the scalp. The growth rate can
then be estimated by examining the hair 4 weeks later. Hair cut from the scalp does
not represent the drug use over the previous month because it has been estimated to
take approximately 3 weeks for the growing hair follicle to reach the surface of the
scalp.
On average 85% of the hairs on the human scalp are in the anagen phase, It is
important when interpreting results of hair tests to keep in mind the different rates of
growth. Hair sampled from the vertex region of the scalp is preferred because it has
the fastest growth rate and the largest percentage of follicles in the anagen phase.
5.2.5 Types of Hair
There are three basic types of hair on the human body. Vellus hair is fine, short, non-
pigmented hair found on the eyelids, forehead and bald scalp. Intermediate hair is
intermediate in length and diameter and is found on the arms and legs of adults.
Terminal hair is coarse, long and pigmented with a large cross-sectional area and is
found on the scalp, beard, eyebrow, eyelash, armpit and pubic areas.
These three different hair types are formed due to differences in hair follicles.
Intermediate hair is produced by non-sexual hair follicles, which are not influenced
by hormones and do not change after puberty. Ambisexual hair follicles are
influenced by hormones and change during puberty, e.g. pubic areas, axilla and
temple of scalp.
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When it comes to analysis, scalp hair is the easiest to collect and causes less
embarrassment. However, scalp hair is also subject to contaminants from the
environment, sweat and cosmetic modifications. Beard hair is thick, has the slowest
growth rate (approximately O.27mmlday) and is subject to the same environmental
contamination as scalp hair. Although sebaceous secretions may not contaminate
beard hair, the specimen is likely to contain pieces of epidermis when obtained by
shaving.
The advantages of using pubic hair include, availability of sample and not being
subject to environmental or cosmetic effects. However, urine and gland secretions
are still potential sources of contamination. Pubic hair grows slower than scalp hair
and has a longer telogen phase.
5.3 Drug Incorporation into Hair
To accurately interpret hair test results requires knowledge of the mechanisms by
which drugs are incorporated into hair, and the factors which affect their binding.
Although a great deal of research is on-going in this key area, the exact mechanisms
by which drugs are incorporated into hair are unknown. Several routes have been
proposed and are illustrated in the following two models:
• Passive Diffusion Model - drugs enter from the blood supply at the base of the
hair follicle 246
• Multi-Pool Model - drugs are incorporated from sweat, sebum, blood and
the environment 247.
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Passive diffusion of drugs from blood into hair would in theory result in a drug
concentration in hair proportional to the drug concentration in blood at the time of
hair synthesis 248. Controlled dosage studies with animals support the concept of a
linear relationship for cocaine 249 and/or benzoylecgonine 246,249-250.
However, this model does not explain the different metabolic profiles in hair and
blood. Cocaine, heroin and 6-mono-acetylmorphine (6-MAM) are rarely detected in
blood but are the primary analyte found in hair. In addition, drug concentrations in
hair can vary substantially in subjects receiving the same dose 251.
The multi-pool model encompasses all major routes by which drugs can enter the
hair. If drugs are incorporated via many pathways, hair tests should be interpreted
with caution until the exact role of external contamination can be assessed 248. Of
particular concern is the exogenous-endogenous shunt 252-253, where drugs can gain
access to systemic circulation by respiration or transdermal adsorption. The
determination of metabolites is of great importance to help distinguish between
passive contamination and ingestion 254.
Binding studies suggest that hair has different affinities and binding capacities for
various drugs and the binding mechanisms may be unique for each drug 231,255.
Factors affecting the incorporation and binding of drugs include, the pKa value, non-
protein bound drug molecules, size, lipophilicity 256, structure 255 and melanin
affinity 245,257. Methadone; buprenorphine, L-a-acetylmethadol (LAAM) and their
metabolites were detected in higher concentrations in pigmented hair than in non-
pigmented hair 258.
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Potsch et al 259, proposed the 'biochemical concept' to explain the endogenous
incorporation of drug molecules into growing hair. This concept tentatively explains
the high parent drug to metabolite ratio in hair, the dependence of incorporation on
the physico-chemical properties of the drug, the incorporation of drugs into non-
pigmented hair and the dependence of drug content on hair pigmentation. Further
work is currently underway to further prove the theories postulated.
Studies to investigate the incorporation of drugs into hair, which involve animal
models do provide useful information when interpreting human hair tests 260.
However, animal and human hair differs with respect to growth cycles and animal
hair is more hollow, which may result in different drug distribution. Alternatives to
animal models include in vitro human hair growth 260 and transplantation of human
hair onto nude mice 261-262. Human studies provide useful information regarding the
stability of drugs in hair but are of limited value for studying the mechanisms of drug
incorporation due to ethical considerations.
The stability of drugs in hair is dependent on the morphology and phsyicochemical
properties of hair. Skopp et al 263, investigated the existence of pathways for drug
molecules to diffuse into and out of the hair fibre. Diffusion of morphine, codeine
and dihydrocodeine did occur. They concluded that the non-keratinous regions in
human hair could provide channels for diffusion of small molecules in the presence
of water. Therefore, the diffusion process can result in external contamination or loss
of drug concentration. This was also illustrated by Potsch and Moeller 264 who used
fluorescence microscopy to exam Rhodamine B stained hair fibres.
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Several researchers have investigated the effect of cosmetic treatments on hair 265-270.
Although the studies carried out varied with respect to the drugs and the cosmetic
treatments investigated, all were in agreement that dyeing, perming and bleaching
have a deleterious effect on the drug concentration detected in hair. Daily
shampooing does not significantly affect drug concentration 246.
Jurado et a1267, focused on the effects of bleaching and dyeing on the concentrations
of opiates, cocaine, cannabinoids and nicotine detected in hair. The decrease in drug
concentrations was more prominent for bleached hair than dyed. Damaged hair
showed significantly lower levels.
Donahue et al 270 investigated five shampoos which individuals or manufacturers
claimed would remove drugs from hair. In general, the treatments did reduce drug
concentrations, however, this was not significant and did not cause negative
screening results.
5.4 New Developments in Hair Testing Methodology
The historical development of hair testing techniques for drugs of abuse was
described by Sachs 271 as having progressed through different phases beginning with
the 'Pre-MSD' period where techniques used were predominantly immunoassay
based, e.g. radioimmunoassay 272-273. Following this was the 'uncritical' use of mass
selective detectors (MSD's) and then the 'critical evaluation' of methods involving
MSD's from 1993 to 1996. 1997 onwards will hopefully see an increase in papers
Application of Solid-Phase Extraction for the Analysis of Drugs in Biological Matrices
Chapter Five: Hair Analysis Page 152
dealing with the areas where a greater understanding is required to further develop
the usefulness of hair testing.
The majority of present day hair testing methods for drugs of abuse involve five
steps:
1. The hair sample is washed to remove external contamination HG9,lO, and is then
measured and cut to the appropriate lengths required.
2. Individual hair samples are then cut into smaller pieces or ground to a powder.
3. The drugs are then extracted from the hair matrix using one of a variety of
techniques. These include methanol and p-glucuronidase which remove the drugs
without damaging the hair and are preferentially used for screening for a range of
different drugs 226. Acidic or alkaline hydrolysis are commonly used 254 while
supercritical fluid extraction has been used lately as an alternative method 275.
4. Once the drugs are separated from the hair they can be extracted by the same
techniques used for blood or urine.
5. Gas chromatography - mass spectrometry (GCIMS) is the method of choice for
confirming the presence of drugs in hair, however GC-MS-MS and LC-MS are
used in several laboratories as alternatives for greater sensitivity 276-277. Capillary
electrophoresis (CE) has also been used to detect drugs in hair 209,278.
Research has centred predominantly on the analysis of opiates 279-281, cocainics 256,282-
283, amphetamines 121,284;285 and cannabinoids 217,246 in hair. Heroin and 6-
monoacetylmorphine have been detected in the hair of heroin users, providing better
alternative markers to morphine for confirming heroin use 286.
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Henderson et al 287 carried out work with isotopically labelled cocaine and
contradicted previous work by claiming that the detection of cocaine in hair does not
provide an accurate record of either amount, time or duration of drug use.
Areas requiring future research include:
• Developing standard procedures for hair testing 288. Welch et al219 compared the
results from an interlaboratory study involving the analysis of drugs users hair
and blank hair fortified with drugs. Qualitatively the results were good and
comparative for both drug users and fortified hair, however, quantitatively, the
results' from fortified hair was better. Analysts had greater difficulty extracting
drugs from drug users hair.
• A greater understanding of how to interpret test results.
• Determining the influence of sweat on the levels of drugs incorporated into hair.
• Conducting tightly controlled human studies to determine dose-response
relationships.
5.5 Applications of Hair Testing
Interpretation of hair test results is at present extremely difficult. Hair testing is
generally agreed to be useful for determining the general exposure of the population
to certain drugs 289. Although there remains many unanswered questions regarding
reliability, hair testing is used for a variety of applications including:
• Proving drug use in drug-related fatalities 229.
• Determining physical fitness to obtain a driving license 290.
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• Criminal responsibility 291-292.
• Prenatal drug exposure 286,293.
• Offenses of drug laws 294.
• Monitoring compliance with medication or abstinence 295.
5.6 Conclusion
Hair testing has enormous potential, however additional studies will have to be
carried out before hair achieves the accuracy and reliability of urine testing 296. There
exists several problematic issues which require resolution. These include
contradictory findings reported for the effectiveness of washing techniques 223,274, the
exact role of external contamination including the effects of cosmetic treatments, the
possible bias in hair testing for drugs due to hair colour, ethnic origin and sex and
unknown mechanisms by which drugs are incorporated into hair.
Many researchers believe that hair testing will become a routine complimentary
technique to urinalysis once the methods have been refined and are made more
amenable to larger-scale applications 297. At present hair tests are expensive with
little or no quality controls 298.
Although hair testing has proved useful for some substances 299 until these issues
have been resolved hair testing will continue to be received with caution.
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5.7 Experimental
5.7.1 The Scottish Centre for Criminology
5.7.1.1 Introduction
The following project was part of a larger study investigating the use of "speed" and
"ecstasy" in Glasgow 300 and involved individuals from multiple disciplines t.
Subjects claiming use of "speed" and "ecstasy" were recruited from the "dance
scene" by chain referral (i.e. subjects nominated other subjects). They were asked to
complete a detailed questionnaire of their drug use over the previous 12 months and
to donate a hair sample for analysis. Subjects were compensated for samples.
The alms of the project were to investigate the accuracy of hair analysis in
confirming self-reported use of "speed" and "ecstasy" and to determine whether or
not a correlation exists between the amount of drug ingested and the levels detected
in hair. Amphetamine (AP) and methamphetamine (MA) were identified to confirm
"speed" use and MDA, MDMA and MDEA for "ecstasy" use.
t Desiree L. Allen,' P.D.F.S.; Karen S. Scott,' Ph.D.; John S. Oliver, 1 Ph.D.; Jason Ditton/ Ph.D. and
lain D. Smith, 3M.R.C.Psych. 'Department of Forensic Medicine and Science, University of
Glasgow, Glasgow, Scotland. 2Faculty of Law, The University of Sheffield and The Scottish Centre
for Criminology, Charing Cross, Clinic, 8 Woodside Crescent, Glasgow, Scotland. 3Consultant
Psychiatrist, Gartnavel Royal Hospital, Glasgow, Scotland.
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5.7.1.2 Hair Analysis and Self-Reported Drug Use
Several independent laboratories in Europe, Japan and the US have confirmed the
accumulation of drugs such as cocaine 219,283,301, heroin and other opiates 279-281,301,
amphetamines 206-207,216,221 and phencyclidine 230,302 in the hair of drug users. Other
studies published have reported a dose-response relationship in hair for a variety of
drugs in controlled animal studies 214,249,303-304. Most of the studies involving human
subjects compared self-reported drug use to hair or urinalysis. A linear relationship
was observed between hair cotinine levels and daily nicotine intake 305, however, this
is an exception to what is generally reported. A relationship between low and high
use and the levels of drugs detected in hair has been observed for cocaine 306, heroin
307 and buprenorphine 220. The lack of a linear dose-response relationship is not
surprising due to the number of unknown variables, such as the exact dose or purity
of drug consumed, the accuracy of the self-report data, individual metabolism
variations and the types and frequency of hair treatments.
5.7.1.3 Sample Collection
100 subjects were interviewed (male:female; 51 :49). 95% of the participants were
Caucasian. Ages ranged from 15-44 years, with a mean age of 24 years. "Ecstasy"
use was recorded as the number of tablets consumed per month for each of the
previous 12 months. "Speed" use was recorded as "ever consumed" and then broken
down into how often they had consumed it in the previous week, month and year.
The hair samples were out close to the scalp in the vertex region, wrapped in
aluminium foil and sealed in labelled plastic bags. Where possible, two 6 cm
segments were analysed. The proximal 6 cm was labelled the "root" sample and the
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distal 6cm the "tip" sample. In total, 139 hair segments were analysed without prior
knowledge of the self-report data.
A summary of the segments analysed is shown in Table 5.1. The hair lengths ranged
from 1.5-12 cm. A total of 56 samples were analysed in full.
Table 5.1 Lengths of hair segments analysed
Sample Type Length (cm) Total
Roots <3 4
3~6 10
6 40
Tips 6 29
Full 6.1 s 12 10
12 46
Total 139
5.7.1.4 Summary of Drug Use History
Of the 100 subjects questioned, 90 admitted taking "ecstasy" during the year prior to
interview. Consumption of "ecstasy" was primarily at one of four locations (night-
clubs, licensed raves, illegal parties and private parties).
The total number of "ecstasy" tablets consumed within these two groups ranged from
1 - 144 (mean = 19, median = 10) over the previous year. In this study, the heaviest
user consumed 144 tablets in the previous year, which translates to more than weekly
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but less than daily consumption of "ecstasy". This is in sharp contrast to heavy
heroin users, who use heroin at least once a day. The control group (n = 9) consisted
of individuals who participated in the dance scene, but denied ever using "speed" or
"ecstasy". This number is low due to the difficulty in recruiting individuals who
satisfied this criteria.
5.7.1. 5 Results and Discussion
Hair segments were analysed as detailed in section 4.4.7. Each hair segment (n =
139) was analysed once by the described method. Of the 139 segments, 73 (52.5%)
tested positive for at least one of the five amphetamines, the remaining 66 segments
were negative for all five. In general, the levels of AP, MA, MDA, MDMA and
MDEA detected in the hair samples are in the same range as those reported
elsewhere 206,218,221,231,308.
Table 5.2 Drug concentrations detected in hair segments
Drug No. (Range) Median Mean
nglmg ng/mg ng/mg
AP 11 (0.7 - 97.7) 2.5 12.5
MA 27 (0.6 - 32.3) 2.6 5.2
MDA 20 (0.1 - 8.4) 1.0 1.9
MDMA 56 (0.1 - 82.9) 0.7 4.6
MDEA 23 (0.1 - 12.0) 0.5 2.8
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Some exceptions to this were found where levels detected were higher than those
previously reported. These cases were few and the median of the results was found to
lie within the reported ranges. The results are summarised in Table 5.2.
The ratio of metabolite to parent drug levels in hair has been used to determine
whether a positive result is due to contamination or from ingestion 309-310. This ratio
is expected to be lower than 1.0 due to the preferential incorporation of the parent
drug to the metabolite. Therefore, a value greater than one is thought to result from
contamination. The Society of Hair Testing recognises set ratios for cocaine and
heroin and their metabolites, but not as yet for amphetamines 310•
The metabolite to parent drug ratios are summarised in Table 5.3. With the exception
of the ratio MDA: MDMA, the ranges of the others were higher than those
previously reported. This can be explained in the case of AP and MA. "Speed" can
contain both AP and MA as the parent drug, which will effect the metabolite to
parent drug ratio. Combining the levels of MDMA and MDEA found in individual
hair samples was carried out to determine if a relationship exists between the
combined levels of these parent drugs in hair and the amount of drug consumed.
Results obtained for the ratio MDA: (MDMA+MDEA) ranged from 0.03 to 6.5 in
contrast to those found by Rothe et al 308 (0.03 to 0.2, n=67). However, they too
reported cases with ratios > 1. A possible explanation for this would be the
consumption of MDA as a parent drug as well as its metabolic contribution from
MDMA and MDEA.
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Table 5.3 Metabolite to parent drug ratios
Ratio No. (Range) Median Mean
AP:MA 9 (0.15 - 44.40) 0.85 7.26
MDA:MDMA 12 (0.01 - 6.28) 0.40 0.54
MDA: MDEA 11 (0.10 - 6.50) 0.67 1.59
MDA:(MDMA+ 14 (0.03 - 6.50) 0.33 0.95
MDEA)
Concordance between the self-reported data and the levels detected in hair was
investigated for all 139 segments. A total of 73 segments tested positive for at least
one of the five amphetamines with 71 of these agreeing with the self-report data. 66
were found to be negative, with only six agreeing with the self-report data. Overall,
agreement or concordance was greater than 50% with a low number of false
positives, consistent with other studies. The results of which are summarised in
figure 5.3.
A large number of false negatives were found. There are a number of possible
explanations for this including the method lacking sensitivity, over reporting of drug
use by the individual and the influence of cosmetic treatment on the hair 265-267.
Unfortunately, no information was available on previous hair treatments (e.g. perms,
bleaching etc.) and so the contribution of this to the results could not be assessed.
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Figure 5.3 Overall concordance between self-report and hair analysis (n = 139)
Comparing the different types of sample analysed, it was expected that root samples
would be more accurate than tip samples as they have been subject to fewer
environmental and cosmetic influences, which have been shown to affect the drugs
stability in hair. In addition, the self-report data would be expected to be more
reliable due to better recollection of drug use in recent months as opposed to 12
months prior to interview.
The root samples have slightly better concordance (59.3%) than the tips (51.7%) and
full (53.6%) samples. Figure 5.4 summarises the concordance between self-report
and hair analysis for each of the segment groups. These consist of roots (proximal
sample s 6cm), tips (distal 6cm) and full samples (» 6cm).
Application of Solid-Phase Extraction/or the Analysis of Drugs in Biological Matrices
Chapter Five: Hair Analysis Page 162
SELF SELF
Ye
Yes No
29 0s (53.7%) (0.0%)
22 3
(40.7%) (5.6%)
Ye
Yes No
13 0s (44.8%) (0.0%)
14 2
(48.3%) (6.9%)
LAB LAB
No No
A B
SELF
Y
Yes No
29 2es (51.8%) (3.6%)
24 1
0
(42.9%) (1.8%)
LAB
N
c
Figure 5.4 Concordance between self-report and hair analysis for each segment
type; A. Roots (n = 54), B. Tips (n = 29) and C. Full (n = 56).
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When comparing the self-report data for the use of "speed" only or "ecstasy" only,
the concordance is very low for "speed" (28.3%) but higher for "ecstasy" (57.5%).
The results are illustrated in figure 5.5. Unlike the "ecstasy" data, the "speed" data
was not recorded for each month of the previous year and in addition, higher limits
of detection were employed. The combination of these factors will decrease the
number of potentially positive results.
SELF SELF
LAB
Yes No
Yes 23 6
(16.7%) (4.3%)
93 16
(67.4%) (11.6%)
No
Ye
N
Yes No
s 58 7
(41.7%) (5.0%)
52 22
0
(37.4%) (15.8%)
LAB
A* B
Figure 5.5 Concordance between self-report data and hair analysis for "speed"
only (A) and "ecstasy" only (B). [One subject did not answer question
on "speed"].
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Of the six false positive segments where individuals denied "speed" use but tested
positive for amphetamine and/or methamphetamine, five admitted "ecstasy" use, and
were also positive for MDA, MDMA or MDEA. Six of the seven false positives for
"ecstasy" admitted taking "speed" but only one case was positive for amphetamine.
It is certainly plausible that the subjects were unaware whether they were consuming
"speed" or "ecstasy" and this would account for some of the false positive or
negatives.
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Figure 5.6 Correlation between the amount of ecstasy consumed and the total
concentration of (MDMA +MDEA) in hair (n = 139).
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Figure 5.6 illustrates the correlation between the total number of "ecstasy" tablets
consumed and the total concentration of "ecstasy" (MDMA + MDEA) detected in
each hair segment. There is a large scatter of results with the majority congregated
along the axes. No linear dose-response relationship was observed (r = 0.0484, P =
0.572). This was also the case when comparing the amount of "ecstasy" consumed
and the total concentrations ofMDMA or (MDA +MDMA +MDEA) measured.
The results for each hair segment were separated into five groups depending on the
average number of "ecstasy" tablets consumed each month. Each group consisted of
approximately 20% of the segments analysed. The mean, median and range are noted
for each group and summarised in Table 5.4.
Table 5.4 Correlation between the number of "ecstasy" tablets consumed/month
and the total concentration of (MDMA +MDEA) detected in hair
No. E Tablets Frequency Mean Median Range
per month * ng/mg nglmg ng/mg
None 29 0.086 0.00 0-1.00
<0.5 29 1.493 0.10 0-20.3
0.5 -1.25 28 4.285 0.00 0-93.4
> 1.25 - 3.5 27 1.615 0.00 0-23.9
>3.5 26 4.285 0.55 0-55.7
Total 139 1.942 2.00 0-93.4
* The average number of ecstasy tablets consumed each month.
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An increase in the mean and the median values for the total concentration of MDMA
+MDEA is observed from low to high frequency of use. The one exception to this is
the group where between 0.5 to 1.25 tablets were consumed each month. The mean
value is higher due to one case which had a total concentration of 93.4 ng/mg.
Another important point here is the high number of false negatives which are
prevalent throughout each of the four groups claiming "ecstasy" use. However, the
number of false negatives did decrease from low to high use.
The data was evaluated with respect to sex and hair colour. There was no significant
difference between the sexes 300. 95% of the participants were Caucasian with the
vast majority with hair of various shades of brown. The lack of a relationship with
hair colour is probably indicative of this.
5.8 Conclusion
Although concordance between self-reported data and laboratory findings was
approximately 50%, there were a high number of false negatives (43.2%) which may
highlight the methods lack of sensitivity in confirming low use of "speed" and/or
"ecstasy". No correlation was observed between the amount of "ecstasy" consumed
and the levels detected in hair. However, there was evidence of a relationship
existing between the level of use (measured in average "ecstasy" tablets consumed
per month) and the levels detected in hair from low to high use.
The data was evaluated with respect to sex and race, however no significant
relationship was observed in either case. The results of this study have given rise to a
number of key questions which need to be answered to fully realise the potential of
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hair analysis, in particular, for the analysis of "ecstasy" in hair. A combination of
low concordance between self-report data and hair analysis results, and the high
number of false negatives, raises questions regarding both the method sensitivity and
the reliability of the self-report data.
The method of collection of hair samples is also of utmost importance. As
highlighted earlier in this paper, the samples obtained for this study were too small to
be analysed more than once. In some cases, this one analysis yielded a false negative
result as the sample size was too small to give a significant level by GC/MS. It is
acknowledged that obtaining larger samples on a voluntary basis could be
problematic due to the sampling area (vertex region). However it is practical to be
able to analyse samples in triplicate in order to decrease experimental errors and thus
increase the validity of analytical results.
The large number of false negatives and low drug levels detected is likely to be a
reflection on low drug consumption, with the heaviest users consuming
approximately one "ecstasy" tablet per week of unknown purity. Comparing this to
heavy heroin or cocaine users (> one per day), approximately 80% of "ecstasy" users
in this study consumed less than one tablet per week.
The parent drug to metabolite ratio is unusual in comparison to the studies carried
out with heroin and cocaine, where ratios of less than one are expected. Tablets
seized from within the- UK prior to the hair samples being collected, had high
quantities ofMDA present 136-137. With this in mind the ratios are not unusual due to
the unknown contribution of MDA as either a parent drug and/or a metabolite.
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Large discrepancies between cases are reflected in the lack of a dose-response
relationship for the segments analysed. Two examples are given which clearly
illustrate this.
One subject reported use of 52 "ecstasy" tablets over a six month period, however
the hair was negative for all five amphetamines. Conversely, another subject denied
use of "ecstasy" but 0.6 ng/mg ofMDMA were found in the corresponding 2 cm hair
segment.
Determining the smallest dose detectable in hair, in combination with dose-response
studies, would certainly help explain why in one case, where only five "ecstasy"
tablets were consumed, a level of 1.1 ng/mg of MDMA was detected. However,
when 50 tablets were consumed by another subject, this only gave rise to a level of
0.5 ng/mg ofMDMA.
The influence of various factors, i.e. cosmetic treatments, individual metabolism
variations, and the uncertainty of the content and dose of the "ecstasy" tablets, are
currently being investigated further. A wealth of information can be gained from
studies involving consumption of known doses and subsequent hair analysis. One
additional factor, highlighted by Rothe et a/308, is the influence of drug incorporation
via sweat. This is of particular relevance with "ecstasy" use, where participants in the
dance scene are known to dance for several hours in hot, humid conditions.
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The relationship observed between the average number of "ecstasy" tablets
consumed per month and the total concentration of (MDMA + MDEA) detected in
hair, gives some indication of the potential of hair analysis as an indicator of
"ecstasy" use. This in addition to the previous points, will aid greatly with future
interpretations of amphetamine levels in hair.
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6. Case Studies
6.1 Introduction
The methods developed for the analysis of both blood and hair were applied to
forensic case samples. Blood and hair samples were collected at postmortem, in
addition to routine biological samples. Hair samples were pulled from the vertex
region of the scalp and blood was collected from peripheral veins, usually the sub
clavea. If this was not available, blood was collected from the femoral vein. This was
done with, the permission of the Procurator Fiscal who is in overall charge of sudden
death investigations in Scotland.
Blood samples were analysed prior to this project by the technical staff at the
Department of Forensic Medicine and Science. The samples were then re-analysed
using the developed methods and a comparison made between the levels detected. In
some cases the blood samples were re-analysed more than 2 years after the initial
analysis, enabling a study of the analytes stability in postmortem blood over a period
of 6 months to 2 years.
Postmortem hair samples were pulled from the scalp to free the root bulbs. The hair
was de-rooted and then segmented depending on the length of the deceased's hair.
The root samples were not washed, but the segments were, to remove any external
contamination. Hair washes were analysed for the analytes of interest in addition to
the hair segments.
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In addition to determining the presence of the analytes, a preliminary investigation
was conducted to determine whether or not a relationship existed between levels of
analytes in blood and the corresponding levels detected in the root bulb. Segmental
analysis of the hair samples was also carried out in an attempt to confirm antecedent
drug use history.
A summary of the relevant case information was noted from the police sudden death
report, including relevant information on antecedent history, medical notes and the
circumstances surrounding the death.
In total, 22 hair samples were analysed and 54 blood samples re-analysed. The
relationship between postmortem analyte levels detected in blood and the root bulb
was investigated in 13 cases. The results of all cases are discussed in the following
chapter.
6.2 Case Information
Reference: GCO1
Circumstances: No police report
Cause of Death: I.a No postmortem report.
Toxicology: I.44mg methadonelL blood, O.76mg morphinelL blood.
Sex: Female Age: ?
Samples Re-analysed: Blood + hair
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Reference: GC02 Sex: Male Age: 36
Circumstances: Evidence of old healing needle puncture marks. IVDA for 15
years. Past 12 years attempted a number of drug rehabilitation programmes. Due to
uplift methadone prescription 12 days prior to being found dead, but never did. Last
seen alive 16 days prior to being found dead.
Cause of Death: 1.a Pneumonia with Multiple lung abscesses. 2. Intravenous Drug
Abuse.
Toxicology: O.12mg methadone/L blood.
Samples Re-analysed: Hair
Reference: GC03 Sex: Male Age: 22
Circumstances: No history of IVDA, but certified unfit for work due to smoking
heroin and cannabis. Administered course of dihydrocodeine and nitrazepam. Day
prior to death, 2100hrs - smoked 2 joints. 2200hrs - fell asleep. 0830hrs - found
dead.
Cause of Death: l.a Inhalation of gastric contents, b. Drugs overdose.
Toxicology: O.18mg methadone/L blood.
Samples Re-analysed: Hair roots only.
Reference: GC04 Sex: Male Age: 39
Circumstances: Possible needle puncture mark in right groin. Evidence of chronic
IVDA. Last seen by Doctor 8 days prior to death, collected weekly prescription of
methadone and diazepam. (Methadone = SOmLs/day + diazepam (l Sml.s/day), 3
days prior to death complained of feeling unwell. 2 days prior to death, 1000hrs -
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feverish. Admitted to being assaulted and condition deteriorated, transferred to ICU.
Suffering from cellulitis of the abdominal wall.
Cause of Death: l.a Sepsis syndrome due to, b. cellulitis anterior abdominal wall,
due to c. chronic IVDA.
Toxicology: O.36mg methadone/L blood, 0.44mg desmethyldiazepam/L blood,
O.25mg diazepam/L blood.
Samples Re-analysed: Blood +Hair
Reference: GC05 Sex: Male Age: 23
Circumstances: Known heroin user for 3 years. Last seen by Doctor 4 days prior to
death. Repeat prescription (methadone, diazepam and temazepam). Released from
prison 1 month previous after serving 13 months. 2330hrs - arrived home under the
influence, OIOOhrs - sleeping soundly. 0430hrs - heard coughing, 0955hrs - found
dead.
Cause of Death: l.a Overdose of morphine.
Toxicology: O.14mg methadone/L blood, 0.23mg morphine/L blood.
Samples Re-analysed: Hair
Reference: GC06 Sex: Male Age: 16
Circumstances: No medical history of note. Under the influence (1750hrs).
Sleeping but still alive (2145hrs), found lying face down (1125hrs, next day).
Informed that decedent had consumed 30mg methadone before midday the previous
day.
Cause of Death: l.a Inhalation of gastric contents, b. Drugs overdose.
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Toxicology: O.07mg methadone/L blood, O.33mg desmethyldiazepamIL blood,
0.33mg diazepamIL blood.
Samples Re-analysed: Blood
Reference: OC07 Sex: Male Age: 25
Circumstances: Evidence of chronic IVDA. Last seen by Drug Clinic day prior to
death. 1745hrs - felt unwell, 1815hrs - struggling to breathe, administered oxygen.
2157hrs - condition deteriorated and died.
Cause of Death: l.a Unascertained.
Toxicology: 19m9 alcoholll OOmL blood, O.055mg methadone/L blood, 2.4mg
lignocaine/L blood, 0.21mg desmethyldiazepamIL blood, O.06mg diazepamIL blood.
Samples Re-analysed: Blood + hair.
Reference: OC08 Sex: Female Age: 35
Circumstances: Old needle puncture marks. Known drug user for 8 years. Last seen
by Doctor 2 months prior to death. Released from prison day prior to death. 1300hrs
- overdosed on methadone, treated with Narcan, signed self out (1430hrs). 2000hrs-
consumed alcohol, smoked two joints, went to bed 2200hrs. Found dead (0900hrs).
Cause of Death: l.a Methadone Intoxication.
Toxicology: 25mg alcohol/lOOmL blood, 15mg paracetamol/L blood, O.68mg
methadone/L blood, 31mg a1cohoV100mL urine, 0.49mg desmethyldiazepamlL
blood, O.27mg diazepamIL blood.
Samples Re-analysed: Hair
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Reference: GC09
Circumstances: No police report.
Cause of Death: No postmortem report.
Toxicology: O.56mg methadonelL blood, 0.46mg amphetaminelL blood, 0.44mg
desmethyldiazepamlL blood, O.25mg diazepam/L blood.
Sex: Male Age: ?
Samples Re-analysed: Blood
Reference: GC I0 Sex: Male Age: 33
Circumstances: Evidence of recent needle puncture marks and old scars. Known
drug addict for 7 years, suffered from deep vein thrombosis. Prescribed methadone 5
months prior to death. Ate (0230hrs) and fell asleep. Found dead (1515hrs). Drug
paraphernalia found at scene.
Cause of Death: l.a Overdose of Morphine.
Toxicology: O.09mg methadonelL blood, O.28mg diazepam/L blood, O.29mg
temazepamlL blood, O.70mg morphinelL blood.
Samples Re-analysed: Blood
Reference: GC 11 Sex: Female Age: 29
Circumstances: Multiple healing needle puncture marks. Long history of drug use,
involved in various detoxification programmes. Last seen by Doctor 6 days prior to
death, requested methadone detoxification (40mLlday). Last seen alive 1700hrs day
prior to death. Drug paraphernalia found at scene.
Cause of Death: l.a Heroin intoxication.
Toxicology: 27.4mg paracetamollL blood, 0.32mg methadonelL blood, 1.1mg
desmethyldiazepam/L blood, 1.6mg diazepamlL blood, O.7mg morphine/L blood.
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Samples Re-analysed: Blood + Hair.
Reference: GC12 Sex: Male Age: 28
Circumstances: Evidence of recent needle puncture marks and old scars. Known
heroin addict for a number of years. Last seen by Doctor 10 days prior to death and
was prescribed methadone (35mg methadone/day), first prescribed 20 months prior
to death. Consumed methadone (1200hrs), returned home, seen to shake violently
and then collapsed unconscious (1640hrs).
Cause of Death: l.a Inhalation of gastric contents, b. Methadone and
Trichloroethanol Intoxication.
Toxicology: 0.41mg methadonelL blood, 33.2mg trichloroethanollL.
Samples Re-analysed: Blood
Reference: GC 13 Sex: Female Age: 27
Circumstances: Old and fresh needle puncture marks. Known drug user for 9 years.
On methadone programme for 2 years. Last seen by Doctor 3 weeks prior to death to
collect methadone (70mLs/day). Last seen 0930hrs, didn't collect methadone, Found
dead (1215hrs) with needle in situ.
Cause of Death: l.a Mixed heroin and temazepam intoxication.
Toxicology: O.l2mg methadonelL blood, 1.29mg desmethyldiazepam/L blood,
2.79mg temazepam/L blood, 0.94mg morphine/L blood.
Samples Re-analysed: Blood +Hair
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Reference: GC 14 Sex: Male Age: 28
Circumstances: Recently developed a drug habit. Diagnosed schizophrenic 6 years
prior to death. Known to use heroin for past 3 years. Witness described decedent as
being agitated and drunk. Demanded medication, but never received anti-
depressants. Injuries consistent with falling from a height.
Cause of Death: l.a Multiple injuries due to, b. Fall from a height.
Toxicology: 115mg alcoholllOOmL blood, O.1mg methadone/L blood, l6lmg
alcohol/lOOmL urine.
Samples Re-analysed: Blood
Reference: GC15 Sex: Male Age: 24
Circumstances: Numerous scars and injuries to body. Known solvent abuser and
agoraphobic after several assaults. Day prior to death, under the influence, + 29
valium and 4 stronger valium. 0430hrs - half a tin of glue, witness stated decedent
smelled of glue (lOOOhrs), went to bed, sleeping at l300hrs and found dead at
l500hrs.
Cause of Death: l.a Solvent and Drug Related Death, conditions contributing to
death: 2. Cardiomegaly and coronary artery atheroma.
Toxicology: 0.34mg methadone/L blood, 0.16mg desmethyldiazepamlL blood,
0.46mg diazepamIL blood, 1.04mg toluenelL blood and 4.08mg toluenelkg brain.
Samples Re-analysed: Blood
Reference: GC 16 Sex: Female Age: 20
Circumstances: Old healing scars. Known drug user, suffered from anxiety and
panic attacks. Last seen by Doctor 6 months prior to death. Week prior to death
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heavily under the influence of valium, temazepam and heroin (smoked). Day prior to
death complained of stomach pains and headaches (withdrawal symptoms). 2IOOhrs
- watched TV in bed until 0300hrs. Found dead at 0940hrs.
Cause of Death: I.a Drug related death due to, b. methadone, diazepam and
temazepam intoxication.
Toxicology: O.36mg methadonelL blood, O.35mg desmethyldiazepam/L blood,
0.14mg diazepamlL blood, O.3Img temazepamlL blood.
Samples Re-analysed: Hair.
Reference: GC 17 Sex: Male Age: 21
Circumstances: Fresh needle puncture marks and old scars. History of drug abuse.
Methadone prescription stopped 2 months prior to death. Using heroin and
temazepam for 2 years. Last seen by witnesses at midnight going to bathroom. Found
dead next morning in bathroom with needle and tourniquet in situ.
Cause of Death: I.a Drug Related Death, due to, b. Morphine (Heroin) and
Temazepam Intoxication.
Toxicology: 33mg alcohol/iOOmL blood, O.036mg methadonelL blood, I.36mg
temazepam/L blood, 0.38mg morphinelL blood.
Samples Re-analysed: Blood
Reference: GC 18 Sex: Male Age: 17
Circumstances: Evidence of old scars. Known to abuse temazepam for 2 years.
Diazepam and alcohol overdose 7 months prior to death. Evening - consumed 5
double strength dihydrocodeine + 7 yellow diazepam, excess alcohol and smoking
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cannabis. Took dog for a walk (0430hrs), ate and fell asleep. Found dead in sitting
position( 1030hrs).
Cause of Death: I.a Inhalation of gastric contents, due to, b. methadone, diazepam,
cannabis and alcohol intoxication.
Toxicology: I03mg alcohol/IOmL blood, O.23mg methadonelL blood, 153mg
alcohol/iOOmL urine, O.I9mg desmethyldiazepamlL blood, 0.40mg diazepamlL
blood, 26ng THC-COOHlml blood.
Samples Re-analysed: Blood
Reference: GC 19 Sex: Female Age: 25
Circumstances: IVDA, treated for depression, Last seen by Doctor 5 days prior to
death for repeat methadone prescription. (S5mL methadone, diazepam,
antidepressants), Decedent smoking hash alone (2200hrs), witness awoken by smell
of smoke but could not rescue decedent due to fire. Extensive charring of body, no
hair remaining.
Cause of Death: I.a Inhalation of smoke and fire gases due to, b. house fire.
Conditions contributing to death: 2. Drug Intoxication (temazepam, methadone,
morphine, diazepam and prothiaden.
Toxicology: 59.9% carboxyhaemoglobin in blood, O.lOmg methadonelL blood,
3.0Smg prothiadenIL blood, 0.41mg desmethyldiazepamlL blood, O.04mg
diazepamlL blood, 4.04mg temazepamIL blood and O.IImg morphine/L blood.
Samples Re-analysed: Blood
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Reference: GC20 Sex: Male Age: 36
Circumstances: Known IVDA for 8 - 10 years. Prescribed methadone on/off basis
for past 3 years. Last prescribed 50mg/day methadone one week prior to death. Last
seen 3 days prior to death under the influence of alcohol. Found dead slumped in a
sitting position. Changes of putrefaction most marked in face.
Cause of Death: 1.a Morphine and Methadone Intoxication.
Toxicology: 55mg alcohol/10mL blood, 1.6mg methadonelL blood, 110mg
alcohol/100mL urine, 0.34mg desmethyldiazepam/L blood, 0.19mg diazeparnlL
blood, 0.19mg temazepam/L blood, 0.26mg morphinelL blood.
Samples Re-analysed: Blood
Reference: GC21 Sex: Female Age: 24
Circumstances: IVDA. Prescribed diazepam daily, also treated for asthma. Suicidal,
treated for overdoses in the 18 months prior to death and attempted to slit wrists.
Evening prior to death, unconscious, roused by slapping appeared drowsy for a
couple of hours. Visited drug centre next morning, no cause for concern. Bought £10
bag of heroin + 3 cans of super lager (1900hrs). Gargling and lips turned blue
(2130hrs). Drug paraphernalia found at scene.
Cause of Death: 1.a Overdose of drugs.
Toxicology: 282mg alcohol/10mL blood, 0.07mg methadonelL blood, 357mg
aicoho1l100mL urine, 0.32mg morphinelL.
Samples Re-analysed: Blood
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Reference: GC22 Sex: Female Age: 19
Circumstances: Known drug user (dihydrocodeine and diazepam). Treated for
overdoses in previous 2 years. Last seen by Doctor 2 weeks prior to death, known to
be abusing valium, temazepam and heroin. Last seen at midnight and found dead at
l5l5hrs the following day.
Cause of Death: l.a Acute pulmonary oedema and congestion due to, b. intoxication
with combined drugs (methadone, amphetamine and ecstasy).
Toxicology: O.75mg methadone/L blood, 9mg alcoholllOOmL urine, OA7mg
amphetamine/L blood, O.84mg MDMAIL blood, OAOmg desmethyldiazepamlL
blood, O.l6mg diazepamlL blood, 99ng THC-COOH/ml blood.
Samples 'Re-analysed: Blood
Reference: GC23 Sex: Male Age: 21
Circumstances: Possible recent needle puncture marks. Known to use alcohol and
drugs (heroin, temazepam). History of depression. Overdosed on prescription drugs
10 months prior to death. Prescribed anti-depressants. Day prior to death, from
I 530hrs consumed vast quantity of alcohol. After 1830hrs, he ate and stated concern
over court case, mentioned suicide. Fell asleep, 1O:45pm, 0145hrs - snoring loudly,
0430hrs - still breathing, 0800hrs - aspirating, choking - signs of vomitlblood from
mouth.
Cause of Death: l.a Methadone Intoxication
Toxicology: 30mg a1coholll OOmL blood, l.lmg methadone/L blood, l04mg
alcohol/lOOmL urine, OA8mg fluoxetine/L blood, O. 94mg Norfluoxetine/L blood,
O.17mg desmethyldiazepamlL blood, O.llmg diazepamlL blood.
Samples Re-analysed: Blood
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Reference: GC24 Sex: Male Age: 37
Circumstances: Known IVDA. Dependent on alcohol and heroin. Last seen by
Doctor 2 weeks prior to death for methadone prescription (20mLlday). Last seen
alive, 1700hrs heavily under the influence. Found dead 3 days later,
Cause of Death: l.a Gastro-intestinal haemorrhage due to, b. oesophageal varices
due to c. cirrhosis of the liver. Conditions contributing to death. 2. Methadone
Intoxication.
Toxicology: O.07mg methadone/L blood, O.33mg desmethyldiazepam/L blood,
0.33mg diazepam/L blood.
Samples Re-analysed: Hair.
Reference: G25 Sex: Male Age: 21
Circumstances: Known drug user, suffered withdrawal seizure. Last seen by Doctor
16 months prior to death. Evening prior to death, smoked 4 joints and consumed
beer (1900hrs). Ate breakfast (0700hrs), returned to bed. 0900hrs - sleeping, 1400hrs
- sick but snoring. 1500hrs - 1645hrs - snoring/sleeping. 1700hrs - found dead.
Cause of Death: l.a Inhalation of gastric contents
Toxicology: 27mg aicohoVI00mL blood, 3.84mg methadone/L blood, 87mg
alcoholllOOmL urine, 2.35mg cocaine/L urine, 0.47mg temazepam/L blood, 26.5mg
BZEIL urine, 0.44mg EMEIL urine.
Samples Re-analysed: Blood
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Reference: GC26 Sex: Male Age: 35
Circumstances: Fresh needle puncture mark. Long history of drug use (15 years).
Prescribed methadone and diazepam. Depressed after recent death of husband. Last
seen day prior to death at 2200hrs drowsy. l430hrs found dead.
Cause of Death: l.a Drug related death due to, b. methadone, heroin, temazepam
and diazepam intoxication.
Toxicology: O.92mg methadonelL blood, 0.44mg desmethyldiazepam/L blood,
O.3lmg diazepam/L blood, O.70mg temazepam/L blood, 0.35mg morphinelL blood.
Samples Re-analysed: Blood.
Reference: GC27 Sex: Male Age: 23
Circumstances: Fresh needle puncture marks. Drug user for 2 to 3 years. Prescribed
methadone and valium. 19l0hrs - under the influence, went to bathroom and then
very sleepy. Drank lager then left. 2000hrs found sleeping on ground, laboured
breathing, mouth to mouth unsuccessful.
Cause of Death: l.a Inhalation of gastric contents, due to b. Methadone and
trichloroethanol intoxication.
Toxicology: 1.27mg methadonelL blood, 96.3mg trichloroethanollL blood.
Samples Re-analysed: Blood +Hair.
Reference: GC28 Sex: Male Age: 21
Circumstances: Abrasions and old scars. Early putrefactive changes. Known to have
drank excessive amounts of alcohol, smoked half of a joint and taken 1 ecstasy tab
the previous day. Lethargic, grey colour and lips blue. Lapsing in and out of
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consciousness. Witness heard gurgling noises night prior to death. 0300hrs, found
dead.
Cause of Death: l.a Pulmonary oedema and congestion due to, b. amphetamine and
methadone intoxication.
Toxicology: O.3lmg methadone/L blood, l.8lmg amphetamine/L blood, O.22mg
desmethyldiazepam/L blood, 0.49mg diazepam/L blood, O.14mg temazepam/L
blood.
Samples Re-analysed: Blood
Reference: GC29 Sex: Male Age: 24
Circumstances: Evidence of chronic drug use. History of asthma and smoking
heroin. Last seen by Doctor 2 days prior to death with acute back strain. Last seen
alive, 1600hrs day prior to death. Witnesses heard TV playing loudly but could get
no answer at door the following day (1200hrs and 1350hrs). Entered house to turn
down TV and found decedent lying on bed (2330hrs).
Cause of Death: l.Heroin Intoxication.
Toxicology: O.23mg morphine/L blood.
Samples Re-analysed: Blood.
Reference: GC30 Sex: Male Age: 29
Circumstances: Advanced signs of decomposition. Registered drug user. Heroin
overdose 3 months prior to death. Released from prison I month prior to death, last
seen alive 3 days prior to death, found with needle at scene.
Cause of Death: l.a Unascertained.
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Toxicology: I02mg alcohol/IOOmL blood, 56mg alcohol/IOmL unne, 1.28mg
chlordiazepoxidelL urine, O.09mg desmethyldiazepamIL urine, O.15mg diazepamIL
urine, 2.24mg temazepamIL urine, l.lmg morphinelL urine.
Samples Re-analysed: Hair
Reference: GC31 Sex: Female Age: 32
Circumstances: Fresh needle puncture mark. Known IVDA for 12 years and heavy
drinker. Released from prison at 0800hrs and took train to city station. Train arrived
at 0902hrs. Found dead at 1350hrs with a needle and tourniquet in situ.
Cause of Death: l.a Heroin and temazepam intoxication.
Toxicology: 12lmg alcohol/iOOmL blood, 205mg alcoholllOOmL urine, 6.85mg
temazepamIL blood, 0.42mg morphinelL blood.
Samples Re-analysed: Blood.
Reference: GC32 Sex: Male Age: 18
Circumstances: Unremarkable medical history. Complained of feeling unwell 8
days prior to death - bloody mucus and sore stomach. Drank evening prior to death.
1300hrs - smoked a joint. I 520hrs - in good spirits. 1700hrs - retired to bed, tired,
flu, heavy stitch in side, had difficulty breathing, choking. Blood from mouth.
Cause of Death: I.a Acute pulmonary oedema and congestion due to, b. Ecstasy
ingestion.
Toxicology: O.02mg MDMAIL blood, I.25mg desmethyldiazepamIL blood, O.62mg
diazepamlL blood.
Samples Re-analysed: Blood
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Reference: GC33 Sex: Male Age: 30
Circumstances: Drug user (cannabis, cocaine, temazepam) for 5 years. 0630hrs -
under influence (alcohol), l530hrs - deep sleep, l850hrs - still thought to be
sleeping. Dead (2030hrs).
Cause of Death: l.a Drug related death due to, b. Heroin, cocaine, amphetamine,
chlordiazepoxide, temazepam and cannabis intoxication.
Toxicology: 0.5mg temazepam!L blood, 1.06mg chlordiazepoxide IL blood,
0.044mg amphetamine/L blood, 1.54mg MDAIL blood, 8.0mg MDMAIL blood,
0.99mg cocaine/L blood, 10.28mg MECIL blood, l4.33mg BZEIL blood, 0.76mg
morphine/L blood.
SamplesRe-analysedr Blood +Hair
Reference: GC34 Sex: Female Age: 17
Circumstances: Evidence of old scars. Known heroin addict, recently prescribed
methadone. Asthmatic and kidney problems. Attempted suicide 5 years previous to
death. Prior to death witness noticed decedents breathing was laboured, believed to
have consumed 2 days prescription of methadone.
Cause of Death: l.a Methadone intoxication.
Toxicology: 0.5lmg methadone/L blood.
Samples Re-analysed: Blood.
Reference: GC35 Sex: Male Age: 29
Circumstances: Drug user for 10 to 15 years. Seen by consultant as addicted to
methadone. Last seen by Doctor about heroin addiction. Witness left house at
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0800hrs, returned at 1740hrs, found decedent lying face down on the bedroom floor.
Syringe nearby.
Cause of Death: l.a Heroin (morphine), diazepam and alcohol intoxication.
Toxicology: 0.44mg morphine/L blood, 0.53mg desmethyldiazepam/L blood,
1.2lmg diazepam/L blood, 166mg alcoholllOOmL blood, 26mg alcoholllOOmL
unne.
Samples Re-analysed: Blood +Hair.
Reference: GC36 Sex: Male Age: 18
Circumstances: Mild asthmatic. Known to smoke heroin, on methadone programme
for two months. Methadone prescription increased from 50 to 60mgs 4 days prior to
death. 1245hrs not well, 1545hrs thought to be asleep, 2200hrs checked again but
thought to be sleeping, 0930hrs found dead.
Cause of Death: l.a Inhalation of gastric contents.
Toxicology: 27mg alcohol/lOOmL blood, 0.21mg methadone/L blood, 12mg
alcoholll OOmLurine, 2.26mg carbamazepine/L blood.
Samples Re-analysed: Blood + hair.
Reference: GC37 Sex: Male Age: 36
Circumstances: Evidence of chronic IVDA. Last seen by Doctor 5 months prior to
death, treated for heroin addiction (13 years). 1l00hrs - decedent left house. Witness
returned home and found decedent lying face down. Syringe still in situ.
Cause of Death: l.a .Drug related Death due to, b. Heroin and methadone
intoxication.
Toxicology: 0.30mg methadone/L blood, 0.53mg morphine/L blood.
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Samples Re-analysed: Blood
Reference: GC38 Sex: Male Age: 18
Circumstances: No evidence of IVDA. Social drug user, mildly asthmatic. Evening
prior to death, l800hrs -left house, returned 0030hrs - claimed to have taken speed.
0400hrs - watching TV, 08l5hrs - left house, l230hrs - feeling unwell, pains in
legs, thought to be under the influence. Went to bed. I630hrs -found dead. Bottle of
green fluid ceased from scene.
Cause of Death: l.a Drug related death due to, b. Methadone intoxication.
Toxicology: 2.llmg methadone/L blood.
SamplesRe-analysed: Blood
Reference: GC39 Sex: Female Age: 24
Circumstances: Evidence of old needle puncture marks. Known drug user who used
heroin, temazepam and temgesic. Developed septicemia 2 years prior to death and
developed cardiac complications. Chronic renal failure and hepatitis. Prescribed
methadone. Last seen alive 2l00hrs, had taken methadone and 10 sleeping tablets.
0820hrs found dead.
Cause of Death: l.a Bacterial endocarditis involving the aortic valve, b. IVDA.
Toxicology: l6mg alcohol/lOOmL blood, O.34mg methadone/L blood, O.20mg
desmethyldiazepam/L blood, 0089mg diazepamIL blood, O.083mg morphine/L
blood.
Samples Re-analysed: Blood.
Applicationof Solid-PhaseExtraction/or theAnalysisofDrugs inBiologicalFluids
Chapter Six: Case Studies Page 189
Reference: GC40 Sex: Male Age: 36
Circumstances: Ligature around neck with superficial incised wound on wrist.
Known to abuse alcohol and diazepam. 3 years prior to death diagnosed with
depression. Suffered from acute pancreatitis 2 months prior to death. On several
medications (Zimobane, dihydrocodeine, omeprazole, metroclepromide, Ventalin
inhaler).
Cause of Death: l.a Hanging.
Toxicology: All analyses were negative.
Samples Re-analysed: Blood.
Reference: GC41 Sex: Male Age: 29
Circumstances: Evidence of IVDA. Known to use heroin. Prescribed methadone
(60mLlday) on the day prior to death, consumed dose in two halves at I630hrs and at
2200hrs. Consumed whole dose at pharmacy next day. Fell asleep (1430hrs), woken
at 1445hrs but still tired, found dead at 1800hrs.
Cause of Death: l.a Acute pulmonary oedema and congestion due to, b. methadone
intoxication.
Toxicology: 0.63mg methadonelL blood, 0.024mg EDDPIL blood, O.lOmg
desmethyldiazepamlL blood, O.llmg diazepamlL blood.
Samples Re-analysed: Blood.
Reference: GC42 Sex: Male Age: 23
Circumstances: Ligature around neck. Recent IVDA. Treated in a psychiatric
hospital 5 years prior to death. Started on a methadone programme (20mg) 4 years
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prior to death, described as suicidal. l700hrs - last seen alive, following day found
dead at 11OOhrs.
Cause of Death: l.a Hanging associated with heroin overdose.
Toxicology: 69mg alcoholllOOmL blood, 0.28mg methadonelL blood, O.12mg
EDDPIL blood, O.llmg desmethyldiazepamIL blood, O.llmg diazepamIL blood,
O.l2mg codeine/L blood, O.66mg morphinelL blood.
Samples Re-analysed: Blood.
Reference: GC43 Sex: Male Age: 27
Circumstances: Known to inhale heroin on a daily basis. Regularly used others'
methadone script. l040hrs - consumed methadone and seen to swagger and act
strangely. Gargling and collapsed unconscious.
Cause of Death: l.a Temazepam, morphine and trichloroethanol intoxication.
Toxicology: O.lOmg methadone/L blood, O.04mg EDDPIL blood, 5.9mg lidocainelL
blood, O.75mg desmethyldiazepamlL blood, 0.45mg diazepamIL blood, 1.39mg
temazepamlL blood, O.06mg codeinelL blood, O.26mg morphinelL blood, 90mg
trichloroethanollL blood.
Samples Re-analysed: Blood.
Reference: GC44 Sex: Female Age: 23
Circumstances: Recent needle puncture mark. History of depression and anxiety -
prescribed anti-depressants. Admitted addiction to diazepam 3 months prior to death.
OlOOhrs admitted taking 2 ecstasy tablets. Difficulty walking, collapsed unconscious
(0130hrs). Pronounced dead (0300hrs), high core body temperature (107.6F).
Cause of Death: l.a Trimipramine and ecstasy intoxication.
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Toxicology: 43mg alcohol/lOOmL blood, 72mg alcohol/lOOmL urine, O.065mg
MDAIL blood, 3.0mg MDMAIL blood, O.96mg trimipramine/L blood.
Samples Re-analysed: Blood + hair.
Reference: GC45 Sex: Female Age: 28
Circumstances: Evidence of IVDA and head injuries. Believed to be on methadone
programme. Under the influence (2030hrs), found lying on ground with laceration to
head (21OOhrs).
Cause of Death: l.a Head injury.
Toxicology: All analyses were negative.
Samples Re-analysed: Blood.
Reference: GC46 Sex: Male Age: 28
Circumstances: Ligature mark. Evidence of IVDA. Known drug user for 6 years.
Prescribed 22mLs methadone/day. Last seen by Doctor one week prior to death for
repeat prescription. Last seen by family 6 days prior to death.
Cause of Death: l.a Hanging.
Toxicology: 30mg alcohol/IOOmL blood, 8mg alcoholll OOmLurine.
Samples Re-analysed: Blood.
Reference: GC47 Sex: Female Age: 28
Circumstances: Possible needle puncture marks. Intermittent drug user for 15 years
(heroin). On methadone programme (80mLs) for 2 months. 8 months pregnant,
didn't look well and complained of sore stomach. Found dead, drug paraphernalia
found at scene.
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Cause of Death: l.a Acute and chronic IVDA.
Toxicology: 0.06mg morphinelL blood.
Samples Re-analysed: Blood.
Reference: GC48 Sex: Male Age: 28
Circumstances: Ligature mark. Possible old needle puncture marks. Known drug
user, on methadone programme for 3 months. In prison, confided to coming off
methadone and feeling shaky. No signs that deceased was depressed prior to
hanging.
Cause of Death: l.a Hanging.
Toxicology: 9mg alcohollL blood.
Samples Re-analysed: Blood.
Reference: GC49 Sex: Female Age: 29
Circumstances: Evidence of chronic IVDA. History of infection and abscess on left
valve of heart. Thought to consume £20 heroin/day. Finished dihydrocodeine
detoxification 1 week prior to death.
Cause of Death: l.a Pulmonary thromboembolism. 2. Chronic IVDA.
Toxicology: 12mg alcohol/lOOmL blood, 0.74mg propoxyphene/L blood, 12ng
THC-COOHlml blood.
Samples Re-analysed: Blood.
Reference: GC50 Sex: Female Age: 18
Circumstances: Evidence of old and fresh needle puncture marks. Known heroin
user. Year prior to death attempted dihydrocodeine and methadone detoxification
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programme. 2000hrs consumed vodka and heroin. 1250hrs the following day
convulsing and stopped breathing.
Cause of Death: l.a Heroin and temazepam intoxication.
Toxicology: 0.30mg morphinelL blood, O.08mg temazepamIL blood.
Samples Re-analysed: Blood.
Reference: GC51 Sex: Male Age: 20
Circumstances: Recent needle puncture marks. Known drug abuser (heroin,
temazepam, cannabis). Victim of several serious assaults. On a methadone
programme for 4 months, ending 2 months prior to death. Suspected heroin overdose
3 days prior to death. Found with tourniquet and needle in situ.
Cause of Death: 1a. Morphine intoxication.
Toxicology: 0.27mg desmethyldiazepamlL blood, O.07mg diazepamlL blood,
O.03mg temazepamlL blood, O.098mg codeine/L blood, 0.43mg dihydrocodeinelL
blood, 0.44mg morphinelL blood.
Samples Re-analysed: Blood.
Reference: GC52 Sex: Male Age: 19
Circumstances: Possible fresh and healing needle puncture marks. Known drug
user. On methadone programme for 3 months. Last seen by Doctor 25 days prior to
death (prescribed 700mL methadone and 18 diazepam tablets). Evening prior to
death consumed methadone and diazepam, police found decedent 2114hrs the
following day.
Cause of Death: 1a. Methadone intoxication.
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Toxicology: 0.28mg methadonelL blood, 0.53mg EDDP/L blood, 0.14mg
desmethyldiazepamlL blood, 0.12mg diazepam/L blood.
Samples Re-analysed: Blood.
Reference: GC53 Sex: Male Age: 30
Circumstances: Recent and healing needle puncture marks. Known heroin IVDA.
Evening - returned to room at 2000hrs. Found dead at 0935hrs with tourniquet and
syringe in situ.
Cause of Death: l.a Unascertained.
Toxicology: l83mg alcohol/lOOmL blood, 199mg alcohol/lOOmL urine, 0.78mg
temazepam/L blood.
Samples Re-analysed: Blood.
Reference: GC54 Sex: Male Age: 28
Circumstances: History of heroin use. On a methadone maintenance programme,
suffering from depression. Believed to have taken 25 to 28 diazepam tablets. Last
seen by Doctor 3 days prior to death, prescribed 7-day course of methadone. Heron
overdose 16 days prior to death. Consumed 2 methadone scripts (1230hrs and
1430hrs). 2000hrs looked "high". 2300hrs - went to bed, OlOOhrs - breathing
heavily, found dead 0755hrs.
Cause of Death: l.a Acute pulmonary oedema and congestion due to, b. Methadone
intoxication.
Toxicology: 0.36mg methadone/L blood, 0.017mg EDDP/L blood, 0.28mg
desmethyldiazepam/L blood, 0.40mg diazepam/L blood.
Samples Re-analysed: Blood.
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Reference: GC55 Sex: Male Age: 23
Circumstances: Suffering from depression. Attempted on two occasions to commit
suicide. Claimed to have cocaine habit (£300/week). Overdosed on amitriptyline and
valium. Developed respiratory failure in hospital and septic shock. Placed on
ventilator, condition deteriorated.
Cause of Death: l.a Bronchopneumonia.
Toxicology: Trace of Fluconazole in blood, O.2lmg desmethyldiazepam/L blood,
O.17mg diazepam/L blood, O.2lmg temazepam/L blood.
Samples Re-analysed: Blood.
Reference: GC56 Sex: Male Age: 26
Circumstances: Evidence of IVDA. History of drug use (heroin). Last seen by
Doctor who prescribed Amitriptyline, decedent seemed agitated. Personality
disorder, history of self-poisoning and over last four years has either been in prison
or attending Forensic Psychiatrist. Last seen alive six days prior to death.
Cause of Death: l.a Acute pulmonary oedema and congestion due to, b.
Amitriptyline overdose.
Toxicology: 3.12mg amitriptylinelL blood, 1.42mg nortriptyline/L blood.
Samples Re-analysed: Blood.
Reference: GC57 Sex: Male Age: 33
Circumstances: Injuries consistent with fall. Known drug user, not on medication at
time of death. Snorted cocaine, became agitated and jumped from window.
Cause of Death: l.a Multiple injuries due to, b. fall from a height.
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Toxicology: 5lmg alcoholllOOmL blood, 3.37mg BZEIL blood, O.05mg cocaine/L
blood, 2.35mg MEC/L blood, 67mg alcohollL urine.
Samples Re-analysed: Blood.
Reference: GC58 Sex: Male Age: 32
Circumstances: History of IVDA problems. On methadone programme 3 days
before death but did not collect script. Last seen alive 2100hrs, found dead the
following day (lOOOhrs) clutching a syringe.
Cause of Death: l.a Acute pulmonary oedema and congestion due to, b. morphine
(heroin) intoxication.
Toxicology: O.Olmg EDDPIL blood, O.07mg methadonelL blood, O.Olmg 6-MAMIL
blood, O.02mg codeinelL blood, O.14mg morphinelL blood.
Samples Re-analysed: Blood.
Reference: GC59 Sex: Male Age: 23
Circumstances: Fresh needle puncture mark, antecubital fossa. Suffered from
schizophrenia and depression. Known IVDA. History of overdoses. Evening prior to
death, consumed excessive amounts of alcohol, plus ecstasy and heroin. 2200hrs -
involved in assault, sustained injuries to eyes. Smoked hash. 1130hrs the following
day, was administered prescribed drugs for schizophrenia. Consumed more alcohol.
2000hrs - unable to stand, sleepy. 2300hrs - found dead.
Cause of Death: l.a Unascertained.
Toxicology: 53mg alcohol/lOOmL blood, O.15mg amphetamine/L blood, 90.9mg
carbamazepine/L blood, 8lng THC-COOH/ml blood, 94.6mg paracetamollL blood,
I08mg alcohol/lOOmL urine.
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Samples Re-analysed: Blood
Reference: GC60 Sex: Female Age: 44
Circumstances: History of alcoholism. Had attempted suicide on several occasions.
Suffered from depression and epilepsy. History of a fall prior to sudden death.
Cause of Death: l.a Multiple injuries due to, b. fall from a height.
Toxicology: O.02mg codeinelL blood, O.07mg dihydrocodeine/L blood, O.05mg
morphine/L blood.
Samples Re-analysed: Blood.
Reference: GC61 Sex: Male Age: 25
Circumstances: History of chronic alcoholism and epileptic. Last seen under the
influence of alcohol and was aggressive. Found dead in a derelict building.
Medication (Eiplin, diazepam, Rantidine)
Cause of Death: l.a Hypothermia due to, b. chronic alcoholism.
Toxicology: 297mg/l00mL blood, 493mg alcoholll OOmLurine.
Samples Re-analysed: Blood.
6.3 Analysis
Postmortem blood .samples were analysed in triplicate where the sample volume
allowed. The majority of hair samples were too small to analyse more than once, the
exception being when bulk hair was available.
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Blood samples were re-screened by EIA for the target analyte (methadone or
amphetamines) and were then confirmed positive or negative by the developed
GCIMS method.
6.4 Methadone
6.4.1 Postmortem Blood
A total of 47 samples were analysed using the optimised extraction method for
methadone and its two major metabolites (EDDP and EMDP) in whole blood. Of
these ~9 samples were confirmed positive and 17 confirmed negative. Only one
blood sample GC 17 was not confirmed positive for methadone when re-analysed.
The initial concentration was O.036mglL. The sample was re-analysed 8 months after
the initial analysis and the condition of the blood had deteriorated which could
explain the negative result when re-analysed.
Fourteen case samples were re-analysed within six months of the initial analysis. The
in use liquid-liquid extraction (LLE) method was not optimised for the detection of
EDDP or EMDP, therefore a comparison could only be made between the methadone
levels determined by both methods.
The results are summarised in Table 6.1.
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Table 6.1 Levels of methadone and EDDP (mg/L) found in case studies by LLE
and SPE (Analysed and re-analysed within 6 months).
Case *LLE (mgIL) tTime (months) tSPE (mgIL)
1 0.32 4 0.29 (0.07)
2 0.23 6 0.18 (0.04)
3 0.09 6 0.07 (0.15)
4 0.41 6 0.45 (0.12)
5 0.12 6 0.13 (0.12)
6 0.10 6 0.08 (---)§
7 0.32 6 0.26 (0.29)
8 --- 5 ---
9 --- 5 ---
10 --- 5 ---
11 0.36 (0.017) 5 0.50 (0.06)
12 --- 5 ---
13 --- 5 ---
14 0.07 (0.01) 5 0.07 (0.01)
* Levels of methadone detected by the in-use liquid-liquid extraction method. Levels of EDDP
detected are noted in (brackets). EDDP was not screened for routinely.
t The time in months, elapsed between the initial analysis carried out by LLE and the 2nd analysis
carried out by the developed solid-phase extraction method.
t Levels of methadone detected by the developed solid-phase extraction method. Levels of EDDP
detected are noted in (brackets).
§ Negative for the analyte analysed.
Application a/Solid-Phase Extraction/or the Analysis a/Drugs in Biological Fluids
Chapter Six: Case Studies Page 200
Methadone levels in the fourteen blood samples ranged from 0 to 0.41 mg/L when
analysed by the in use LLE method and from 0 to 0.50 mg/L using the described SPE
method. As seen in figure 6.1, results obtained by SPE correlate well with those
found by the LLE method (r = 0.96, m = 1.07).
Figure 6.1
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developed SPE method (Analysed and reanalysed within 6 months).
EDDP was detected in eight of the fourteen cases. Figure 6.2 shows the GC/MS
trace obtained for Case 5 which was positive for methadone and EDDP. EMDP was
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Figure 6.2 GC/MS selected IOn chromatogram of methadone, EDDP and
methadone-dj (Case 5).
Table 6.2 summarises the results for all blood samples analysed for methadone and
its two major metabolites by LLE and the developed extraction method. The samples
were stored for longer than 6 months prior to reanalysis by SPE, but less than one
year.
Methadone levels in the sixteen blood samples ranged from 0 to 1.60 mg/L when
analysed by the in use LLE method and from 0 to 0.57 mg/L using the described
solid-phase extraction method. As seen in figure 6.3, results obtained by SPE
correlate with those found by the LLE method (r = 0.94, m = 0.36). However, it
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would appear that storage for greater than 6 months does have a detrimental effect on
the analyte concentrations in whole blood.
Table 6.2 Levels of methadone and EDDP (mg/L) found in case studies by LLE
and SPE (Analysed and re-analysed after 6 months of storage but less
than one year).
Case *LLE (mgIL) +Time (months) tSPE (mgIL)
1 0.06 8 0.21 (0.16)
2 0.036 8 ---
3 1.60 7 0.57 (0.99)
4 --- 10 ---
5 0.63 (0.024) 10 0.27 (0.05)
6 0.28 (0.12) 9 0.23 (---)
7 0.10 (0.04) 9 0.04 (---)
8 --- II ---
9 --- 10 ---
10 --- 10 ---
11 --- 10 ---
12 --- 9 ---
13 --- 9 ---
14 --- 9 ---
15 0.28 (0.53) 9 0.12 (0.25)
16 --- 9 ---
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* Levels of methadone detected by the in-use liquid-liquid extraction method. Levels of EDDP
detected are noted in (brackets). EDDP was not screened for routinely.
t The time in months, elapsed between the initial analysis carried out by LLE and the 2nd analysis
carried out by the developed solid-phase extraction method.
t Levels of methadone detected by the developed solid-phase extraction method. Levels of EDDP
detected are noted in (brackets).
Figure 6.3
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samples were stored for longer than 12 months prior to reanalysis by SPE.
developed SPE method (Analysed and reanalysed within 6 to 12
months).
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Table 6.3 summarises the results for all blood samples analysed for methadone and
its two major metabolites by LLE and the developed extraction method where the
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Table 6.3 Levels of methadone and EDDP (mg/L) found in case studies by LLE
and SPE (Analysed and re-analysed after 12 months of storage.
Case *LLE (mgIL) tTime (months) tSPE (mgIL)
1 1.44 36 0.39 (0.17)
2 0.36 36 0.41 (0.16)
3 0.10 29 0.07 (0.01)
4 0.07 27 0.03 (---)
5 1.10 27 0.25 (0.46)
6 3.84 27 0.56 (0.06)
7 0.92 27 0.28 (0.11)
8 1.27 27 0.2 (0.06)
9 --- 26 ---
10 --- 25 ---
11 0.51 2 0.53 (---)
12 --- 23 ---
13 0.21 22 0.40 (---)
14 0.30 21 0.21 (---)
15 2.11 21 0.43 (0.06)
16 0.34 21 0.17(0.19)
17 0.07 13 0.21 (0.16)
* Levels of methadone detected by the in-use liquid-liquid extraction method. Levels of EDDP
detected are noted in (brackets). EDDP was not screened for routinely.
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t The time in months, elapsed between the initial analysis carried out by LLE and the 2nd analysis
carried out by the developed solid-phase extraction method.
:j: Levels of methadone detected by the developed solid-phase extraction method. Levels of EDDP
detected are noted in (brackets).
Figure 6.4
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developed SPE method (Analysed and reanalysed within 12 to 36
Methadone levels in the seventeen blood samples ranged from 0 to 3.84 mg/L when
o
months).
analysed by the in use LLE method and from 0 to 0.56 mg/L using the described SPE
method. As seen in figure 6.4, results obtained by SPE show a slight correlation with
those found by the LLE method (r = 0.66, m = 0.12). The decrease in the analyte
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concentrations in whole blood are greater in this group where storage of the whole
blood was greater than 12 months between analysis and reanalysis.
6.4.2 Postmortem Hair
In total, 15 post-mortem hair samples were segmented (n = 34) and screened for
methadone following methanolic extraction. The results are summarised in Table 6.4
along with any antecedent history mentioned in the police report and the toxicology
results pertaining to the consumption of methadone in the six months prior to death.
A comparison is made between the detection of methadone and whether or not this
agrees (A) or disagrees (D) with the police report.
Where no police report was not available the comparison was not applicable (N/A).
Out of the 37 segments analysed, five were omitted due to a lack of antecedent
history. An agreement of 65.5% was obtained for the segments which tested positive
and confirmed the antecedent history. The majority of the cases which were negative
and disagreed (34.5%, n =10) with the antecedent history had low sample weights
below 20mg, and this may have contributed to the number of false negative results.
It is important to note the difference in methadone levels detected in Case GC04.
When the hair sample was washed prior to analysis, the concentration of methadone
was 2.3ng/mg in comparison to 25.0ng/mg when the sample was not washed. The
loss of methadone during washing could be removal of external contamination or
from within the hair shaft.
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Table 6.4 Comparison of Methadone Detected in Hair and Antecedent History.
Sample Weight Concentration Methadone Agree or
(mg) (nglmg) History Disagree
GCOI Roots 20.75 -ve No Report D
Bulk 35.16 -ye No Report N/A
GC02 Roots 17.75 40.9 Yes A
1st 3cm 80.62 10.3 Yes A
Bulk 132.17 16.5 Yes A
GC03 Roots 53.19 1.1 No A
GC04 Bulk (W)* 50.04 2.3 Yes A
Bulk (UW)t 38.55 25.0 Yes A
GC05 1M3cm 3.68 -ve Yes D
Bulk 5.79 -ve Yes D
GC07 Roots 12.39 -ve No Report D
Bulk 24.73 1.1 No Report N/A
GC08 Roots 4.01 -ye Yes D
Bulk 24.58 -ve No A
GCll Roots 4.90 -ve Yes D
i" 6cm 26.99 -ve Yes D
2nd 6cm 11.78 -ve Yes D
BulkA 39.73 1.1 Yes A
BulkB 48.45 0.6 Yes A
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Sample Weight Concentration Methadone Agree or
(mg) (nglmg) History Disagree
GC13 Roots 4.80 -ve Yes D
1st 3cm 45.35 1.0 Yes A
Bulk 38.02 -ve Yes D
GC16 1S[ 6cm 32.18 -ve No Report N/A
2nd 6cm 23.93 1.3 No Report N/A
Bulk 39.67 0.9 No Report N/A
GC24 Bulk 46.80 8.9 Yes A
GC27 Roots 6.16 29.1 Yes A
Bulk 27.25 17.6 Yes A
GC30 Roots 4.84 -ye No A
Bulk 8.79 -ve No A
GC35 Roots 4.40 -ye No A
Bulk 44.74 -ve No A
GC36 Roots 3.89 18.6 Yes A
Bulk 43.60 3.0 Yes A
>I< Bulk (W) - sample washed prior to analysis
t Bulk (UW) - sample not washed prior to analysis
Too many of the root samples analysed were of low weight and produced a negative
response. The results are summarised in Table 6.5 along with the postmortem blood
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level quantified during the initial analysis and the level quantified when re-analysed
by the optimised solid-phase extraction method.
Table 6.5 Comparison of Methadone Detected in Postmortem Hair Roots and
Blood.
Sample Concentration Initial [Blood] Re-analysis
(nglmg) mgIL mgIL
GCOI -ve 1.44 0.39
GC02 40.9 0.12 nla
GC03 1.3 0.18 nla
GC07 -ve 0.06 0.21
GC08 -ve 0.68 nla
GCll -ve 0.32 0.26
GC13 -ve 0.12 0.13
GC27 29.1 1.27 0.20
GC30 -ve -ve nla
GC35 -ve -ve -ve
GC36 18.6 0.21 0.40
Of the four cases where the root sample was positive for methadone (GC02, GC03,
GC27 and GC36) only case reference GC27 died as a result of methadone
intoxication. It is not possible to draw any firm conclusions from these results due to
the limited sample size with respect to the number of root segments analysed and the
small sample weights.
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Methanolic extraction followed by enzyme immunoassay correctly identified
methadone use in almost 66% of the hair segments analysed. No false positives were
identified however there were a high number of false negatives (n = 10). The
combination of small sample weights and high calibrator weights would effect the
sensitivity of this assay!
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6.5 Amphetamines
6.5.1 Postmortem Blood
A total of seven samples were analysed using the optimised solid-phase extraction
method for amphetamines in whole blood. Of these, six were confirmed positive and
one confirmed negative. The results are summarised in Table 6.6.
Table 6.6 Comparison of amphetamines detected in postmortem blood by the
Initial Analysis and when Re-analysed by the Optimised Extraction
Method.
Sample Initial Analysis (mgIL) Re-Analysis (mgIL)
GC09 0.46 Amphetamine 1.34 Amphetamine
GC22 0.47 Amphetamine 1.45 Amphetamine
0.84MDMA 0.36 MDMA
GC32 0.02MDMA 0.16MDMA
GC33 +ve Amphetamine 0.02 Amphetamine
MDA 0.11 MDA
MDMA 0.84MDMA
(urine only) 0.08MDEA
GC44 0.07MDA 0.11 MDA
3.00MDMA 3.99MDMA
0.05 MDEA
GC57 -ve -ve
GC59 0.15 Amphetamine 0.42 Amphetamine
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In general the specific amphetamines detected in the initial analysis were identified
when re-analysed by the optimised extraction method. MDEA was detected in two
cases (GC33 and GC44) in addition to the amphetamines detected in the initial
analysis.
In the majority of cases, the concentrations of analytes detected in blood was greater
when re-analysed by the developed method. This may highlight the greater efficiency
of the developed method at disrupting the protein binding effects compared with the
initial in-use extraction method.
6.5.2 Postmortem Hair
Two cases were analysed by the optimised solid-phase extraction method for the
analysis of amphetamines in hair.
Case One (GC33)
The first case involved a 30 year old male, who was a known drug abuser,
predominantly using cannabis, cocaine and temazepam. The cause of death was
established as a drug related death due to heroin, cocaine, amphetamine,
chlordiazepoxide, temazepam and cannabis intoxication. The deceased was
witnessed to be under the influence, and was checked throughout the day and was
thought to be sleeping. He was later found dead in bed.
Case Two (GC44)
The second case involved a 23 year old female who had a history of depression and
was addicted to diazepam. The cause of death was established as trimipramine and
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ecstasy intoxication. The deceased admitted taking two ecstasy tablets at a dance
event and complained of feeling unwell. She had difficulty walking and collapsed.
Resuscitation was unsuccessful and she was pronounced dead some two hours after
she first complained of feeling unwell. Her core temperature was noted as 42°C
shortly after admission to hospital.
The results of the analysis of blood and hair from case one are shown in Table 6.7. In
this case, the hair sample was separated into the root sample and a one cm segment.
The blood was negative (-ve) for MA but positive for the other four amphetamines.
Unfortunately, the sudden death report only contains details of the events leading up
to the deceased's death with only a brief medical history. From this we were not able
to determine whether or not the positive results in the one cm segment from the scalp
confirmed use of ecstasy by the deceased in the month prior to their death.
Its interesting to note that the drugs detected in the postmortem blood sample
correspond to those detected in the root sample.
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Table 6.7 Amphetamines Detected in Postmortem Blood and Hair Samples
(Case One)
Analyte Blood Hair (nglrng)
(rngIL) Roots ISIIern
AP 0.04 I.S -ye
MA -ve -ve -ye
MDA I.S4 3.S I.S
MDMA 8.00 16.0 S.2
MDEA 0.07 7.6 -ve
Table 6.8 Amphetamines Detected m Postmortem Blood and Hair Samples
(Case Two)
Analyte Blood Hair (ng/mg)
(rngIL) Roots 1~13ern 2"u 3ern
AP -ye -ye -ye -ve
MA -ye -ye -ye -ve
MDA 0.11 I.S -ve -ve
MDMA 3.99 42.1 2S.2 6.0
MDEA O.OS 18.2 2.4 -ve
Table 6.8 summarises the results from case two. The hair was analysed in three
segments, the root sample, the first 3cm segment from the scalp and then a second
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3cm segment. The blood sample was positive for all three
methylenedioxyamphetamines with corresponding positives in the root sample.
Again, it wasn't possible to confirm use of ecstasy in the six months prior to the
deceased's death.
6.6 Conclusion
Postmortem blood and hair samples were analysed for the presence of methadone, its
two metabolites (EDDP and EMDP) and amphetamines (amphetamine,
methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-
methamphetamine (MDMA) and 3,4-methylenedioxyethylamphetamine (MDEA»,
using the developed solid-phase extraction methods detailed in Chapters Two and
Four.
Both SPE methods successfully extracted the drugs from the matrices involved. The
results obtained were comparable to the in-use liquid-liquid extraction methods even
though many samples were re-analysed more than six months after the initial
analysis.
The Cozart enzyme immunoassay kit was readily adapted to screen for methadone in
hair. Antecedent drug use history was confirmed in 65.5% of all cases There were no
false positives identified. The limiting factor of this assay was sensitivity due to a
combination of small sample weights and high calibrator weights.
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7. Conclusion
The first aim of this project involved the development of improved extraction
methods for the analysis of methadone and its metabolites and for the analysis of
amphetamine and related compounds from whole blood and hair.
Solid-phase extraction methods were developed for the successful extraction of all
analytes from whole blood by manipulating the pH of the extraction system. The
recoveries of methadone, EDDP and EMDP were not affected by the carbon number
or carbon loading of the solid-phase extraction columns investigated.
Improvements were made with respect to recovenes, linear ranges, extraction
efficiency and analysis time for all analytes studied in both whole blood and hair. In
particular, the improvements with stability of the volatile amines by addition of
tartaric acid has resulted in a robust and reproducible extraction method.
The stability of methadone and its two major metabolites in whole blood was
investigated under various conditions. Methadone and EDDP remained stable for up
to six months when stored at all three temperatures (-20, 5 and 25°C). EDDP was
slightly more stable when stored in foil wrapped vials, but not sufficiently to warrant
the expense of light sensitive vials as routine pathology specimen containers.
EMDP was extremely unstable under all conditions with a recovery of only 57.6% of
the original concentration ofEMDP after six months storage at -20°C. Silanising the
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hypovials prior to storage did not result in greater recoveries of methadone, EDDP or
EMDP from whole blood.
A total of 61 postmortem cases were analysed by the developed methods. Methadone
levels detected in blood samples which were re-analysed within six months
correlated well with the initial levels. After six months the correlation decreased.
It has been shown that solid-phase extraction has successfully extracted several
analytes of differing physico-chemical properties from whole blood and hair using
the same method by manipulating the sample pretreatment steps and pH of the
extraction system. The same basic extraction method was used to extract methadone,
EDDP and EMDP from whole blood and amphetamine, methamphetamine, MDA,
MDMA and MDEA from whole blood and hair.
In addition, 15 postmortem hair samples were successfully screened and semi-
quantitated for methadone using the Cozart methadone microplate enzyme
immunoassay kit which was easily adapted for hair. This technique could prove
useful for the initial screen prior to confirmation using GCIMS.
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7.1 Further Work
The initial work completed on the adaptation of the Cozart methadone microplate kit
for hair samples proved useful for screening spiked hair samples and postmortem
hair samples. To fully realise the potential of this technique the procedure requires
validation with a view to adapting and validating other drug specific immunoassays
for hair analysis.
A solid-phase extraction method was developed for the analysis of amphetamines in
hair. This method successfully removed the analytes of interest from the
endogeneous material and produced a clean extract. The applicability of this
extraction method for the analysis of other drugs of abuse would be an interesting
subject for future work.
In addition to improving extraction methods for the analysis of drugs in hair, a
greater understanding is required of the mechanisms by which drugs are incorporated
into the hair. The analysis of postmortem hair and blood samples during this study
gave strong indications that a relationship could exist between drug levels detected in
blood and hair roots at the time of death. This could potentially provide more
information on the cause of death and antecedent drug use history of the deceased, as
well as aiding researchers in understanding drug incorporation into hair.
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Abstract
Drug use histories were collected from 100 subjects recruited from the "dance scene"
in and around Glasgow, Scotland. In addition, each subject donated a hair sample
which was analysed by gas chromatography - mass spectrometry (GCIMS) for
amphetamine (AP), methamphetamine (MA), 3,4-methylenedioxyamphetamine
(MDA), 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-
methylenedioxyethylamphetamine (MDEA).
The hair samples were analysed in two 6cm segments or in full, ranging from 1.5 -
12cm depending on the length of the hair. Approximately 10mg of hair was ground
to a fine powder before treatment with p-glucuronidase/aryl sulphatase. A solid-
phase extraction procedure was carried out followed by derivatisation with
pentafluoropropionic anhydride (PFPA). All extracts were analysed by gas
chromatography/mass spectrometry (GCIMS).
Of the 139 segments analysed, 77 (52.5%) were positive for at least one of the five
amphetamines. The drug concentrations found in the hair were compared with the
self-reported drug histories. A concordance of greater than 50% was found between
the self-report data and levels detected in hair. However no correlation was found
between the reported number of "ecstasy" tablets consumed and the drug levels
detected in hair.
An increase in the average drug levels measured was observed from low to high use
(number of "ecstasy" tablets/month). A large number of false negatives and a low
number of false positives were observed.
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Abstract
Aims. To compare self reported "ecstasy" use with the results of the analysis of hair
harvested from the same users. Design. A survey using a detailed questionnaire with
subjects recruited by multi-site chain-referral sampling. Hair donated after
questionnaire administration. Setting. The "dance scene" in Glasgow. Participants.
One hundred and forty nine subjects. Findings. Overall gross concordance between
self reported "ecstasy" use, and discovery of MDMA (or related compounds) in
analysed hair did not surpass 65 per cent, and no relationship had a Cohen's Kappa of
more than 0.19. Within the positive concordant data set (n=83), scatter was
considerable, with no correlation being significant, and none more strongly positive
than -0.0444. Conclusions. It is elsewhere acknowledged that analysis of hair for the
the presence of drugs does not reach a level of sophistication or accuracy that would
permit its use as a criminal justice (or other) individual sanction. The results
presented here indicate that, as far as MDMA is concerned, hair does not reach a
level of apparent accuracy that would permit its use as a general population
estimator. Large scale inter- and intra-laboratory comparative research is
recommended.
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Abstract
Solid-phase extraction (SPE) has become the standard approach to
sample preparation for the GC or GCIMS analysis of drugs in biological
fluids. While this technology has proven to be applicable to a wide
variety of compounds, the determination of amphetamines has been
especially challenging because of their volatility. Significant loss of
analyte occurs both when the elution solvent is evaporated and under the
thermal conditions employed during thederivatisation procedure. A SPE
method, which addresses both these limitations, is described for the
improved recovery, and quantitation of amphetamine (AP),
methamphetamine (MA), 3, 4-methylenedioxyamphetamine (MDA), 3,
4-methylenedioxy-methamphetamine (MDMA) and 3, 4-
methylenedioxyethylamphetamine (MDEA) in blood and hair.
The initial extraction was achieved using ISOLUTRID CONFIRM HeX
mixed-mode SPE columns. The drugs were determined using GCIMS
with ds - amphetamine (ds - AP) as the internal standard. The problems
with volatility were addressed by simple addition of 10Q!1of tartaric
acid (lmg/ml in ethyl acetate) to each standard and analytical sample
prior to evaporating to dryness. All of the amphetamine compounds
demonstrated significant increases in recovery.
Data is also presented on the kinetics of the derivatisation of these
compounds using pentafluoropropionic anhydride. In contrast to many
reports in the literature which call for elevated temperatures (> 40°C)
for extended times (> 20 minutes) our data shows that the reaction is
complete for all species in less than 2 minutes at room temperature. This
represents a significant reduction in the total time of analysis. Recoveries
were greater than 87% for all five amphetamines from both blood and
hair and were linear over the concentration ranges studied (r2 > 0.993).
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Abstract
The accurate interpretation of drug levels detected in postmortem blood is an
important aspect of forensic toxicological analysis. The stability of the analytes of
interest depends not only on their physicochemical properties but also on the storage
conditions employed.
Methadone, a synthetic morphine substitute, is commonly used in the treatment of
heroin addiction and has been associated with illicit use and fatalities. In humans,
methadone is metabolized by mono- and di-N-demethylation, with spontaneous
cyclization to form 2-ethylidene-l,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) and
2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP). The determination of these
analytes in whole blood is important for studying the toxicity of methadone, and for
investigating factors affecting its metabolism.
The stability of methadone, EDDP and EMDP was investigated in whole blood at
various temperatures (- 20°C, 4°C, 25°C), over a six month period. Whole blood was
spiked for each analyte at a concentration of 1ug/ml, Deionised water was also
spiked for each analyte (Iug/ml) to allow a comparison to be made between the
amount of chemical decomposition and the degree of putrefactive degradation for
each analyte. In addition to this, a comparison was made between EDDP stored in
foil wrapped vials and EDDP stored in unwrapped vials. Methanolic EDDP
standards are routinely stored in foil wrapped containers to prevent exposure to light,
which degrades EDDP.
Three vials for each measurement of spiked blood, spiked deionised water and
blank blood were stored at different temperatures before reanalysis. The time interval
of storage between each analysis was two, four, six and eight weeks and three and six
months. The storage temperatures were monitored throughout the experiment. A
solid-phase extraction procedure, developed specifically for the optimised recovery
of methadone, EDDP and EMDP (1) from whole blood was used in conjunction with
gas chromatography - flame ionisation detection. The recoveries were greater then
80% for all three analytes.
Methadone and EDDP were found to be stable when stored under these conditions,
where at least 83.5% and 85.4% of the original concentration were recovered for
methadone and EDDP respectively. EMDP was found to be very unstable, with a
loss of approximately 98% of the original concentration after six months when stored
at 4°C. In all cases, blood samples stored at - 20°C were more stable (methadone =
89.8%, EDDP = 91.8%, EMDP = 57.6%).
The EDDP spiked samples stored in foil wrapped containers resulted in higher
recoveries than those stored in unwrapped containers, 94.9% and 85.4% respectively.
However, the difference in recoveries isn't significantly large enough to warrant the
expense incurred by using light sensitive containers for all samples taken for
toxicological analysis.
The results presented here may give a possible explanation as to why EMDP has
not been detected in postmortem cases (1,2) to date, and confirms the observation
that EMDP is a more active substrate for hydroxylation than EDDP (3). Methadone
and its main metabolite, EDDP remain relatively stable under the conditions
employed in this study for up to six months.
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